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Preface 
Analytical chemistry is the science of separation, identification and 
measurement of analytes [1]. The results provided by analytical chemistry 
are crucial for understanding characteristics of natural materials or synthetic 
products and for making right decisions when they have to be assessed as 
appropriate for a certain application. 
In developing and producing pharmaceutical products, specifically vaccines, 
analytical methods and the related data have a key role to ensure the 
required and predefined product quality, as well as monitoring product and 
process consistency. In that context, implementation of Quality by Design 
(QbD) approach has been assessed as a powerful approach to provide 
significant advantages in terms of (I) data quality, (II) method knowledge and 
(III) robustness in a prospective method life cycle.  
The present thesis study describes an integrated approach for the 
implementation of Quality by Design principles to screening and development 
of analytical methods applied to vaccines physical-chemical testing, 
according to Analytical QbD (AQbD) published in literature.  
In particular, the present study is focused on application of the risk 
assessment and the experimental design tools to be used to build knowledge 
about the analytical methods performance and to mitigate the risks of failure. 
The risk management concept is one of the most relevant values of the 
AQbD framework. The recent years have seen an expansion in developing 
and using of management tools for risk assessment, risk control (design of 
experiment) and risk review (control strategy). In the experimental study here 
described, risk management tools and mathematical / statistical models have 
been applied to study and define well characterized analytical methods 
(based on understanding of method parameters-performance relationships), 
in order to establish an analytical procedure able to ensure  the desired 
performance and to identify the method design space. The AQbD structured 
approach clearly mitigates the risk of failure and provides advantages in a 
life-cycle management prospective.  
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Chapter 1 contains an overview of the research activities and introduces the 
liquid chromatography and the chemometrics for experimental 
designs, in the context of the analytical quality by design for 
vaccines.  
Chapter 2 focuses on vaccines and provides a brief overview of the 
Bexsero product, with respect to the application of the AQbD 
principles developed in the present study refers.  
Chapter 3 describes in details the AQbD framework and how its principles 
can be applied to vaccine analytical methods. 
Chapter 4 lists the AQbD applications to different Bexsero analytical 
methods. Experimental design and risk assessment tools 
employed for method development are shown. 
Chapter 6 summarizes the study experimental activities and provides 
remarks and statements for AQbD application to vaccines. 
Chapter 7 deepens the conflict of interest statements. 
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Abbreviations list 
4CMenB: four components MenB vaccine (registered as Bexsero) 
A.A: Amino Acid 
AAA: Ammino-Acidic Analysis 
ACN or MeCN: Acetonitrile 
ACQ: 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
aka: also called as 
AMQ: 6-amminoqinolone 
AQbD: Analytical Quality by Design 
ARD: Analytical Research and Development 
AU: Adsorption Unit 
BCA: Bicinchoninic Acid assay 
BSA: Bovine Serum Albumin 
C&E: cause and effect 
C&E: cause and effect matrix  
CCC: Central Composite Circumscribed design 
CCF: Central Composite Faced design 
Chap: Chapter 
CMA: Critical Method Attribute 
CMP: Critical Method Parameter 
CPP: Critical Process Paramenter 
CPS: capsular polysaccharide  
CQA: Critical Quality Attribute 
DF: Dilution Factor 
DoE: Design of Experiment 
dp: diameter of particles 
DP: Drug Product 
DS: Design Space 
DS: Drug Substance 
EMA: European Medicines Agency 
FDA: Food and Drug Administration 
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FFD: full / fractional Factorial Design 
fHbp: factor H binding protein 
FMEA: failure mode and effect analysis 
GAVI: Global Alliance for Vaccines and Immunization 
GNA1030: Genome-derived Neisseria Antigen 1030 
GNA2091: Genome-derived Neisseria Antigen 2091 
GSK: GlaxoSmithKline 
HEPT: Height Equivalent of Theoretical Plates 
ICH: International Conference on Harmonization 
ID: Internal Diameter 
IEX: Ionic Exchange 
IUPAC: International Union of Pure and Applied Chemistry 
LC-FC: Liquid Chromatography - Fraction Collection 
LC-MS: Liquid Chromatography - Mass Spectroscopy 
KS: Knowledge Space  
MenB: Neisseria meningitidis serogroup B 
MeOH: methanol 
MLR: Multi Linear Regression 
MODR: Method operable design region (aka analytical design space) 
MW: Molecular Weight 
N: Number of theoretical plates  
NadA: Neisseria adhesin A 
NHBA: Neisseria Heparin Binding Antigen 
NIST: National Institute of Standard and Technology 
OFAT: One Factor At Time 
OMV: Outer Membrane Vesicles 
PCA: Design of Experiment 
pCMP: potential-Critical Method Parameter 
PFPA: Poly Fluoro Pentanoic Acid 
PhOH: phenol (C6H6O) 
PLS: Partial List Square 
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PorA: porine protein A of OMV 
PorB: porine protein A of OMV 
RA: Risk Assessment 
RA: risk assessment 
rMenB: recombinant protein of MenB 
RP: Reverse Phase 
RP-UHPLC: Reverse Phase UHPLC 
RSD: relative standard deviation 
RSM: Response Surface Methodology 
SDS-PAGE: sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
SE: Size Exclusion  
STD: standard 
TFA: Tri-Fluoro Acetic acid 
tR: Retention Time 
TRD: Technical Research and Development 
UHPLC: Ultra-high performance Liquid Chromatography 
UniFi: University of Florence 
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Chapter 1: Introduction 
Over the past 10 years Quality by Design (QbD) concepts have been 
increasingly appreciated and applied by the pharmaceutical and 
biopharmaceutical industry, following the overall guidance from International 
Conference on Harmonization (ICH) [2] [3] [4] [5]. QbD approach is now 
largely adopted by the industry as a common practice for connecting 
knowledge of product attributes to drug safety and efficacy and in 
understanding how the control of manufacturing process permits to 
consistently ensure the product quality.  
In such product development context, the analytical methods are definitely 
critical elements due to their roles in assisting product and process 
development and assuring product batches quality by means of suitable 
assays. Inadequate analytical methods can lead to inaccurate outcome, 
resulting in misleading information, detrimental for the drug development 
program [6]. As well, in the commercial phase, high quality methods ensure 
reliable product release, also reducing testing operational costs. Moreover, 
the deep and structured knowledge gained during QbD method development 
provides robust information and rationales related to  regulatory submission 
activities, for justifying the  parameters selected for assays validation and 
supporting method changes or removal of unnecessary tests from product 
specifications [6] [7]. 
Although, the Quality by Design principles are extensively applied in the 
pharmaceutical field, especially for small molecules. Quality by design 
application to analytical methods development has been well adopted by the 
pharmaceutical analytical professionals, with extensive or partial 
implementation of the systematic AQbD approach [6] [8] [9] [10] [11]. 
However, regarding biopharmaceutical molecules, as the vaccine antigens, 
the QbD principles even if enough consolidated in supporting process 
development and understanding, are not yet largely applied to analytical 
aspects. The aim of the present thesis is to improve the application of the 
Quality by Design (QbD) principles to analytical method development and in 
particular to investigate the application of Analytical QbD (AQbD) to vaccine 
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analysis. The application of AQbD to vaccines represents an opportunity for 
method development, to achieve a higher degree of confidence and 
knowledge on the method performance (i.e. precision and trueness of data) 
and method robustness. The application of Quality by Design principles to 
analytical method development is specifically based on the concept to build 
quality during the development stage itself [2] [7]. A good AQbD developed 
method can generate reliable data for product and process development; it 
allows confident decision making and contributes to improve the product 
safety and efficacy. 
Applications of Quality by Design for analytical method development is 
reported in literature for several, different, analytical techniques. Mostly of 
recent examples of AQbD refer to the pharmaceutical field, mainly 
concerning the development of separation methods as high-performance 
liquid chromatography (HPLC) [12] [13] [14] [15], ultra-high-performance 
liquid chromatography (UHPLC) [16] [17], hydrophilic interaction liquid 
chromatography [18], supercritical fluid chromatography [19], capillary zone 
electrophoresis [20] [21] [22] [23] [24], micellar electrokinetic chromatography 
[25] [26] and microemulsion electrokinetic chromatography [27] [28] [29]. 
However, there are not analytical examples, or case studies, published for 
bio-molecules such as vaccine products. In this context the present study 
represents a pilot experimentation for AQbD application on vaccines. 
The most popular assays used as release tests and for characterization by 
pharma and bio-pharma industries are chromatographic methods. The liquid 
chromatography (LC) is certainly one of the most employed, due to its 
feasibility, reproducibility, transferability to Quality Control labs and flexibility 
for a broad spectrum of applications. Many LC techniques, such as reverse 
phase (RP), size exclusion (SE), ionic exchange (IEX) and many others, are 
routinely used for testing very different product attributes, e.g. identity and 
purity of active ingredients, process related impurities, molecular dimension, 
aggregation, concentration, etc. In this context, the development of a LC 
method based on UHPLC technique was considered and investigated in this 
study by applying the AQbD framework. 
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The basic principles of UHPLC are provided below in bottom heading.  
In addition, a smattering of the basic concepts of chemometrics and 
experimental design will be provided. Design of Experiment (DoE) is a 
strategic tool for AQbD risk management and control and it is based on 
chemometric methods and mathematical models. The DoE is crucial to know 
the analytical system under development and to drive the method design 
space.  
UHPLC 
According to IUPAC definition, "chromatography is a physical method of 
separation, in which the components to be separated are distributed 
between two phases, one of which is stationary whilst the other moves in 
a definite direction". In chromatography the stationary phase is either a 
solid, porous, surface active material in small particle form, or a liquid 
which is coated onto micro-particulate beads of an inert solid support 
(usually silica, but not limited to). The mobile phase is a liquid that moves 
through the packed bed of stationary phase in the column under pressure 
[30]. 
As it is very well known from Van Deemter equations (Equation 1), the 
efficiency of chromatographic process is inversely proportional to particle 
size. This model describes relationship between height equivalent of 
theoretical plate (HETP) and linear velocity (u), one of the terms (path 
dependent term C ), is dependent on a diameter of particle packed into the 
analytical column. Smaller particle diameter can significantly reduce 
HETP which results in higher efficiency and the flatter profile of Van 
Deemter curve (Figure 1). Consequently, the mobile phase flow-rate 
increase does not have negative influence to the efficiency for sub-2μm 
particles [31] [32].  
It is possible to increase the linear velocity and maintaining good 
chromatography performance, namely low HEPT values. Furthermore, 
increasing the linear velocity, the chromatographic peaks band boarding 
(diffusion dependent term B ) is decreased, hindering the longitudinal 
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column diffusion of analytes, contributing to increase the chromatographic 
efficiency. The negative aspect of small particle packed columns for LC is 
the high back-pressure generating. For this reason, new Ultra-High 
Performance Liquid Chromatography (UHPLC) systems and new column 
technologies able to withstand the back pressure due to sub-2µm 
particles [33] were developed by several suppliers. Sharper peaks and 
higher resolutions are obtained in lower analysis time using UHPLC 
system; enhancing the LC throughput respect to traditional HPLC. 
UHPLC could be considered to be a new direction of liquid 
chromatography. UHPLC chromatographic system is designed in a 
special way to withstand high system back-pressures [34] [35]. 
Additionally, the analyst can investigate the temperature effect, solvent 
type and composition to find the best operating combination of these 
parameters (Figure 2, Figure 3 and Table 1) to reduce mobile phase 
viscosity and back-pressure.  
HEPT = 𝐴 +  𝐵 
𝑢
+ 𝐶 𝑢 
 Equation 1: the Van Deemter equation 
Where: HETP = height equivalent of theoretical plate. It is a measure of the column 
resolving power [m] A = Eddy-diffusion parameter, related to channelling through a non-ideal 
packing [m] B = diffusion coefficient of the eluting particles in the longitudinal direction, 
resulting in dispersion [m2 s−1] C = Resistance to mass transfer coefficient of the analyte between mobile 
and stationary phase [s] u = Linear Velocity [m s−1] 
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Figure 1: Van Deemter curves for different particle sizes [33]. 
The separation mechanism is still the same between HPLC and UHPLC, 
chromatographic principles are maintained while speed, sensitivity and 
resolution are improved. The result is a higher performance coupled with 
a lower analysis time; a very important aspect for analytical laboratories in 
term of solvent consumption and analysis cost. 
 
Figure 2: viscosity of reverse phase solvent mixture [36] 
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Figure 3: effect of temperature on Van Deemter curve [37] 
 
 
Table 1: Viscosity of common HPLC solvents at various temperatures [37] [38] 
  
H
E
P
T 
(u
m
) 
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Reverse Phase Chromatography 
Reversed Phase (RP) chromatography involves the separation of 
molecules on the basis of their hydrophobicity. Historically it came second 
after the silica polar separation (called “normal” or “direct” phase 
chromatography, NPC) and by this chronology takes the name of 
“reverse”. In RP chromatography a solute molecule in a polar solvent 
(mobile phase) binds to immobilized hydrophobic molecules (stationary 
phase). This partitioning occurs as a result of the solute molecule tending 
to have hydrophobic patches at its surface, and binding via those patches 
to the matrix [39]. Typical reversed phase stationary phases are 
hydrophobic molecules bonded to the surface of a silica support particle. 
Recently, other support materials and bonded phases became 
commercially available (monolithic phases, solid-core particles, fused-
particles and many others), increasing the potentiality of RP 
chromatographic technique. The hydrophobic interaction between the 
exposed patches and the immobilized matrix is less favourable than the 
interaction between the bound molecule and the solvent, using buffer of 
increasing hydrophobicity [39]. Each on-off partition is called theoretical 
plate (N). The molecule releases from the matrix and elutes with a specific 
retention time (tR) due to the specific hydrophobic / hydrophilic ration 
(partition coefficient, K).  
𝐊 = [𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑝ℎ𝑠𝑠𝑎 𝑠𝑠𝑠𝑎𝑠𝑠𝑎 𝑠𝑎𝑠𝑢𝑠𝑠][𝑎𝑠𝑚𝑠𝑎𝑎 𝑝ℎ𝑠𝑠𝑎 𝑠𝑠𝑠𝑎𝑠𝑠𝑎 𝑠𝑎𝑠𝑢𝑠𝑠]  
Each molecule has a specific K value and is a measure of the time the 
sample component resides in the stationary phase relative to the time it 
resides in the mobile phase: it expresses how much longer a sample 
component is retarded by the stationary phase than it would take to move 
through the column with the velocity of the mobile phase [30]. 
The resolution between analytes (RS) depends by retention times, due to 
K values of the chemical species, selectivity (α) and efficiency (N).  
The fundamental resolution equation is expressed by Equation 2.  
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The influence of the three terms on resolution performance is plotted in 
Figure 4. 
𝑅𝑠 = �√𝑁4 �  �𝛼 − 1𝛼 �  � 𝑘′1 + 𝑘′� 
Equation 2: fundamental resolution equation 
 
Figure 4: chromatography resolution dependencies [36] 
Efficiency ( N): 
N is the number of theoretical plates and physically represents the 
number of partition between stationary and mobile phases for the analyte. 
It is a dimensionless number computed as the ration between column 
length (L) and HEPT (L / HEPT). All the considerations made for HEPT 
(Equation 1) are still valid and the Van Deemter equation terms explain 
the influence of mobile phase linear velocity and stationary particles size 
on chromatography efficiency (pick width) [30] [37]. 
𝑁 = 𝐿
𝐻𝐻𝐻𝐻
= 16 �𝑠𝑅
𝑊
� 2 = 5.54 � 𝑠𝑅
𝑊1/2� 2 
Equation 3: N / HEPT relationship and equation 
Were W is the base width of the peak and W1/2 is the width at halt peak height;  
tR is the peak retention time as stated above. 
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 23 of 157 
 
Retention ( k'): 
Capacity factor (k') is the retention factor and depends by the K partition 
coefficient of the chemical species. It is a means of measuring the 
retention of an analyte on the chromatographic column. The retention 
factor is equal to the ratio of the retention time of the analyte on the 
column (tR) to the retention time of an unretained compound. The 
unretained compound has no affinity for the stationary phase (t0), which is 
also known as the hold-up time [30] [37]. It is a dimensionless number 
compute according to Equation 4. 
𝑘′ =  𝑠𝑅 −  𝑠0
𝑠0
 
Equation 4: capacity factor equation 
Selectivity (α): 
Selectivity is the separation factor and expresses the difference of 
retention between peaks. The selectivity factor α is the ability of the 
chromatographic system to distinguish between different components. It 
is measured as the ratio of the capacity factors k’ of the two peaks in 
question (k’2 and k’1) and can be visualized as the distance between the 
apices of the two peaks. By definition, the selectivity is always greater 
than one, as when α is equal to one the two peaks are co-eluting [30] 
[37]. Selectivity is a dimensionless number according to Equation 5. 
𝛼 = 𝑘′2
𝑘′1
=  𝑠2 −  𝑠0
𝑠1 −  𝑠0     
Equation 5: selectivity equation 
Were t1 and t2 are the retention time of the two peaks; t0 the hold-up time; k’1 and k’2 
the related retention factors. 
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Proteins analysis by Reverse Phase Chromatography 
Reverse Phase chromatography is a very powerful technique for the 
analysis of proteins and bio-molecules in general due to a number of 
advantages as excellent resolution, selectivity and reproducibility. 
These advantages make reverse phase the election chromatography to 
monitor and control important vaccine attributes such as purity, identity 
and antigen content. Moreover, the RP is a suitable technique to couple 
with a broaden spectra of detectors: photo diode array for UV-Vis. 
detection, fluorescence, evaporative light scattering and mass 
spectroscopy (MS); thus expanding the RP technique potentiality also for 
characterizing antigens [40] [41] [42]. However, RP technology can cause 
the irreversible denaturation of proteins and bio-samples thereby reducing 
the potential recovery of material in a biologically active form [39].  
The reverse phase chromatography for the analysis of protein antigens 
usually consists of an n-alkyl stationary phases (C4 or C8 to prevent 
adsorptions due to strong affinity for stationary phase), links to silica-
based sorbent [39]. The experimental system is visualized on Figure 5 
below. Considering the bigger dimension of protein antigens, respect to 
small drugs, there is the technology necessity to use particles with higher 
porous dimensions for stationary phase. The most frequently available 
columns have 100 Å pore particles, designed to analyse small molecules. 
100 - 200 Å pore particles are not suitable for large macromolecules and 
can be used only for small recombinant proteins with a narrow molecular 
weight (MW: 50 - 100 kDa). Protein antigens and higher macromolecules 
in general (MW > 100 kDa) needs a broader porosity (300 Å pore 
particles) to permeate the stationary phase. 
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Figure 5: Schematic representation protein binding to RP sorbent 
An organic solvent gradient is recommended for complex mixtures that 
cannot be easily separated by isocratic methods because of their wide K 
range. In gradient elution the eluent strength is increased during the 
separation by changing the composition of the mobile phase. As a result, 
the analysis time is reduced and the quality of the separation is improved 
as well as the detection limit. Binary linear gradients are the most 
common and they are obtaining by mixing an aqueous phase and an 
organic phase such as acetonitrile. An ionic modifier such as 
trifluoroacetic acid (TFA) or formic acid (HCOOH) can be also used. The 
selection of the right acid agent could be critical for the chromatographic 
resolution of mixture products, because of it could enhances lipophilic 
interactions by the following action mechanisms: 
acid modifier – inducing the denaturation of the protein structures and 
exposing the lipophilic amino-acid to the external 
environment. 
ion-pair agent – binding to the solute by ionic interaction with the protein 
charges, which results in the modification of the solute 
hydrophobicity. For this purpose long-chain and poly-
fluoro acids are preferable to TFA, especially for low 
lipophilic compounds.  
mobile phase 
stationary phase 
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 26 of 157 
 
Typical examples of organic solvents and ion-pair agents used for reverse 
phase are reported on Table 2 and Table 3. 
The RP separations can be easily influenced by changing the gradient 
elution, the operating temperature, the ionic-pair agent, the organic 
solvent composition, the linear velocity of the mobile phase and by 
choosing the right chemistry and technology of the stationary phase [39] 
[43]. Complex macromolecular-antigen mixtures (proteins, protein-
conjugates, polysaccharides, lipopolysaccharides and DNA / RNA) can be 
routinely separated and picomolar or even femtomolar amounts of 
material can be analysed with a good sensitivity using reverse phase 
chromatography. 
 
Table 2: organic solvents for reverse phase chromatography [44] 
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Acid formula 
pKa 
(25°C) 
H2O 
solubility 
(25°C) 
name 
Formic Acid HCOOH 3.75 1.0 M FA 
Trifluoroacetic Acid CF3-COOH 0.52 0.5 M TFA 
Perfluoropropionic Acid CF3-CF2-COOH 0.18 0.5 M - 
Perfluorobutyric Acid CF3-(CF2)2-COOH  0.4 0.5 M PFBA 
Perfluoropentanoic Acid CF3-(CF2)3-COOH - 2.29 0.5 M PFPA 
Perfluorohexanoic Acid CF3-(CF2)4-COOH - 0.16 5 mM - 
Perfluoroheptanoic Acid CF3-(CF2)5-COOH 0.31 5 mM - 
Perfluorooctanoic Acid CF3-(CF2)6-COOH 2.8 5 mM PFOA 
Perfluorodecanoic Acid CF3-(CF2)1-COOH - 5.2 5 mM PFDA 
Table 3: ion-pair agents for reverse phase [45] [46] [47] 
Chemometrics 
The application of Quality by Design Approach to analytical method 
development leads to datasets that require sophisticated mathematical 
tools to efficiently extract information and understand the physical-
chemical problem. 
Chemometrics is the science of extracting information from chemical 
systems by data-driven means. Chemometrics utilizes methods frequently 
employed in core data-analytic disciplines such as multivariate statistics, 
applied mathematics, and computer science, in order to address 
problems in chemistry, biochemistry, medicine, biology and chemical 
engineering. Chemometrics can be applied to obtain knowledge about the 
analytical method [48] [49] [50].  
The chemometrics guiding principles that are applied for analytical 
method development data interpretation are the following:  I) sampling – doing a representative sampling of the sample population 
under study is the first step for the right experiment design. Wrong 
sampling could lead to wrong conclusions and untrustworthy. 
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II) experimental designing – set up the right design for the 
experimentation is crucial for the extrapolation of the system 
information. III) information extraction – analyse the data critically, interpreting the 
system input-output relationships for conclusion making.  
Setting an experiment by using multivariate technique could help 
obtaining more information on the effect of inputs (method variables) on 
outputs (responses) [51]. The quality of the information is higher because 
it is possible: 
1)  to understand not only the effect of each single variable, but to gain 
additional knowledge about variables interaction and the dependences 
between factors and their impact on responses.  
2) to reduce the number of experiments, with time and cost saving.  
All the above mentioned aspects, especially the latter, are important for 
the analytical application field and pharmaceutical in general, because the 
knowledge and the quality of the analytical / process systems are 
improved and the project costs and the time required for information 
gathering decrease. 
Experimental Design 
A well designed experiment is an efficient method to improve knowledge 
about the analytical assay under development. The statistical models are 
crucial for an efficient design and analysis. The Design of Experiment 
(DoE) methodology makes possible to acquire more information about 
experimental factors and their interactions, in shorter time and minimizing 
the number of experiments respect to traditional One Factor at Time 
(OFAT) approach. Figure 6 provides a picture of the above mentioned 
concept. Considering two parameters X1 and X2 (e.g. time and 
temperature), the following experimental design opportunities can be built: 
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• traditional OFAT experimentation by which a first experiment to find 
the optimum for X1, keeping X2 factor fixed at an arbitrary level (a), 
and a subsequently second experiment for optimization of X2 factor, 
keeping fixed X1 factor at the best (b), are performed. The resulting 
point found (blue point) does not take into account the interaction 
between the two variables and therefore depends on the condition 
from which the OFAT experiment is conducted. As a consequence, 
the identified point (blue point) can be a relative maximum within the 
whole performance surface of the experiment and not necessarily the 
absolute maximum point within the performance surface.  
• DoE approach by which the absolute optimization of X1 and X2 factors 
is targeted. In particular (c) evidence an interaction effect (orange 
arrow) and the best performance is in the orange circle. By only one 
DoE experiment (indeed two by OFAT) you get more information and 
the absolute maximum of the experimental performance surface is 
found. In this context, it is possible to find the whole set of possible X1-
X2 combinations (orange space) by which the absolute maximum is 
found; a maximum performance surface is reached instead of only a 
single point. This concept is key and will be deeper discussed in the 
AQbD chapter (Chap. 3). 
  
Figure 6: DoEs Vs OFAT experimentation 
1st OFAT:  
X1 optimization 
2nd OFAT:  
X2 optimization 
DoE experiment:  
X1-X2 optimization 
(a) (b) (c) 
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As proclaims by A.C. Atkinson and A.N. Donev in the Optimum 
Experimental Design book, “a well-designed experiment is an efficient 
method of learning about the world” [51]. In pharmaceutical analytical 
development, the assay purpose and the answer to give are often known 
before starting the method development. The Analytical Target Profile 
(ATP) is crucial for that purpose and will be discussed in the dedicated 
section in chapter 3. To know the intended purpose of the method is an 
essential starting point to define the analytical development strategy and 
to set up the right experimental design. 
Quantitative factors 
Quantitative factors are those acting on the analytical system that can 
take numerical value (e.g. rate, time, percentage, amount, etc...). Among 
all, the majority are continuous variables and can therefore be set at any 
value. However, basing on physical-chemical understanding of the 
phenomenon that is intended to be studied, the analytical technique, 
physical principles limits and their impact on analytical method application 
(e.g. the pH range restriction suitable for a chromatographic column), the 
continuous factors / variables are studied within a defined range or at 
discrete levels. Unless otherwise stated, a quantitative factor is assumed 
continuous [52]. 
Qualitative factors 
Qualitative factors take only discrete value. In pharmaceutical 
development, an example of analytical qualitative factors might be the 
type of column for a screening (e.g. pore-, monolithic- and solid-core 
column; RP-C4 and RP-C8), organic eluent type (e.g. ACN, THF and 
MeOH), ion-pair agent (e.g. all the acid substances listed on Table 3) and 
many other development parameter for different analytical techniques 
(e.g. spectroscopy, electrophoresis, bio-assay, etc…). 
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Factor space and experimental domain 
The factor space is the n-dimensional space defined by the coded 
variables Xi for the continuous quantitative factors being investigated.  
If only two variables (factors) are investigated it is a bi-dimensional space, 
for n factors it is a n-dimensional space. The factor space is defined in 
term of n independent variables. Only a part of the factor space, which is 
defined as experimental domain, is of interest for pharmaceutical 
applications. Sometimes it is also called region of interest, it is the part of 
the factor space enclosed by upper and lower limits of the coded 
variables. As an example of this definition a simplified one dimensional 
space for pH can be considered. The factor space is the pH range 
possible (0 – 14), while the experimental domain can be any space 
contained within it, for example the space 6 – 12, if referred to the pH 
range of use of a silica chromatographic column.  
For qualitative factors, the factor space consists of discrete points and the 
experimental domain is equal in number to the product of the available 
levels of all the qualitative factors [52]. Exemplificative illustrations of bi-
dimensional experimental domains of continuous and qualitative factors 
are reported in Figure 7 below. 
 
Figure 7: factor space (U) and experimental domain (X)  
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Responses 
Responses (Y) are measured properties of the analytical method, 
sometime referred to as dependent variables. The measured response for 
experiment nth will be written as Yn [52]. The identification of the 
responses to be measured (method out-puts) is depending by the 
intended purpose of the assay and in this context it is important what is 
defined in the analytical target profile (ATP). The discussion concerning of 
the ATP is postponed to AQbD chapter 3. Now it is important to 
understand that ATP drives the selection of the responses to control the 
method performance. 
Mathematical models 
A mathematical model is an expression defining the dependence of 
responses (dependent variables) on the independent variables: factors or 
parameters. The models most frequently used are the linear models 
(Equation 6), that should not be confused with first order models. A linear 
model is a model in which all terms may be represented by a constant 
coefficient βi multiplied by a variable (xi; xi xj; xi2; xi3; etc.) [52]. The linear 
model, also called linear regression models, could be a polynomial of the 
first-order without interaction (Eq.A) or with interaction between variables 
(Eq.B); polynomial of the second-order (Eq.C), knows as quadratic models; 
more rarely third-order (cubic models) or superior order models are used. 
The purpose is to use the simplest possible model fitting the analytical 
problem. Eq. A:  Y = β0 + β1X1 + … + βiXi + ε Eq. B:  Y = β0 + β1X1 + … + βiXi + + β12X1X2 + … + βijXiXj + ε Eq. C:  Y = β0 + β1X1 + … + βiXi + + β12X1X2 + … + βijXiXj + β11X12 … + βiiXi2 + ε 
Equation 6: equation of linear models 
Where: Y = response 
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β0 = model constant term 
βi = constant coefficient of variable (factor effect) Xi = variable 
ε = experimental error 
The linear models are the most used to represent relationship between 
variables and responses in an analytical experiment. Nevertheless, there 
are some situations when models with non-linear parameters have to be 
preferred; particularly if the error assumptions are violated by the 
transformed model [37]. Non-linear modelling can be utilized efficiently in 
a vast number of situations where traditional modelling is impractical or 
impossible to apply. Nonlinear modelling approaches are generally 
formulated by differential or exponential equations and include non-
parametric methods, such as feed forward neural networks, kernel 
regression, multivariate splines and many others.  
Multi-linear regression (MLR) 
During the development of an analytical method as well as for chemical 
process, the factors to be studied are more than one (X1, X2 … Xi) as well 
as the responses (Y, Y’…Yk) and each Yk output should be studied at 
different levels (Y1, Y2 … Yn ;  Y’1, Y’2 … Y’n  ;  Yk1, Yk2 … Ykn). As an 
example, for separation method, responses to be controlled have to be 
peaks resolution, column capacity, run time, peaks symmetry / purity. The 
type of responses to be controlled depends on the basic principle of the 
assay, (e.g. bio-assay, spectroscopic method). 
The assumption behind the modelling of an analytical system is that each 
experimental result can be represented by the same equation (Equation 6) 
for every response and each level (Ykn).   
The overall analytical system will then be described by the combination of 
all equations Ykn = f(Xn1 … Xni). In the Equation 7 below, as application 
example, the analytical problem is represented for a first-order two-factor 
linear-model with interactions, for one response.  For a more sophisticated 
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analytical system, one equation for each of responses of the analytical 
system under study must be defined [52]. Y1 = β10X01 + β1X11 + β2X12 + β12X11X12 + ε1 … Y2 = β20X02 + β1X21 + β2X22 + β12X21X22 + ε2 … Yn = βn0X0n + β1Xn1 + β2Xn2 + β12Xn1Xn2 + εn 
Equation 7: firs-order multi-linear equation with interaction for two factors  
Where: Y1 = the value of the response Y in the 1st experiment condition Y2 = the value of the response Y in the 2nd experiment condition Yn = the value of the response Y in the Nth experiment condition Xn1 = the level of the X1 factor in the Nth experiment condition Xn2 = the level of the X2 factor in the Nth experiment condition 
β1 = effect coefficient of X1 factors for each Nth condition (β1Xn1) 
β2 = effect coefficient of X2 factors for each Nth condition (β2Xn2) 
β12 = effect coefficient of X1-X2 interaction for each Nth condition (β12Xn1Xn2) 
β10 ; β20 ; βn0 = model constant terms for each Nth  measurement 
ε1 ; ε2 ; εn = experimental error for each Nth  measurement 
Always considering only the response Y, the Equation 7 could be written 
in a matrix form to represent the system of equations as a table for a 
direct and visual interpretation of the multivariate conditions tested. 
Appling Equation 8, Equation 7 is translated in matrix Equation 9. Y = Xβ + ε 
Equation 8: general matrix equation 
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Y = �𝑠1𝑠2
𝑠
𝑠
�  X = �𝑥11 𝑥12 𝑥11𝑥12𝑥21 𝑥22 𝑥21𝑥22
𝑥𝑠1 𝑥𝑠2 𝑥𝑠1𝑥𝑠2
�  β = �𝛽1𝛽2
𝛽12
�   ε = �𝜀1𝜀2
𝜀𝑠
� 
Equation 9: general matrix for firs-order multi-linear model with interaction of two 
factors 
 
Where: 
X is a N x p matrix, called the model matrix and known also as effect 
matrix, having as many columns as there are the coefficients 𝛽 in the 
model (p) and as many rows as there are the experiments (N: the 
experiments number depend by the design chosen and the number of 
factors and levels) [52]. 
Y is the column matrix and is the vector of the experimental responses.  
ε is the vector of the experimental errors and β is the vector of the factors 
coefficients [52]. 
Appling a fractional design to the 2 factors (X1; X2) and studying at two 
levels each factor (-1; +1), with the inclusion of a central point (0; 0) and 
two replicates for all conditions tested, we obtained the following 
experimental matrix showed by Equation 10 and related Table 4. 
Y = �𝑠1𝑠2
𝑠
𝑠
�  X =
⎣
⎢
⎢
⎢
⎢
⎡
+1 −1 −1+1 −1 −1
−1 +1 +1
−1 +1 +10 0 00 0 0 ⎦⎥
⎥
⎥
⎥
⎤
 β = �𝛽1𝛽2
𝛽12
�   ε = �𝜀1𝜀2
𝜀𝑠
� 
Equation 10: matrix of the 2-level 2-factors (22) Fractional Design  
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The model matrix X (blue dash box on Equation 10) has been and will 
normally to be represented as a table; as in following Table 4. The column 
for the model matrix corresponds for a 2-level fractional design 
corresponds to the linear combinations of factors for calculating its 
coefficients [52]. 
X1 X2 X1X2 
measured  
Y response 
+1 -1 -1 Y1 
+1 -1 -1 Y2 
-1 +1 +1 Y3 
-1 +1 +1 Y4 
0 0 0 Y5 
0 0 0 Y6 
Table 4: experimental matrix for Equation 10 
The MLR model is the foundational of regression models applied to the 
experimental design discussed in this thesis. 
Alternative chemometric regression models 
Different regression models could be used for the factor assessment and 
responses prediction, e.g. partial least squares (PLS) and principal 
component regression (PCR) methods. 
Principal component regression (PCR) is a regression analysis technique 
that is based on principal component analysis (PCA). Typically, it 
considers regressing the responses on a set of covariates (independent 
variables) based on a standard linear regression model, while uses 
principal component analysis (PCA) for estimating the unknown 
regression coefficients in the model. PCA is a statistical procedure that 
uses an orthogonal transformation to convert a set of observations of 
possibly correlated variables into a set of values of linearly uncorrelated 
variables called principal components (PC). In PCR, instead of regress the 
dependent variables, the principal components of the explanatory 
variables are used as repressors. One major advantages of PCR lies in 
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overcoming the multicollinearity problem. For analytical application, PCR 
does not represent a viable solution since all variables have a different 
effect on the analytical system and multicollinearity is not relevant [53] [54] 
[55] [56]. 
Partial least squares regression (PLS regression) is a statistical method 
that bears some relation to principal components regression; instead of 
finding hyperplanes of maximum variance between the response and 
independent variables. PLS finds a linear regression model by projecting 
the predicted variables and the observable variables to a new space. 
Because both the X and Y data are projected to new spaces, the PLS 
family of methods are known as bilinear factor models. PLS is used to find 
the fundamental relations between two matrices (X and Y), i.e. a latent 
variable approach to modelling the covariance structures in these two 
spaces. A PLS model will try to find the multidimensional direction in the X 
space that explains the maximum multidimensional variance direction in 
the Y space. PLS regression is particularly suited when the matrix of 
predictors has more variables than responses [53] [57]. 
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Screening of Factors (Screening DoEs) 
The screening purpose is to select from the factors which may possible 
influence the analytical process being studied those which factors have a 
real effect on responses, an influence that is unequivocally 
undistinguishable from the background noise [52].   
Screening DoE is normally done very early in the life of the method 
development in order to simplify the analytical problem and thus to 
concentrate attention and resources to optimize the main important 
factors. Although, many factors can often be listed as possibly important, it 
is not unusual that a large part of the experimental variation for responses 
can be explained by a small number of the factors studied. The objective 
of a screening study is not to obtain numerical data for method factors 
effect, but rather to discriminate between factors that have effect on 
analytical responses and factor that do not have a significant effect. Both 
qualitative (typically) and quantitative (discrete) factors could be studied 
by screening DoEs [52]. The screening goal is to perform a minimum 
number of experiments exploring the highest possible number of factors 
[58]. 
As previously mentioned, screening DoEs are generally performed before 
and in preparation to optimization DoE, to identify the “trivial many” vs. the 
“vital few” parameters and subsequently deprioritize the first and continue 
to study the latter. It is possible that the experiments carried out in the 
screening study might be exhaustive to identify the optimal value for some 
parameters, typically for the qualitative factors. A practical analytical 
example could be the column type selection or the ion-pair agent 
screening for liquid chromatography. 
A second employment of Screening DoEs for analytical pharmaceutical 
purposes is for testing assay robustness (small changes in set point 
conditions) and ruggedness (e.g. replicates of set point conditions) [58]. 
The intended purpose of these studies is to demonstrate that the explored 
changes are not significant for responses. It is particularly useful (I) during 
method development, for the identification of a suitable control space and 
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a good control strategy, e.g. system suitability test, and (II) during 
validation to demonstrate robustness and ruggedness by multivariate 
techniques. 
Two examples of screening DoEs are reported as graphic effect analyses 
on Figure 8 and Figure 9. Graphic effect analysis is a simply histogram 
representation of the model-factor coefficients, with related variance 
estimation. It is generally used to understand if the change of level for the 
selected factors and interactions has influence on the selected response.  
The example on Figure 8 shows the effects of the five factors b1...b5 on 
response Y. It appears clear that when b2 and b5 are at their higher levels 
the response increases, contrariwise to b1 that prefers the lower factor 
level. b3 factor does not impact the response, while b4 shows an effect 
close to pure error of the model.  
Figure 9 shows the robustness of the Y response against the method 
factors (ACN, time and temperature). The estimation of the model 
coefficient parameters are not significant by ANOVA and the effects 
(green bars) are lower than model variability. 
  
Figure 8: example of graphic effects for screening by NEMROD-W 
Y 
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Figure 9: example of screening DoE output for robustness by MODDE 
The DoE possibilities are not only restricted to Factorial,  
D-Optimal and Plackett-Burman design; others could be available for 
different analytical purposes, e.g. Rechtschaffner design and many others.  
Factorial design 
Factorial designs identify experiments at every combination of factor 
levels. There are Lk combinations of L levels of k factors. In full factorial 
designs (see example in Figure 10) every experiment is performed, 
while for fractional factorial designs a specific subset is performed that 
allows calculation of certain coefficients of the model (see example in 
Figure 11). Two-level designs are typically chosen for screening factors 
since can provide main and interaction effects, without providing 
indications on higher orders interactions. Higher number of levels are 
used for the screening design (3, 5, n levels) mainly as fractional design 
in order to provide indications on main effects and interactions with 
fewer runs respect to full factorial.  
Calculation of effects in two levels designs is easy. If the two levels are 
coded +1 and −1, then the column of +1 and −1 under each factor is 
multiplied by the response for each experiment. The result of this 
product is then added by the half of the experiments number and finally 
divided by the half of the number of the performed experiments, leading 
to the main effect for the factor. For the interaction effect, a new column 
Y 
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is created, it is the product of the level codes and the procedure 
outlined above is applied to this column [58]. 
 
Figure 10: full factorial design 22 (a) and 32 (b) 
 
Figure 11: fractional factorial design 22 (a) and 32 (b) 
Full factorial design is typically chosen for screening few parameters or 
for robustness studies. Fractional factorial design with high resolution 
are generally chosen when the number of factor to screen is high (e.g. 
for early analytical screening) and a high number of information are 
required from a restricted number of experiments. 
D-Optimal design 
The D-optimal design is able to define the optimal distribution of the 
experimental points based on a defined number of design points [59]. 
This occurs when the determinant of the matrix X XT is maximised, 
where X is the matrix of design points and XT denotes the transpose. 
+1; -1 -1; -1 
+1; +1 -1; +1 
0; -1 
0; +1 
0; 0 +1; 0 -1; 0 
+1; -1 -1; -1 
+1; +1 -1; +1 
+1; -1 
-1; +1 
0; -1 
0; +1 
+1; 0 -1; 0 
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The approach allows stepwise refinement: upon a minimal design 
output is analysed, further points can be added to refine knowledge 
[58]. D-optimal designs might represent an advantageous solution in the 
following situations: 
a) When the factor space is not uniformly accessible, for example 
when combinations of solvent composition and solute concentration 
are not possible. 
b) To pre-define a limited number of experiments that guarantees 
adequate analysis of the output (that corresponds to the number of 
effects plus a constant term). 
c) When there are limitations in the sample set, (e.g. the maximum 
runs possible within the same analytical session) or when values or 
combinations of parameters are not possible for practicability limits. 
An example of a D-Optimal design for two factors and 9 runs is 
reported in Figure 12 below. The combinations of high value for 
factor 1 and low value for factor 2 are excluded by the design. 
 
Figure 12: D-Optimal design for two factor and 9 runs 
Plackett–Burman design 
Plackett-Burman design requires 4n experiments to be performed to 
investigate a maximum of 4n − 1 factors at two levels. Plackett and 
Burman design has become particularly popular for robustness tests 
because one of the runs requires the base level of each factor. When 
deciding the levels, if ‘−’ is allocated to the base level of the factor, then 
‘+’ is this base plus a small change that is being investigated as part of 
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the robustness study (see the example on Figure 13 below for a three 
factors design). Note that the change can be an increase or a decrease. 
The main effect that is obtained from the analysis of the DoE is an 
estimate of the change in response as the factor goes from the ‘−’ level 
to the ‘+’ level [58] [60]. This peculiarity makes Plackett-Burman design 
an useful tool for confirmation and validation of the design space model 
and/or to identify the so called control space, a robust and controlled 
space within the design space where the analytical performance is not 
affect by the factors variation.   
 
Figure 13: Plackett-Burman design 
Optimization DoEs 
Optimisation is the process of determining where the desired target values 
for factors lie. The graphically representation of the relationship between 
responses and factors (Yk = fX1,X2…Xi) are so called response surfaces 
(Figure 14). There is not always a single maximum (or minimum, 
depending on assay purpose) in the response surface. Often the response 
plateaus and there is an area of response surface with approximately the 
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 44 of 157 
 
same value (minimization example b). Sometimes the response function 
shows a saddle with maximum values at the edges (maximization 
example a). For chromatographic separations the goal is to find conditions 
whose responses meet the target criteria, by operating in a range that can 
be considered applicable from an operational point of view (e.g. for time 
and temperature, according to Figure 14 example), rather than find the 
absolute optimum. This makes DoE very powerful when the polynomial 
function does not fit the data perfectly, but does describe the response 
sufficiently to locate an acceptable region, in order to have the possibility 
to identify a maximization or minimization on responses. Mathematically, 
to find the maxim / minimum optimum at least quadratic terms are needed, 
refer to previous Equation 6 for models discussion [52] [58]. 
  
Figure 14: response surface examples 
In the reality, during the development of an analytical method (and a 
process in general) there is not only one response, but more responses to 
be optimize at the same time: e.g. chromatographic outputs could be 
resolution (R1, R2 ... Rn), capacity (k’) or selectivity (α) parameters 
between peaks. For this reason, it is of crucial importance the definition of 
the target criteria (refer to ATP paragraph on chapter 3). It is important to 
define not only a target but an acceptable region for responses, where the 
output values are suitable. Certain responses could oppose another one; 
changes of a factor that improve a response may have negative effect on 
a second [52]. In that context it is crucial the “a-priory” definition of the 
Y1 Y2 
time 
Temp. 
time 
Temp. 
(b) (a) 
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method intended purpose by formalization of the analytical target profile 
(ATP). The ATP is the key tool for the prioritization between method 
responses, and is also useful to identify the desirability values and ranges 
for the specific method-output responses. The definition of the desirability 
values / ranges is crucial and leads the definition of the final design space 
by the implementation of the desirability function to response surfaces. 
Refer to AQbD chapter 3 for a deeper discussion on desirability, while 
response surface methodology is presented below.   
Response Surface Methodology (RSM)  
Response surface analysis is a graphical optimization technique of 
multiple responses. The polynomial models estimated by measured 
responses are graphically represented by response surfaces plots. The 
graphical representation of the responses behaviour helps to 
understand and visualize the effect of the method parameters. It is a 
relatively simply technique for finding the optimum combination of 
factors to satisfy the desirability values. Designing the optimization DoE 
for response surface methodology (RSM) it is important to consider 
that, to estimate a model we need to carry out as many experiments as 
many coefficient there are in the model. More replicates, central points 
and additional test points help to improve the quality of the predictive 
RSM model. RSM is typically applied to quantitative and continuous 
factors and the resulting response surface can be visualised by contour 
plots or three-dimensional diagrams. As can be easily understood, RSM 
cannot be used, at least not directly, for discontinuous responses.  
A good RSM model should be predictive over the whole experimental 
domain and the prediction goodness should be validated, e.g. by 
Plackett-Burman design as previously discussed [52].  
The DoE possibilities are not only restricted to Face Centred and 
Central Composite designs, e.g. Box-Behnken, D-Optima, Doehlert and 
Full Factorial designs, could be available and chosen for different 
optimization analytical purposes. In the following sections, the two 
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experimental designs used for the factors optimization in this PhD 
thesis will be described in details.  
Central Composite design (CCD) 
Two-level designs can only lead to linear models of responses and so 
cannot give information about maxima or any non-linear relationships.  
Moreover, for full factorial designs conducted at levels greater than two, 
the number of required experiments to achieve a suitable description of 
the model becomes challenging for a concrete application. Designs that 
allow greater numbers of levels cover the factor space near the centre 
with more points than at the periphery, without performing experiments 
at every combination of factors and levels. One such design is the 
central composite design, so named because it combines a two-level 
factorial design with a star design and centre points. The star (±α) and 
factorial points can lie equidistant from the centre (circumscribed design 
- CCC, see Figure 15), or the star points can lie within the space of the 
factorial design (inscribed design), or they can lie on the faces of the 
factorial design points (faced design - CCF, see Figure 16). Central 
composite designs require Lk + Lk + nc experiment [58]. Thus it results 
composed by a full factorial design (Lk), or a fraction factorial design if 
the numbers of runs is higher (Lk-p), to estimate the linear coefficient of 
factors (βi) and their interactions (βij). Additional 2k experiments, also 
called star point, symmetrically distributed at ±α along the factors axis 
and used for the estimation of the quadratic effect coefficients (βii). The 
α value depends by the number of experiment due to factorial term. 
Namely, for a 2-factor design α = ±1.414 (half diagonal of the square 
experimental domain); for a 3-factor design α = ±1.627 (half diagonal of 
the cubic experimental domain); and so on for larger factor numbers. 
Finally, nc are the number of replicate centre points chosen. The centre 
point replicates are introduced for the experimental variance estimation. 
On the following example figures, the star points (α) of CCC and CCF 
design are coloured by red.  
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Figure 15: CCC design for two (a) and three (b) factors 
     
Figure 16: CCF design for two (a) and three (b) factors 
Design variability and quality 
The model error estimation is used to estimate if a factor has a higher / 
lower effect respect the pure model error. In this context, the variability 
associated to the measurement of the response must be taken into 
account and used to determine the number of replicates of each 
measurement of the response to obtain reliable information from the 
model. Predictive models, determined by multi-linear regression, are 
tested by ANOVA.  Analysis of variance (ANOVA) should be used while 
analysing RSM designs. ANOVA is used to analyse the results depending 
by simultaneous factors variation, evaluating significance and lack of fit 
(validity) of the regression model used, by partition of the total variation of 
(a) (b) 
α = ±1.627 
α = ±1.414 
(a) (b) 
α = ±1 
α = ±1 
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a selected response SS (SS - Sum of Squares corrected for the mean)  
into a part due to the regression model and a part due to the residuals:  
SSTot = SSregr + SSresid. If there are replicated observations (experiments), 
the residual sum of squares is further partitioned into pure error (SSpe) and 
Lack of fit (SSlof): SSTot = SSregr + SSpe + SSlof [52] [53] [61]. 
Analysing the quality of the design and regression model, it is to be 
controlled as well determination coefficient (R2), adjusted-R2 (R2adj) and Q2 
values [62]. Few general concept are following describe for the R and Q 
square values to understand the meaning and the using on experimental 
section, without deeper discussions on computation. 
R2 estimate goodness of fitting for the multi-linear regression. 
Determination coefficient is the proportion of the variance in the responses 
(dependent variables) that is predictable from the method variables 
(independent factors). A R2 value equal to 1 corresponds to a perfect fit.   
Q2 estimate the prediction goodness of the identified regression model. 
Q2 value come from cross-validation and wants to estimate how accurately 
a predictive model will perform in practice. Dimensionally it could assume 
values from 0 to 1, rather than absolute value it is to consider in 
relationship of adjusted-R2. 
R2adj gives an idea of how many data points fall within the multi-linear 
regression model identify. R2adj is an adjustment of R2 taking into account 
the number of factors (predictors) and the total multivariate conditions 
tested, including replicates (sample size).  
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Chapter 2: Vaccines 
Vaccine administration has been demonstrated as one of the most effective 
and large scale applicable health-care approach in preventing infection 
disease. Due to successful immunization programs, some of the common 
diseases of the early 20th century almost disappeared [63]. Vaccines 
available today have an outstanding impact on human health, preventing 
every year over 2.5 million deaths caused by infection diseases worldwide 
[64] [65]. Development of vaccines against a variety of diseases, including 
diphtheria, tetanus, polio, measles, mumps, rubella, hepatitis B, and 
meningitis, have reduced the associated mortality by 97–99% [66]. In the 
near future the beneficial impact of vaccination will further increase thanks to 
several factors including: the enhanced coverage of children vaccination in 
developing countries promoted by Expanded Program on Immunization and 
by the Global Alliance for Vaccines and Immunization (GAVI); the increased 
use of vaccines in elderly and pregnant women; the full implementation of 
vaccines that have been recently licensed (e.g., Meningococcus B and 
Dengue); the launch of novel vaccines that have successfully concluded 
phase III trials (e.g., Malaria and Zoster) [65]. However, even with multiple 
successful vaccination campaigns, infectious diseases remain the second 
leading cause of death worldwide, disproportionately affecting children under 
the age of 5 and people in low income countries [67] [68]. A large number of 
infectious diseases caused by viruses, bacteria (often resistant to multiple 
antibiotics) or parasites are not yet preventable by vaccination and are 
responsible for millions of death every year. For the majority of these targets, 
traditional approaches have failed and there is a need to apply innovative 
science and novel technologies to develop effective vaccines. In addition, 
people in the world continue to experience pathogen outbreaks such as 
Pandemic Influenza, Ebola and, more recently, Zika virus, which have 
highlighted the need of more rapid vaccine discovery and development 
strategies supported by breakthrough scientific innovation [65]. In fact, five of 
the top ten leading causes of death in low income countries are caused by 
infectious agents: lower respiratory infections (e.g. pneumonia), HIV/AIDS, 
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 50 of 157 
 
diarrheal disease, malaria, and tuberculosis. While some of these pathogens 
currently lack a vaccine necessary for disease control, an estimated 20% of 
these deaths still results from vaccine-preventable diseases, indicating the 
need for substantial improvement in vaccine technology and administration 
[67] [69] [70]. Hence, innovative strategies are essential in development of 
novel vaccines [63] to rationally design effective vaccines where drug-based 
conventional approaches have failed [71]. Most of the promising strategies 
include design of an appropriate recombinant antigens as well as 
development of properly formulated vaccines to obtain the appropriate 
immune-response and the sufficient potency. Any case, a well-designed 
analytical control strategy is important to ensure an appropriate monitoring of 
the vaccine product quality. 
In the present thesis work the AQbD framework was applied for the 
development of new analytical methods related to some critical quality 
attributes (CQAs) of Neisseria meningitidis serogroup B vaccine. Bacterial 
meningitis is an infection of the membranes and cerebrospinal fluid 
surrounding the brain and spinal cord and it is a major cause of death and 
disability worldwide. Three organisms are responsible for most cases of 
bacterial meningitis: Neisseria meningitidis, Haemophilus influenzae type b 
and Streptococcus pneumoniae [72] [73] [74] [75]. Neisseria meningitidis is a 
pathogen bacterium that is transmitted through contact with respiratory 
droplets. Transmission and colonization typically results in asymptomatic 
carriage in the upper respiratory tract, leading to bacteraemia that can quickly 
become life-threatening invasive meningococcal disease, which most often 
presents meningitis and/or septicaemia, and less commonly pneumonia, 
septic arthritis, otitis media and epiglottitis [76]. Neisseria meningitidis is 
classified into serogroups based on the immunological reactivity of the 
bacteria capsular polysaccharide. Meningococcal serogroups A, B, C, W, Y 
and recently X account for the majority of meningococcal diseases [77], with 
serogroup B (MenB) being now the most prominent cause of infant bacterial 
meningitis and septicaemia in Europe, Latin America, US and Canada [78] 
[79]. Serogroup B capsular polysaccharide (CPS), that consists of a 
homopolymer of α (2-8)-linked polysialic acid, is immunologically similar to 
that of neural-cell adhesion molecules and thus is poorly immunogenic, 
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hindering its use in the traditional polysaccharide conjugate-vaccine 
approach [79]. To overcome this problem the new genome-based approach 
of reverse vaccinology was employed to identify new candidates for the 
development of a vaccine against Meningitidis B disease [80]. The 
application of reverse vaccinology to MenB vaccine development allowed the 
identification of bacterial proteins able to induce bactericidal antibodies [65]. 
The genomic era has radically changed the vaccine development approach. 
Reverse vaccinology defines the process of antigen discovery starting from 
genome information, by the availability of whole genome sequences. From its 
first application to Neisseria meningitidis group B, this approach has 
gradually evolved and is now accepted as a successful method of vaccine 
discovery, as it can be exploited to develop vaccines against many types of 
pathogens. Current reverse vaccinology approaches include comparative in 
silico analyses of multiple genome sequences, in order to identify conserved 
antigens within a heterogeneous pathogen population. The purpose is the 
identification of antigens that are unique to pathogenic isolates but not 
present in commensal strains. In addition, transcriptomic and proteomic data 
sets are integrated into a selection process that yields a short list of 
candidate antigens to be tested in animal models, thus reducing the costs 
and time of downstream analyses [81]. 
Bexsero vaccine (4CMenB) 
Bexsero is the first approved vaccine for active immunization of 
individuals from 2 months of age and older to prevent invasive disease 
caused by Neisseria meningitidis serogroup B. Using reverse 
vaccinology, three MenB surface-exposed proteins were identify as 
potentially immunogenic antigens: Neisseria Heparin Binding Antigen 
(NHBA), factor H binding protein (fHbp) and Neisseria adhesin A (NadA), 
constituting the three core proteins of recombinant meningococcal B 
vaccine (rMenB). NHBA and fHbp have been fused to two additional 
antigens (Genome-derived Neisseria Antigen: GNA1030 and GNA2091, 
respectively) to increase their immunogenicity [82] [83] [84].  
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 52 of 157 
 
NHBA-GNA1030, fHbp-GNA2091 and NadA, have been combined with 
Outer Membrane Vesicles (OMV), mimicking the vesicles naturally 
released by Neisseria meningitidis and displaying protein antigens in a 
context similar to their native environment. In particular OMV contains 
Porin A (PorA) and Porin B (PorB), the most abundant outer membrane 
proteins. OMV have been shown to be safe and efficacious in many 
clinical trials and effective to MenB outbreaks, by inducing immunity that 
is mostly due to the highly variable PorA outer membrane protein, but can 
also involve outer membrane proteins PorB, OmpC, FetA, and 
Lipooligosaccharides [84] [85]. The rMenB components of the vaccine 
(HBA-GNA1030, fHbp-GNA2091 and NadA) are produced in Escherichia 
coli by recombinant DNA technology, while Outer Membrane Vesicles 
(expressing Porin A and Porin B proteins) are produced by fermentation 
of Neisseria meningitidis strain NZ98/254. The three rMenB antigens and 
OMV are formulated in a four component vaccine, named 4CMenB 
(Bexsero, GSK), where all these active components are adsorbed on 
aluminium hydroxide and the unadsorbed antigens content is a product 
critical quality attribute. Bexsero vaccine is the first MenB vaccine based 
on recombinant proteins able to elicit a robust bactericidal immune 
response in adults, adolescents and infants against a broad range of 
isolated serogroup B [82]. Bexsero has been recently licensed for use in 
Europe, US and elsewhere [86] [87] [88].  
A schematic representation of the Bexsero vaccine antigens on the 
surface of Neisseria meningitis is provided in Figure 17. The different 
bacterial compartments (outer membrane, periplasmic space, cytoplasmic 
membrane) and the main antigens identified through reverse vaccinology 
approach (NHBA, fHbp and NadA) are depicted. The representation of 
NHBA and fHbp in the picture is derived from the NMR structural data 
available and reported as cartoon. NadA is a model based on the 
structural homology with other members of the Oca family. Other 
components of the meningococcal membranes are also shown (pilus, 
polysaccharide capsule, lipooligosaccharide and integral inner and outer 
membrane proteins) [82]. 
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Figure 17: schematic representation of the Bexsero antigens on the surface of 
N. meningitidis [82]. 
The structure of the recombinant antigens in the Bexsero vaccine are well 
characterized by spectroscopy techniques (NMR, X-Ray, etc...) and 
several publications are available for a deep understanding of the vaccine 
components [82] [89] [90] [91] [92] [93] [94] [95]. A schematic 
representation of the Bexsero vaccine formulation is following provided by 
Figure 18. The image shows the main antigens identified through Reverse 
Vaccinology approach (NHBA, fHbp and NadA) on the left and the OMV 
on the right [89]. 
 
Figure 18: schematic representation of the Bexsero vaccine formulation [89]. 
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Chapter 3: Analytical QbD 
The application of Analytical Quality by Design (AQbD) to methods for testing 
vaccines is the core scope of the present experimental thesis study, in order 
to build quality into the assay during its development. The objective should 
be achieved by controlling method performances within predefined 
boundaries that ensure quality expectations are met. AQbD approach 
represents an useful tool to understand and develop the assay quality from 
the early method development stages, without waiting the final performance 
verification by method qualification and validation activities. The knowledge 
expected from this methodology provides several advantages, in terms of 
data confidence, method robustness and, additionally, in terms of assay 
failure probability evaluation. The application of AQbD approach during 
development contributes to decrease the probabilities of faults both during 
the validation and the routine use, with time and costs saving. 
In 2004, the US Food and Drug Administration outlined a new science- and 
risk-based approach that encourages manufacturers to develop robust 
processes and appropriate control strategies, thus supporting continuous 
improvement and product quality [96]. Over the years this approach has been 
evolved by the regulatory authorities and the pharmaceutical industry to 
establish a core concept called Quality by Design (QbD), now formally 
recommended and supported by International Conference on Harmonisation 
(ICH) guidelines [2] [3] [4] [5]. The ICHQ8(R2) guidance defines QbD as  
“a systematic approach to development that begins with predefined 
objectives and emphasizes product and process understanding and process 
control, based on sound science and quality risk management” [2].  So far, in 
the field of vaccine production, QbD principles have been mainly applied to 
accelerate process development to manufacture a vaccine candidate at 
commercial scale [97]. 
Many of the concepts associated with QbD for the product and the 
manufacturing process can be as well considered in the analytical method 
development [7] [98] [99]. The analytical control strategy for vaccine 
development starts from the definition of the Critical Quality Attributes 
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(CQAs) of the vaccine, namely the characteristics of the product that could 
affect the safety and the efficacy of the vaccine. However, as the CQAs may 
not yet be known in the early development stage, a risk-based approach 
should be followed in developing the control strategy [100]. The starting point 
of the AQbD method development is the Analytical Target Profile (ATP). For 
each product attribute to be tested, a specific ATP should be generated and 
formalized in order to define (I) the intended purpose of the assay 
measurement, (II) the Critical Method Attributes (CMAs) to be measured to 
ensure the assay performance and (III) the confidence and quality level with 
which we want to control the CMAs. Hence, starting from the ATP, AQbD 
emphasizes the need to thoroughly understand the candidate analytical 
system by an in-depth understanding of Critical Method Parameters (CMPs) 
based on risk assessment tools and experimental multivariate studies for 
managing the risk of failure [52] [101]. Such AQbD framework leads to the 
definition of the analytical design space, also known as Method Operable 
Design Region (MODR). MODR is the core of the AQbD approach. Adapting 
the ICHQ8(R2) definition set for the “process design space”, MODR could be 
defined as the multidimensional region of successful operating combinations 
and interactions of CMPs (method input variables), which lead to desired 
values for critical method attributes (CMAs), providing assurance of method 
quality [2] [7]. The MODR represents a step up for building the method life 
cycle and control strategy, since ensures the intended performance and the 
quality of the method. MODR prevents the generation of inaccurate results 
and help to identify the method failure modes. The concept of failure 
probability is the added value of the AQbD approach on pharmaceutical 
method development. AQbD systematically investigates CMPs leading to an 
increased knowledge of their effects on the CMAs and establish a reduced 
variability by controlling assay conditions and risks [98]. Additional 
advantages, due to MODR knowledge, are related to regulatory flexibility 
since supports that [102]: modifications of operative conditions within the 
MODR are not considered method changes. 
The conceptual AQbD flowchart that has been proposed and adapted in the 
present thesis work is reported in Figure 19. A parallelism between 
application of QbD for process and AQbD is also described in Table 5. 
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Figure 19: AQbD flowchart [7] 
Recent examples of AQbD applications to pharmaceutical field, mainly 
concerning the development of separation methods, adapting a similar 
flowchart are reported in literature for HPLC [103] [104] [105], UHPLC [106] 
[107], hydrophilic interaction liquid chromatography [108], supercritical fluid 
chromatography [109], capillary zone electrophoresis [110] [111] [112] [113], 
micellar electrokinetic chromatography [114] [115] [116] and microemulsion 
electrokinetic chromatography [117] [118]. 
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Table 5: Process and analytical QbD comparison [98]. 
ATP 
In the AQbD context the upfront definition of the desired method 
performance, by formalization of the Analytical Target Profile (ATP), is 
crucial. Independently by the assay that will be chosen by screening of 
different candidate technologies to approach the method development,  
it is necessary to define the requirements of the measurement itself. The 
ATP includes, beyond a tight definition of what has to be measured, a set 
of criteria that define the target assay performance in terms of accuracy, 
precision, range, specificity, etc. ATP requirements are defined in 
consideration of the context and objective of the test, in order to ensure 
that an assay will be able to appropriately measure the product attribute. 
In other words, the ATP defines the critical method attributes (CMAs) and 
the respective acceptance ranges / limits, including the associated 
confidence levels (probabilistic confidence that method actually ensure 
those acceptance criteria).  
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However, for the analytical scientist approaching the method 
development, it may be important to define surrogate attributes for the 
assay that will be developed. Similar concepts concerning CMAs 
surrogate measurements and reportable values are introduced also by 
USP chapter <1220> [119]. 
The definition of the desirability values and acceptance ranges for the 
method requirements is crucial to lead the definition of the final analytical 
design space, by impacting the desirability function for response surface 
methodology. Furthermore, the ATP should represent the key mechanism 
for the prioritization between method responses, avoiding different degree 
of subjectivity. Hence, ATP gives robustness to decision making process. 
The ATP should be drafted as soon as possible in the method 
development life-cycle, as a life document for guiding method evolution, 
amended as the method requirements evolve in line with improvements in 
product knowledge or in manufacturing process development. In parallel 
with ATP (that is focus on method performance related to the quality of 
the data) practical and feasibility requirements (focus on method 
applicability at the final lab, e.g. throughput, time / costs, simplicity, 
expected percentage of invalid test, etc...) should be also defined. 
Depending on the method scope (e.g. release, stability, characterization, 
in-process control) the practical and feasibility requirements can be 
crucial for driving method selection and assay development. 
Method Scouting 
Starting from ATP and keeping also in consideration the feasibility 
requirements, as appropriate, the method scouting is the next step to 
approach the development for a CQA measure and control. The method 
selection process begins with an evaluation of all the possible assays 
potentially applicable to the measurement, identified on the base of 
previous experiences and the literature data. After an appropriate 
scouting to identify the most promising methods among the previously 
listed analytical technologies, an experimental screening has to be 
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executed to preliminarily verify the candidate methods performance vs. 
the criteria set for predefined critical method attributes. 
Different approaches can be applied for screening phase to identify 
method/s potentially suitable for the intended use. One-factor-at-time 
(OFAT) or more structured experimental designs (DoEs) could be 
employed. Both method performance (ATP requirements) and feasibility 
criteria have to be considered to lead the method selection. During the 
product life cycle, the same assay could be screened several times to 
verify its fitting for purpose in different project phases and contemporary 
with respect to technological innovations; allowing the identification of 
technological innovations and their implementation. 
The technical innovations help the analytical scientist to optimize the 
methods screening phase. High-throughput and automatized instruments 
facilitate the simultaneous testing of multiple technologies. 
Risk Assessment 
Risk assessment (RA) is the first stage of a risk management process, as 
defined in ICHQ9 guideline [3] (Figure 20). The guidance defines the risk 
assessment as “A systematic process of organizing information to support 
a risk decision to be made within a risk management process. It consists 
of the identification of hazards and the analysis and evaluation of risks 
associated with exposure to those hazards” [3]. The concept is applicable 
to AQbD framework, where analytical methods hazards correspond to 
“unreliable results” [98]. 
The risk assessment goal is to identify, analyse and evaluate the method 
factors with respect to a potential impact on the measurement, by 
theoretical evaluations based on experience, literature and previous 
knowledge to finally provide a list of potential critical method parameters 
(pCMPs). Criticality will be then confirmed (or not) by appropriate 
experimental activities (see next section). By the risk assessment 
exercise, the initial list of parameters related to the method and which can 
affect CMAs can be quite extensive. The parameters list can be 
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significantly and confidently reduced, by using the proper risk assessment 
tools [4], for example Ishikawa diagrams (aka fishbone), cause and effect 
matrix (C&E), process map, failure mode effects analysis (FMEA) and 
many others.  
 
Figure 20: typical quality risk management process [3] 
In the present thesis work combinations of fishbone diagram, process 
map and C&E matrix tools has been selected for the risk assessment 
exercise (identification, analysis and evaluation of risks / impacts). The 
fishbone diagram is helpful to identify, list and cluster all the method 
parameters. The design of a process map could be useful to brainstorm 
the method. The C&E matrix is powerful for ranking the impact of each 
method parameter and identifying the potentially critical (pCMPs) to be 
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studied by experimental design. Practical examples of those tools have 
been provided in the chapter 4. 
Knowledge Space by DoEs 
After the theoretical exercise of risk assessment, the method quality risk 
control continues with the screening experimentation to evaluate the 
criticality of the identified potentially critical method parameters. 
Screening studies, by means of DoE-effect analysis (see the example 
Figure 8), can be used to evaluate the effect of the higher-ranked method 
parameters (pCMPs) and to finally establish the factors that have a 
greater effect on CMAs and / or their surrogates. The objective of the 
screening phase is to identify the most important pCMPs (the most 
impacting, expected to be a limited number) with respect to method 
parameters that have not or small impact. Thus allows the identification of 
the pCMPs that will be later studied in detail by Response Surface 
Methodology (RSM). A first assessment of the method performance and 
factors criticality is obtained at this step. 
The ideal approach for screening is to perform a minimum number of 
experiments on a maximum number of factors to build knowledge about 
the method, by determining cause-effect relationships between pCMPs 
and CMAs, including factors interactions. DoE approaches yield three 
major advantages over OFAT: (I) the total number of runs is typically 
smaller and (II) the statistical power (i.e. the ability of detecting significant 
effects) of the study is higher, (III) information about factor interactions is 
also obtained. Nevertheless, OFAT studies can also be used in 
appropriate cases, for example when no method parameters interactions 
are supposed, or when it is practically unfeasible to combine different 
levels for different parameters. 
The design region explored by DoEs (ranges studied for each parameter) 
should be as broader as possible, compatibly with the assay feasibility, 
applicability and previous experiences on similar assays. The 
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experimental region investigated by DoE, is so called knowledge space 
(KS). 
Screening designs are also applicable to discontinuous parameters, e.g. 
column, buffer and solvent choice. As deeply discussed on experimental 
design chapter, Screening DoEs generally involve testing of only two 
levels of the parameters under study (i.e. a low and an high values) and 
should always include several repeats of a central condition (also called 
“centre point”, chosen as reference conditions), run  in order to obtain a 
first estimate of the residual noise. 
RSM for MODR 
As the influence of the method parameters onto the CMAs has been 
qualitatively understood by the screening study performed to identify the 
CMPs, the method development proceeds with the definition of the 
analytical design space (MODR: Method Operable Design Region), that is 
the core of the AQbD approach. Such multi-dimensional space defines 
the combination of the method parameters within which the method 
requirements are satisfied, with predefined confidence, to ensure the 
desired method performance and the data quality. The design space 
boundaries are the so-called edges of failure, outside which the method 
performances are not acceptable. This approach supports the idea that 
the analytical method should not be designed (and potentially qualified) in 
one fixed condition, but verified under a range of conditions around the 
set point. In this context, any method deviations or modifications occurring 
within the design space, where the method performance and robustness 
are ensured, should not consider “method changes”. Hence allows 
regulatory advantages and flexibility. 
Usually, the MODR can be identified using an optimization DoE (also 
called response surface methodology). RSM models explore the 
relationships between CMPs and one or more method responses (an 
attribute or a surrogate). The purpose of the RSM is to obtain 
experimental knowledge on responses for an appropriate set of 
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multivariate conditions of method parameters to predict the responses 
over the whole experimental domain. 
With respect to the space investigated by screening DoE, generally the 
space to be considered for establishing the MODR can be restricted 
around the best performing sub-region previously identified. All the 
predefined method requirements need to be satisfied within the MODR. 
For this purpose, the most useful approaches in elaborating the 
experimental data to identify a combined design space are response 
overlay and desirability functions, taking also into account the uncertainty 
of the RSMs predictions (e.g. via tolerance intervals). The uncertainty cut-
off must also be defined in order to ensure the desired confidence of the 
identified design space. Monte-Carlo simulations of the propagation of the 
model’s predictive errors (as it has been applied in the present thesis 
work), or alternative Bayesian approaches, may be considered for 
estimating the risk of not meeting the requirements. 
The analytical design space can be mathematically represented by 
equations describing the effects of method parameters on the response. 
[2] (e.g. by Equation 7 for multi-linear regression models). In the real 
analytical development, multiple CMAs and other responses are 
controlled at the same time and the mathematical model could be 
relatively complex and difficult to be interpreted from a physical 
perspective. For the analyst scientist it is more practical and easier to 
present the MODR graphically by using a probabilistic surface plot, such 
as shown in the example Figure 21. The surface plot makes an immediate 
visualization of the design hyper-space and the possible combination of 
method parameters (CMPs) able to satisfy the ATP requirements. i.e. to 
provide quality for data with the required confidence level. In the example, 
the green area represents to the MODR for CMP1 and CMP2 with a 
confidence level of 95% (the probability of failure allowed is lower or equal 
to 5%). 
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Figure 21: graphical presentation of MODR by probabilistic surface plot 
The RSM study provides also the opportunity to refine the criticality 
assessment for each parameter under study. Namely, the criticality level 
is finally estimated by the response surface model for MODR, through the 
evaluation of effects and interactions of method parameters on 
responses. 
Although the MODR is in principle expected as a curve space, from 
practical point of view, MODR is conveniently expressed as a set of 
ranges, one range for each CMP. For the MODR definition (I) the method 
performance (based on ATP criteria) is a “must do” requirement. 
However, we need to also consider other important factors such as (II) 
analytical feasibility and practicability considerations, (III) assay needs 
and peculiarities and (IV) robustness and controllability of the method 
parameters, to finally restrict MODR to a more practical space. 
All the points within the MODR hyperspace represent potential acceptable 
working conditions. However, definition of a set point for describing the 
assay standard operative conditions has to be defined for routine use. 
The selection of the optimal set point conditions, and the surrounding 
control space in which the method should be operated during routine 
application, can be based on: 
- desirability function (possibly weighing different responses); 
- multiple response regression models (taking into account the 
correlation between CMAs); 
- practical considerations (e.g. robustness indicated by plateau in 
response surface); 
CMP2 
C
M
P
1 
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- feasibility considerations (e.g. feasibility for preparations, costs, toxicity 
of materials, et...) 
- analytical requirements for routine use (e.g. high-throughput and/or 
time of analysis for in-process test, etc...); 
- failure probability (e.g. low risk of failure for the prediction model). 
Model Confirmation & Robustness 
The statistical models used to drive the MODR should be experimentally 
validated by executing a subset of runs through the identified analytical 
design space. 
In order to validate the RSM model, the MODR predictions are verified by 
testing the boundary ranges of the identified hyperspace, since the risk of 
failure of the response surface prediction model is higher at the edges of 
the space. It is a good rule to also include an experimental verification of 
the selected working point (candidate set point for routine use). The 
verification of the MODR can be achieved by a new designing for testing 
different multivariate conditions respect to conditions tested by 
Optimization DoE. The MODR is so confirmed by comparing the 
verification data (experimentally obtained) with the design space model 
predicted data. 
The analytical design space itself can be considered as a theoretical 
robust area, since within MODR variation of the factors condition does not 
significantly influence the quality of the method [99] [120] [121]. 
Robustness is an integral part of development, contrarily to past 
traditional OFAT approach, where robustness testing was performed at 
the end of the development process (during the assay validation) with a 
higher risk of failure. Therefore, the final step of the AQbD approach is the 
verification of the method robustness within the MODR boundaries. The 
DoE robustness test is not redundant, but it is still necessary to verify if 
the chosen factor ranges are suitable and could be applied as control 
space for the assay routine use. The robustness DoE makes possible to 
identify the so called control space, a robust and controlled space within 
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the design space where the analytical performance is not affect by the 
method factors variation. An example of robustness by DoE-effect 
analysis has been provided on previous Figure 9. Thus, the control space 
boundaries should be moved inside the design space to accommodate 
robustness and optimize the operating space. As discussed in chapter 1, 
Plackett-Burman design has become particularly popular for the 
robustness tests and with the same experimental design it is possible to 
perform also the confirmation / validation of the design space model. 
Control Strategy & Life Cycle 
System suitability testing (SST) is an integral part of analytical 
procedures. System suitability parameters to be established for a 
particular procedure depend on the type of procedure being validated. For 
chromatographic analysis, USP <621> [122] and European 
Pharmacopoeia (EP) chapter 2.2.41 [123] have both specified 
requirements for SST to demonstrate that a chromatograph is fit for the 
analysis. System suitability are run each time an analysis is undertaken 
and each SST is specific for an individual method with pre-defined 
acceptance criteria (e.g. precision, peak shape, resolutions, and many 
others parameters on the base of assay peculiarities). 
Definition of a SST and the related acceptance criteria is the first step to 
design an adequate control strategy for routinely applying the developed 
method. The responses obtained from the worst-case results of the 
robustness DoE can be used to determine the SST limits. The SST 
ensures the confidence of the method results only in case the method has 
been demonstrated robust. For a long term control strategy, the SST 
supports the monitor of the method performance. A control strategy based 
on SST needs to be completed and consolidated during the method life 
cycle through a strategic Continued Procedure Performance Verification, 
to ensure that the method performance (quality of the data produced by 
the assay) and the control of critical method parameters still remain under 
control during the method life cycle [98].  
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Chapter 4: Experimental activities 
In the present thesis study, the quality by design approach was applied to 
design analytical methods aimed to the quality control of a vaccine product. 
The scope of this research work is the implementation and application of 
QbD principles to analytical method screening and development for vaccines 
analysis. It is the first time in literature that AQbD is applied to a vaccine 
product. Bexsero is the vaccine chosen for the analytical researches as 
application of AQbD framework. 
AQbD principles were applied to development of new UHPLC methods for 
the control of the Bexsero vaccine CQAs. Three different analytical 
applications were investigated to improve the analytical control strategy of 
Bexsero and identify new methods potentially applicable for: 
1) Not adsorbed antigen content determination by RP-UHPLC; 
2) rMenB quantification assay by Amino Acid Analysis (A.A.A); 
3) OMV protein pattern analysis by RP-UHPLC. 
The AQbD quality risk management framework, used for the three analytical 
methods, builds adequate method knowledge to ensure regulatory flexibility 
during lifecycle, as well as method robustness and safety for product quality 
control. 
RP-UHPLC Adsorption percentage 
A fundamental critical quality attribute of Bexsero vaccine is the unadsorbed 
antigens content. The actual method used for unadsorbed antigens 
determination in the commercial vaccine product is a sodium dodecyl 
sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) test. Following 
the analytical target profile requirements, the AQbD framework was applied 
increasing the assays throughput by reducing the manual operations, 
improving selectivity and sensitivity with respect to the current SDS-PAGE 
assay used to control the above CQA.  
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 Chemicals and reagents 
For the development of the chromatographic method a mock standard 
solution was used. The mock solution was a mixture with the same 
composition of antigens and excipients of the vaccine product, apart from the 
aluminium hydroxide adsorbent which was removed for analytical needs and 
apart from the addition of 0.15% (p/v) Zwittergent 3-14 detergent. The mock 
solution was used as calibration for the analysis and its composition enabled 
the target concentration range to be achieved. The drug substances used for 
mock formulation were produced by GSK group of companies (Siena, Italy). 
L-histidine ≥ 99% (ReagentPlus grade), trifluoroacetic acid (TFA) ≥ 99% 
(LCMS & HPLC grade), methanol (CH3OH) ≥ 99.9% (HPLC grade), tween 80 
(cell Biology grade) and sucrose (C12H22O11) ≥ 99.5% (BioUltra grade) were 
purchased by Sigma-Aldrich (Saint Louis, MO, USA). Sodium chloride (NaCl) 
99.99% (Suprapur grade), potassium di-hydrogen phosphate (KH2PO4, 
EMSURE ISO grade), Hydrochloric acid fuming (HCl) 37% (ACS ISO 
Reag.Ph.Eur. grade), Potassium hydroxide (KOH) 45% w/w solution 
(Reagent grade) and Zwittergent 3-14 detergent (EMSURE ISO grade) were 
purchased by Merck KGaA (Darmstadt, Germany). Acetonitrile (ACN) 99.8% 
(LC-MS grade) was purchased by Panreac (Radnor, PA, USA). Ultrapure 
water was produced by Millipore Milli-Q system (Billerica, MA, USA) and 
filtered on a nylon membrane of 0.22 µm porosity using Nalgene clepsydra 
filters (Nalgene, Rochester, NY, USA). 
Solutions and sample preparation 
The L-Histidine buffers and the phosphate buffers were adjusted to the 
proper pH by adding HCl and KOH solutions, respectively. A 5% Zwittergent 
3-14 detergent solution was prepared in pH 6.5 phosphate buffer 1M. 
The mock standard solutions were prepared each day by dilution of the 
proper volumes of the drug substance bulks (each aliquot of rMenB proteins 
stored at -20°C and of OMV sample stored at 4-8°C) in 200 mM L-Histidine 
pH 6.3 buffer plus 90 mg ml-1 NaCl and 5% (p/v) sucrose solutions up to 100 
μg ml-1 rMenB proteins and 50 μg ml-1 OMV sample. The working solutions 
were obtained by diluting the samples to the final concentration of 10 µg ml-1 
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rMenB proteins and 5 μg ml-1 OMV sample, maintaining the same matrix 
composition, with 0.15% (p/v) Zwittergent 3-14 detergent in pH 6.5 
phosphate buffer 1M, added for the analytical purpose of applying the 
UHPLC procedure also to the antigen content determination. The working 
solutions were stored at 4-8°C before the analysis. The samples were stored 
in the autosampler using three different vials type: Clear Glass Total 
Recovery (Waters Corp., Milford, MA, USA), LCMS Certified Total Recovery 
vials (Waters Corp., Milford, MA, USA) and Polypropylene Total Recovery 
vials (Thermo Fisher Scientific, Waltham, MA, USA). 
For mobile phase preparation, 500 µl of TFA ≥ 99% were diluted up to 500 ml 
ultrapure water to obtain a 0.1% (v/v) TFA aqueous solution and 500 µl of 
TFA ≥ 99% were added to 450 ml of ACN plus 49.5 ml of ultrapure water to 
prepare a 0.1% (v/v) TFA and 90% (v/v) ACN organic phase. All buffers and 
solutions were filtered by a nylon membrane of 0.22 µm porosity using 
Nalgene filters (Nalgene). 
Chromatographic equipment and analysis 
Different chromatographic columns were screened: Acquity RP-C4 BEH 
300Å, 1.7µm, 2.1x150 mm (C4pore) and Acquity UHPLC BEH 130Å C8, 
1.7µm, 2.1x150 mm (C8pore) from Waters Corp. (Milford, MA, USA) and 
Aeris WIDEPORE C4 200Å, 3.6 µm, 4.6x150 mm (C4shell) from 
Phenomenex (Torrance, CA, USA) [124]. 
For the method screening the NexeraX2 method scouting UHPLC series 30 
system was used, equipped with LC-30AD pump, DGU-20A5R degasser unit 
and LPGE-unit, SIL-30AD autosampler, CTO-20AC oven with 180 µl mixer 
and FCV-34AH UHPLC switching valve, SPD-M30A PDA detector with high 
sensitive flow-cell (85 mm; 9 µl) from Shimadzu Corp. (Kyoto, Japan). For 
response surface methodology (RSM) the Acquity H-Class Bio UHPLC 
system (Waters Corp.) was used, equipped with bio-Quaternary Solvent 
Manager (bioQSM) with 100 µl mixer, bio-Sample Manager (bioSM-FTN) 
with 15 µl injector needle and 50 µl extension loop, column oven CH-A with 
pre-heater and photodiode array detector (ACQ-PDA) with analytical flow-cell 
(10 mm; 500 nL). The detection wavelength was 210 nm. Sample injections 
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were done by 30 µl of the working solution stored in the autosampler at  
4-8°C. A new column was conditioned with the mobile phase for 60 min 
before starting the analysis. After the analysis the column was stored in pure 
ACN filtered on 0.22 µm nylon membrane. 
The optimal separation of the antigens was achieved using the C4pore 
column. The working conditions (with the interval corresponding to the 
MODR) were as follows: starting organic phase concentration, 33.0% (32.0-
34.6%) (%v/v); ramp time, 4.0 min (4.0-5.6 min) to 75% (v/v) organic phase 
final concentration; column temperature, 60°C (60-68°C). After each injection 
the column was washed with 90% of ACN for one minute and equilibrated for 
3 min in the starting conditions. 
Calculations and software 
The chromatographic resolutions (R) between two adjacent peaks were 
calculated using the retention times (tR) and the peak widths at half height 
(w), according to the following formula: 
1.18 (tR2 - tR1) / (w1+w2). 
The capacity factor (K’) of NHBA-GNA1030 antigen, measurement of the 
retention time relative to column void volume (V0), was calculated 
according to the formula: 
K’= (tR - Vo) / Vo. 
LabSolution Version 5 software equipped with Method Scouting start-up 
kit and licensed by Shimadzu Corp. [125] was used for the NexeraX2 
UHPLC instrument control and for the chromatographic data computation 
in the screening phase. Empower3 software [126] licensed by Waters 
Corp. was used for the Acquity H-Class Bio UHPLC instrument control 
and for the chromatographic data computation in RSM. 
Nemrod-W software [127] was used to generate the two asymmetric 
screening matrices used for investigating the knowledge space and the 
two Full Factorial Designs used for selecting the verification points at the 
edges of the design space and for testing robustness. MODDE software 
[128] was purchased from S-IN (Vicenza, Italy) and was employed to 
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generate the Central Composite circumscribed design (CCD) used for 
RSM, to perform data analysis and to find the design space by means of 
risk failure maps calculated using the Monte-Carlo simulations. The runs 
of all the DoE plans were carried out in a randomized order. 
Method development and results 
The method development followed the systematic approach of AQbD 
workflow for separation methods [7], involving the following steps:  
I) Analytical target profile definition, method scouting and definition of the 
CMAs;  
II) Quality risk assessment and identification of potential CMPs;  
III) Investigation of knowledge space by screening DoE;  
IV) RSM and definition of MODR;  
V) Working point definition and robustness testing; 
VI) Method control. 
Analytical target profile, method scouting and critical method 
attributes 
The analytical target profile is the intended purpose of the method and is 
defined by the selection of the analytes and of the analytical 
performances to be achieved [128] [129]. In this study, it consisted in 
obtaining the accurate quantitation of the five proteins NHBA-GNA1030, 
fHbp-GNA2091, NadA, PorA and PorB. Moreover, general validation 
requirements according to ICHQ2(R1) guideline [129] [130] had to be 
fulfilled, including an adequate selectivity and sensitivity, which 
corresponded in obtaining baseline resolution of the peaks and adequate 
peak areas, to be able to monitor the unadsorbed antigens content 
identified as a product CQA. 
In order to reach this target, different preliminary aspects had to be 
considered. First, scouting of different UHPLC operative modes for 
obtaining the separation of the five antigens in the vaccine was 
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performed. Prior knowledge and experimental studies led to choose 
reverse phase UHPLC (RP-UHPLC) as analytical technique for method 
development. Different RP-UHPLC operative modes were tuned and 
screened by the NexeraX2 method scouting system, operating at 60°C 
and changing type of organic phase (mixtures of ACN/TFA or 
methanol/TFA), organic ramp (%/min), starting concentration (from 30% 
to 40%) and ending concentration (from 75% to 100%) of the organic 
phase. The aim was to approach to the experimental conditions leading to 
good selectivity and fast analysis. The best results were achieved using 
an organic mixture of 90/0.1/9.9 ACN:TFA:H2O (v/v) as organic phase 
and a 4 minutes gradient from 34% to 75% of organic phase. These 
conditions constituted the starting point for further in-depth optimization by 
DoE. In these conditions, the retention order of the peaks was the 
following: NHBA-GNA1030, PorB, PorA, fHbp-GNA2091, NadA. 
The second aspect was the definition of the surfactant needed for the 
analysis, which was based on prior knowledge of antigens desorbing from 
aluminium hydroxide and on preliminary experimental runs. Different 
surfactants were tested, i.e. Tween 80 and Zwittergent 3-14 detergents in 
phosphate buffers. The selected surfactant was 0.15% (p/v) Zwittergent 
3-14, since it made it possible to maintain consistent over time the 
chromatographic area of the proteins in the mock solution without 
aluminium hydroxide. 
The selected CMAs, reported in Table 6, were the resolution values 
between the peak pairs, named as R1 (NHBA-GNA1030/PorB), R2 
(PorB/PorA), R3 (PorA/fHbp-GNA2091), R4 (fHbp-GNA2091/NadA), the 
peak areas A1 (NHBA-GNA1030), AB (PorB), AA (PorA), A2 (fHbp-
GNA2091), A3 (NadA), and NHBA-GNA1030 capacity factor K’, 
considered in the RSM for controlling the elution of the first antigen peak 
with respect to column void volume. 
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Abbreviation CMA CMA requirement 
K’ NHBA-GNA1030 capacity factor 1.5≤K’≤3 
R1 NHBA-GNA1030/PorB resolution ≥1.5 
R2 PorB/PorA resolution ≥1.5 
R3 PorA/fHbp-GNA2091 resolution ≥1.5 
R4 fHbp-GNA2091/NadA resolution ≥1.5 
A1 NHBA-GNA1030 area ≥6x105 µV s 
AB PorB area  ≥8x104 µV s 
AA PorA area ≥5x104 µV s 
A2 fHbp-GNA2091 area ≥8x105 µV s 
A3 NadA area ≥5x105 µV s 
Table 6: RP-UHPLC critical method attributes and selected requirements 
Risk assessment and potential critical method parameters 
The objective of a risk assessment is to develop understanding of 
procedure variables and their impact on the method reportable values for 
the identification of hazards and the analysis and evaluation of risks 
associated with exposure to those hazards [119] [131]. Tools such as 
process maps and fishbone diagrams may be used, in addition to prior 
knowledge, to provide structure to a brainstorming and information-
gathering exercise to identify pCMPs [119]. In this study, a fishbone 
diagram (Figure 22) was used to formalize the risk assessment and point 
out the risk factors associated with the characteristics of the RP-UHPLC 
analysis and thus to highlight the potential CMPs which were supposed to 
potentially affect the selected CMAs. Some of the CMPs, including 
detector type and settings, sample surfactant, ion pair type and 
autosampler temperature, had been already studied and fixed by 
preliminary experiments and scouting tests. Other pCMPs, underscored 
and with grey background in Figure 22, needed to be risk managed and 
in-depth studied by DoE to enhance knowledge on their effects on 
method performances. 
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Figure 22: Fishbone diagram for RP-UHPLC method risk assessment. 
Screening experimental designs 
As a result of RP-UHPLC scouting and risk assessment, the selected 
pCMPs to be investigated by DoE were represented by vial type (VIAL), 
sample concentration (CONC), injection volume (INJ), column type 
(COL), starting organic phase concentration  (ACN%), elution ramp time 
(RAMP) and column temperature (T). 
The first screening study involved the investigation of the effects of VIAL 
and CONC for optimizing sample preparation, with the aim of reaching 
adequate sensitivity before starting the optimization of the RP-UHPLC 
method conditions. The considered CMAs were the peak areas of the five 
antigens A1, AB, AA, A2, A3. The vial type was studied at 3 levels (Clear 
Glass Total Recovery vial, Polypropylene Total Recovery vial and LCMS 
Certified Total Recovery vial). Sample concentration was examined at 4 
levels (1-4-10-20 μg ml-1) in order to evaluate the possibility of 
aggregation and/or aspecific absorption of antigens on vials walls. The 
injection volume was adapted to inject, at each different sample 
concentration, the same amount of sample in column. 
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Nemrod-W software [127] was employed to generate the asymmetric 
screening matrix used to estimate the coefficients of the following Free-
Wilson model with interactions [52]: 
Y=b0+b1A(X1A)+b1B(X1B)+b2A(X2A)+b2B(X2B)+b2C(X2C)+b1A2A(X1AX2A)+b1A2B
(X1AX2B)+b1A2C(X1AX2C)+b1B2A(X1BX2A)+b1B2B(X1BX2B)+b1B2C(X1BX2C) 
where X1 is VIAL and X2 is CONC, b0 is the constant term and bi are the 
linear and interaction coefficients. 
The model contains one constant term plus, for each factor, a number of 
terms equal to its number of levels minus one. The 12-run experimental 
plan (2131//12) is reported in Table 7. Each analysis was duplicated in 
order to obtain a reliable estimate of the experimental variance. 
The graphical plots describing the effects of changing the levels of the 
factors on antigens areas are shown in Figure 23, where A stands for the 
type of vial (A1, Clear Glass Total Recovery vial; A2, Polypropylene Total 
Recovery vial; A3, LCMS Certified Total Recovery vial) and B stands for 
level of sample concentration (B1, 1 μg ml-1; B2, 4 μg ml-1; B3, 10 μg ml-1; 
B4, 20 μg ml-1).  
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Exp. No VIAL[a] CONC 
(μg ml-1) 
A1 AB AA A2 A3 
1 CGTR 1 111548 15795 6969 106500 96167 
2 CGTR 1 103531 15496 6681 112164 94654 
3 PTR 1 112098 16092 7096 136009 96749 
4 PTR 1 112603 16047 6823 136327 98119 
5 LCTR 1 113487 15834 6998 96654 97152 
6 LCTR 1 107375 16255 7316 99655 97554 
7 CGTR 4 120501 16409 8255 120172 105465 
8 CGTR 4 116850 17062 8646 119865 105864 
9 PTR 4 119772 16986 7227 144156 106183 
10 PTR 4 118731 16606 7761 143789 105702 
11 LCTR 4 117253 16704 8181 114013 106466 
12 LCTR 4 114513 16579 8083 114136 105747 
13 CGTR 10 118815 17499 7837 130611 104159 
14 CGTR 10 117589 17263 7739 132962 103094 
15 PTR 10 119313 17011 7589 143451 103054 
16 PTR 10 118560 16416 7467 143023 104131 
17 LCTR 10 119206 16768 7353 129208 103752 
18 LCTR 10 119346 16942 7508 129389 103708 
19 CGTR 20 119720 16641 7380 133652 100225 
20 CGTR 20 118017 17035 7507 136242 101005 
21 PTR 20 118058 17152 7236 141458 100299 
22 PTR 20 116870 16683 7332 141455 100198 
23 LCTR 20 117089 17337 7408 135222 101717 
24 LCTR 20 118369 16930 7312 134535 100791 
Table 7: Asymmetric screening matrix for sample preparation with two replicates 
for each run. 
[a]CGTR, Clear Glass Total Recovery vial; PTR, Polypropylene Total Recovery vial; LCTR, LCMS 
Certified Total Recovery vial. 
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Figure 23: Graphic analysis of effects of VIAL and CONC on chromatographic 
area responses 
(a) A1, NHBA-GNA1030; (b) AB, PorB; (c) AA, PorA; (d) A2, fHbp-GNA2091; (e) A3, NadA. A1, 
A2 and A3 indicate the different levels of vial type (A1, Clear Glass Total Recovery vial; A2, 
Polypropylene Total Recovery vial; A3, LCMS Certified Total Recovery vial), while B1, B2, B3, 
B4 indicate the different levels of sample concentration (B1, 1 μg ml-1; B2, 4 μg ml-1; B3, 10 μg 
ml-1; B4, 20 μg ml-1). 
The type of vial had a significant influence only on area responses of 
PorA and fHbp-GNA2091. The effects were opposite, as the use of Clear 
Glass Total Recovery vial slightly enhanced PorA area but reduced fHbp-
GNA2091 area. The use of Polypropylene Total Recovery vial had a 
negative effect on PorA area and an important positive effect on fHbp-
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GNA2091 area. Glass Total Recovery Silicone Coated vial caused the 
decrease of fHbp-GNA2091. As for the effects of CONC, in general a 
decrease of the areas was observed by using the lower concentration 
value. The maximization of the areas was obtained by using 4 μg ml-1 for 
PorA and NadA, 10 μg ml-1 for NHBA-GNA1030 and PorB, and 20 μg ml-1 
for fHbp-GNA2091. Some interactions were also noticed, evidencing in 
particular an important positive interaction between 1 µg ml-1 
concentration value and polypropylene vial on A2 (A2-B1) and other 
positive interactions involving AB (A1-B3) and A2 (A1-B2). Hence, the vial 
type selected was Polypropylene Total Recovery vial and sample 
concentration was fixed at 1 µg ml-1, taking into account the presence of 
the positive interaction A2-B1 for fHbp-GNA2091, the importance of 
quantitation of fHbp-GNA2091 antigen (a rMenB protein) with respect to 
the OMV PorA and PorB antigens, and the possibility to reach a lower 
range concentration required by analytical target profile in terms of 
sensitivity gain. 
Once the sample conditions were selected, the AQbD framework 
continued with the screening study of the chromatographic parameters 
INJ, COL, ACN%, RAMP and T. The following Free-Wilson model was 
postulated [52]: 
Y=b0+b1A(X1A)+b2A(X2A)+b2B(X2B)+b3A(X3A)+b3B(X3B)+b4A(X4A)+b4B(X4B)+b5
A(X5A)+b5B(X5B) 
where X1 is INJ, X2 is COL, X3 is ACN%, X4 is RAMP and X5 is T, b0 is the 
constant term and bi the linear coefficients of each factor. INJ was studied 
at two levels, while the other four factors were studied at three levels, as 
reported in Table 8. A new asymmetric screening matrix was designed for 
obtaining preliminary information throughout the knowledge space on the 
effects of the five selected factors on chromatographic CMAs, i.e. 
resolutions R1, R2, R3 and peak areas AB and AA. In this step R4 was 
excluded from the study, as it presented values above 2 in all the runs, 
while the other resolutions were critical. Only the OMV areas were taken 
into account because PorB and PorA present the lowest areas among the 
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 79 of 157 
 
five antigens peaks, also due to the lower concentration in the sample 
with respect to rMenB components. 
Critical method 
parameter 
Screening 
levels 
RSM 
experimental 
domain 
Design 
space 
limits 
 
Injection volume (INJ) 20-50 μl 30 μl 30 μl  
Column (COL) C4pore-C4shell-
C8pore 
C4pore C4pore  
Organic phase starting 
concentration (ACN%) 
24.0-29.0-34.0% 28.0-38.0% 32.0-34.6%  
Ramp time (RAMP) 2.0-4.0-6.0 min 3.0-6.0 min 4.0-5.6 min  
Temperature (T) 50-60-70 °C 50-70 °C 60-68 °C  
 Table 8: Experimental domain/optimized values for critical method parameters 
in the screening phase, in Response Surface Methodology, and in the 
definition of the design space. 
The screening asymmetric matrix used to estimate the model coefficients 
was made by 16 runs (2134//16), with three replicates for each experiment 
in order to obtain a reliable estimate of the experimental variance. Table 9 
reports the experimental matrix with the measured responses. The 
graphic analysis of effects made it possible to obtain two types of plots. 
The first type of plot, reported in Figure 24, shows the effects of the 
different levels of the factors on the responses, with the bar length 
proportional to the effects (a longer bar corresponds to a maximization of 
the response). The second type of plot, shown in Figure 25, shows the 
difference of the effects between the two considered levels, and the bars 
coloured in orange, exceeding the reference line, correspond to the pair 
of factors for which a change of level is significant on the response. 
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No. Exp. INJ 
(μL) 
COL[a] 
 
ACN% 
(% v/v) 
RAMP 
(min) 
T 
(°C) 
R1 
 
R2 
 
R3 
 
AB 
 
AA 
 
1 20 C4pore 24.0 2.0 50 0.46 0.76 1.43 74105 15775 
2 20 C4pore 24.0 2.0 50 0.51 0.82 1.43 72825 14619 
3 20 C4pore 24.0 2.0 50 0.76 1.20 1.60 56603 12740 
4 20 C4shell 29.0 4.0 60 0.98 n.m. n.m. n.m. n.m. 
5 20 C4shell 29.0 4.0 60 0.90 n.m. n.m. n.m. n.m. 
6 20 C4shell 29.0 4.0 60 0.74 n.m. n.m. n.m. n.m. 
7 20 C8pore 34.0 6.0 70 2.61 5.04 3.38 38037 10110 
8 20 C8pore 34.0 6.0 70 2.46 4.25 3.05 36104 11306 
9 20 C8pore 34.0 6.0 70 2.57 4.25 3.05 30549 36104 
10 20 C4pore 24.0 2.0 50 0.61 0.99 1.47 61427 17336 
11 20 C4pore 24.0 2.0 50 0.60 0.98 1.58 57619 12284 
12 20 C4pore 24.0 2.0 50 0.51 0.84 1.36 68829 17482 
13 50 C4pore 29.0 6.0 50 2.06 3.29 3.59 137639 47219 
14 50 C4pore 29.0 6.0 50 2.13 3.26 3.55 148624 45943 
15 50 C4pore 29.0 6.0 50 1.84 3.33 3.69 149765 41934 
16 50 C4shell 24.0 2.0 70 0.33 0.80 0.52 252144 72987 
17 50 C4shell 24.0 2.0 70 0.32 0.78 0.55 282327 60408 
18 50 C4shell 24.0 2.0 70 0.32 0.77 0.51 288066 62828 
19 50 C8pore 24.0 2.0 60 0.74 1.01 1.15 147498 30831 
20 50 C8pore 24.0 2.0 60 0.64 0.94 1.14 145162 33618 
21 50 C8pore 24.0 2.0 60 0.70 0.96 1.13 151450 36951 
22 50 C4pore 34.0 4.0 50 2.21 2.80 2.86 131703 49740 
23 50 C4pore 34.0 4.0 50 2.21 3.02 3.00 111981 46155 
24 50 C4pore 34.0 4.0 50 2.21 2.78 2.77 126437 47672 
25 20 C4pore 34.0 2.0 60 1.41 2.42 2.12 53342 13901 
26 20 C4pore 34.0 2.0 60 1.41 2.44 2.10 50820 13877 
27 20 C4pore 34.0 2.0 60 1.72 2.44 2.11 38824 13348 
28 20 C4shell 24.0 6.0 50 n.m. n.m. n.m. n.m. n.m. 
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29 20 C4shell 24.0 6.0 50 n.m. n.m. n.m. n.m. n.m. 
30 20 C4shell 24.0 6.0 50 n.m. n.m. n.m. n.m. n.m. 
31 20 C8pore 24.0 4.0 50 2.02 2.30 1.88 20868 11633 
32 20 C8pore 24.0 4.0 50 2.03 2.28 2.11 27053 12302 
33 20 C8pore 24.0 4.0 50 1.96 2.42 2.15 29004 13175 
34 20 C4pore 29.0 2.0 70 0.56 1.35 1.80 66099 11488 
35 20 C4pore 29.0 2.0 70 0.60 1.51 1.81 63891 12028 
36 20 C4pore 29.0 2.0 70 0.62 1.55 1.85 80214 11253 
37 50 C4pore 24.0 4.0 70 0.89 1.51 3.05 198604 37440 
38 50 C4pore 24.0 4.0 70 0.98 1.99 3.40 150100 33814 
39 50 C4pore 24.0 4.0 70 0.93 1.93 3.56 163760 4483 
40 50 C4shell 34.0 2.0 50 1.25 2.00 1.65 119055 23262 
41 50 C4shell 34.0 2.0 50 1.33 2.18 1.71 119690 19659 
42 50 C4shell 34.0 2.0 50 1.28 2.06 1.65 126697 24961 
43 50 C8pore 29.0 2.0 50 1.17 1.37 1.41 114977 25790 
44 50 C8pore 29.0 2.0 50 1.16 1.36 1.42 114421 24496 
45 50 C8pore 29.0 2.0 50 1.25 1.37 1.40 87813 18504 
46 50 C4pore 24.0 6.0 60 1.89 3.54 3.59 114771 35997 
47 50 C4pore 24.0 6.0 60 2.45 3.35 3.39 121570 41358 
48 50 C4pore 24.0 6.0 60 2.44 3.25 3.32 101252 42953 
Table 9: Screening of knowledge space: 16-run asymmetric screening matrix 
with three replicates for each run. 
n.m.: not measured; due to particular peak patterns, the result of the experiment was excluded 
from data treatment. 
[a] C4pore, Acquity RP-C4 BEH 300Å, 1.7µm, 2.1x150 mm; C4shell, AerisTM WIDEPORE C4 
200Å, 3.6 µm, 4.6x150 mm; C8pore, Acquity UPLC BEH 130Å C8, 1.7µm, 2.1x150 mm. 
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By examining the following plots, it was possible to select the optimal 
value for some CMPs and to decide which others should be further 
studied more deeply by RSM. As for injection volume, its change exerted 
a limited or no effect on resolution values, but the 50 μl value was 
definitely better for increasing both the areas, as expected. Hence, this 
factor was fixed at an intermediate value of 30 μl, in order to find a 
compromise between selectivity and sensitivity. As regards the column, 
C4pore was selected for further studies, since it gave the maximization of 
R3 value and led to good results also for the other responses, taking into 
account that in general this column is preferred for protein studies and for 
avoiding absorption. The highest level for ACN% led to maximize all the 
resolution values, while low-medium values were preferred for increasing 
area responses. Hence, the new domain to be investigated was moved 
towards the values 28.0-38.0%. When considering RAMP, the value of 6 
min led to the maximization of all the responses apart from AB, and it was 
decided to further study this CMP in the range 3-6 min, in the perspective 
of keeping low analysis time. As concerns T, in general it presented a 
lower influence on the CMAs with respect to the other CMPs, but it 
showed conflicting effects on the different responses, thus it was decided 
to continue to study this factor by RSM in the domain 50-70°C. 
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Figure 24: Graphic analysis of effects for investigation of chromatographic 
resolutions and area responses. 
Resolutions: (a)  R1, NHBA-GNA1030/PorB; (b)  R2, PorB/PorA; (c)  R3, PorA/fHbp-GNA2091. 
Areas: (d) AB, PorB; (e) AA, PorA. The length of each bar indicates the effect of the each level of 
each factor under study. 
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Figure 25: Graphic analysis of effects for resolution and area responses 
The length of each bar indicates the effects of changing level of the factors. Resolutions: (a) R1, 
NHBA-GNA1030/PorB; (b) R2, PorB/PorA; (c) R3, PorA/fHbp-GNA2091. Areas: (e) AB, PorB; 
(f) AA, PorA. 
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Response surface methodology and design space 
RSM was applied for in-depth investigations of the effects of ACN%, 
RAMP and T on the CMAs in the new experimental domain reported in 
Table 6. A three-factor circumscribed CCD, fractionating the experimental 
domain for each factor into 5 levels, was employed for building a 
quadratic model with interactions making it possible to study all the 
selected chromatographic CMAs, namely resolutions (R1, R2, R3, R4) and 
peak areas (A1, AA, AB, A2, A3) as above described. Additionally, NHBA-
GNA1030 capacity factor K’ was also considered among the CMAs in 
order to control the elution of the first antigen peak with respect to column 
void volume. As a matter of facts, from screening DoE it was observed 
that high organic phase starting concentration values anticipate the 
chromatographic pattern of the antigens. 
The 15-run CCD experimental plan with the measured responses is 
reported in Table 10, where each condition was twice replicated, including 
a central point. The responses R1 and AB were respectively reverse (Y-1) 
and logarithmic (Log10Y) transformed to stabilize the variance and makes 
the data more normal distributed-like. The others CMA models were 
obtained without mathematical transformation. All the ten models, 
calculated by multiple-linear regression, were significant in terms of 
ANOVA, and in general the goodness of fitting (expressed by 
determination coefficient R2) and of prediction (expressed as cross 
validated Q2) were good, as reported in bottom Table 11. Only for AA, A2 
and A3 low Q2 coefficients were obtained, but in these cases the validity of 
the models was satisfactory (lack of fit p > 0.050). 
Hence, contour plots were drawn reporting the calculated isoresponse 
curves, in order to obtain detailed information on the behaviour of each 
CMAs throughout the experimental domain investigated. The contour 
plots are shown in Figure 26 for K’ and resolution responses and in Figure 
27 for area responses. The investigation of these plots, combined with the 
analysis of the coefficients reported in Figure 28, allowed understanding 
the method performance behaviour in function of the selected CMPs. 
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Exp 
No. 
ACN% 
(v/v) 
RAMP 
(min) 
T 
(°C) 
K’ 
 
R1 
 
R2 
 
R3 
 
R4 
 
A1 
 
AB 
 
AA 
 
A2 
 
A3 
 
1 30.0 3.6 54 2.33 2.74 4.38 4.40 12.34 827072 120153 61532 954229 695159 
2 36.0 3.6 54 0.40 8.87 3.07 4.97 13.69 192518 77833 61966 946606 679564 
3 30.0 5.4 54 2.54 3.47 5.52 5.58 15.60 744264 112250 57937 874339 639877 
4 36.0 5.4 54 0.38 7.62 3.78 6.26 17.04 172650 65528 64237 918216 664891 
5 30.0 3.6 66 2.28 2.44 4.69 4.31 11.84 786301 99240 60278 920390 689505 
6 36.0 3.6 66 0.28 4.11 18.45 4.89 12.82 512063 91635 61987 927961 690779 
7 30.0 5.4 66 2.47 2.96 5.81 5.43 14.44 815790 107843 62408 883211 688962 
8 36.0 5.4 66 0.27 3.65 22.61 6.02 15.79 533282 79175 60218 929630 693485 
9 28.0 4.5 60 2.55 2.91 5.08 4.81 13.39 834298 103214 61695 957885 688684 
10 38.0 4.5 60 0.28 n.m. n.m. n.m. 15.17 n.m. 63088 n.m. n.m. 691094 
11 33.0 3.0 60 2.04 2.64 4.37 4.17 11.47 831260 117138 60337 961178 692585 
12 33.0 6.0 60 2.22 3.77 6.53 6.25 16.78 732744 97817 55479 801380 621264 
13 33.0 4.5 50 2.18 3.50 5.33 5.30 14.88 815698 119205 60706 900552 648673 
14 33.0 4.5 70 2.06 2.80 5.68 4.95 13.19 570167 81423 45961 692391 503270 
15 33.0 4.5 60 2.13 3.23 5.56 5.21 14.28 856186 109521 62729 964840 685766 
16 30.0 3.6 54 2.34 2.77 4.34 4.43 12.52 691623 100595 53493 812879 588620 
17 36.0 3.6 54 0.43 12.48 3.98 4.90 13.47 295265 88196 64728 959019 688298 
18 30.0 5.4 54 2.55 3.49 5.7 5.66 15.83 763914 115626 56247 897206 657636 
19 36.0 5.4 54 0.33 8.27 4.73 6.26 16.58 197803 60159 64686 924911 662633 
20 30.0 3.6 66 2.28 2.40 4.76 4.26 11.75 813741 98845 61369 947682 688511 
21 36.0 3.6 66 0.27 3.59 23.19 4.98 12.89 517853 80352 61431 898508 691444 
22 30.0 5.4 66. 2.47 2.91 5.83 5.27 14.35 816902 108987 62429 895531 688421 
23 36.0 5.4 66 0.27 3.75 21.94 5.94 15.37 533917 83108 61752 930497 693814 
24 28.0 4.5 60 2.56 2.82 4.94 4.76 13.1 773774 100973 58040 898587 636369 
25 38.0 4.5 60 0.24 n.m. n.m. n.m. 15.64 n.m. 48332 n.m. n.m. 680147 
26 33.0 3.0 60 2.04 2.68 4.51 4.26 11.78 789085 111594 60534 917929 671487 
27 33.0 6.0 60 2.21 3.66 6.50 6.04 16.57 849670 111872 62340 912363 702199 
28 33.0 4.5 50 2.19 3.47 5.15 5.30 14.95 723611 114196 55352 812261 590733 
29 33.0 4.5 70 2.08 2.73 5.48 4.79 13.11 647595 90466 52648 779225 562611 
30 33.0 4.5 60 2.14 3.20 5.47 5.16 14.08 754701 98261 55638 854503 607587 
Table 10: Response surface methodology: 15-run Central Composite Design 
experimental plan with two replicates for each run. 
n.m.: not measured; due to particular peak patterns, the result of the experiment were excluded 
from data treatment. 
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CMA R2 Q2 Regression 
p value 
Lack of fit 
p value  
K’ 0.907 0.800 0.000 0.000  
R1 0.950 0.885 0.000 0.000  
R2 0.844 0.722 0.000 0.000  
R3 0.992 0.982 0.000 0.366 
R4 0.993 0.983 0.000 0.852 
A1 0.850 0.652 0.000  0.000  
AB 0.876 0.725 0.000 0.056 
AA 0.514 0.105 0.011  0.233 
A2 0.523 0.135 0.010 0.388 
A3 0.425 -0.121 0.033 0.092 
Table 11: Response surface methodology: quality of the calculated models for 
all the CMAs. 
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Figure 26: Isoresponse surfaces drawn by plotting RAMP vs. ACN% for:  
(a) NHBA-GNA1030 capacity factor K’, (b) R1,(c) R2, (d) R3, (e) R4 
at three different values of temperature: 50°C, 60°C, 70°C. 
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 Figure 27: Isoresponse surfaces drawn by plotting RAMP vs. ACN% for: (a) A1, 
(b) AB, (c) AA, (d) A2, (e) A3 at three different values of 
temperature: 50°C, 60°C, 70°C. 
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Figure 28: Response Surface Methodology: graphic analysis of effects of the 
CMPs on the CMAs 
The precision of the regression coefficient was calculated as the 95% confidence interval and was 
superimposed as an error on each coefficient bar. 
As for K’ (Figure 26 a), the only significant effect was exerted by ACN%, 
which showed both a negative linear and a negative quadratic effect; high 
values of this factor anticipate the NHBA-GNA1030 peak toward the 
column void volume and the zone corresponding to the maximization of 
this factor was located at medium levels of all the CMPs. As concerns the 
four resolution CMAs, they were all maximized by high levels of ACN% 
(Figure 26 b-e). RAMP presented a strong positive effect on resolution R3 
and R4. T had a negative effect on R1 and R4 and a positive effect on R2. 
Quadratic effects of ACN% were evidenced on all the resolution CMAs 
apart from R4. Some significant interactions were also noticed: ACN%-
RAMP and ACN%-T on R1 and ACN%-T on R2. As for the CMAs related 
to areas (Figure 27), different trends and curvatures in the contour plots 
were noticed. The graphical analysis of effects in Figure 28 evidenced 
negative effects for ACN% on A1 and AB and a positive effect on AA, while 
T showed a positive interaction with ACN% on A1 and AB. RAMP showed 
no influence on area responses. 
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The sweet spot plots, shown in Figure 29, highlight by different colours 
the areas where one or more predicted CMAs fulfil the related 
requirements. For all the CMAs related to resolution, a desired minimum 
value of 1.5 was set, while for the other CMAs the limits were set as 
reported in Table 6. The different colours had the following meaning: 
purple, from 1 to 3 CMAs criteria met; different blue gradations, from 4 to 
5 and from 6 to 7 criteria met; light blue, from 8 to 9 criteria met; and 
finally, green where all the ten CMAs criteria were fulfilled, namely the 
zone corresponding to the sweet spot. Anyway, the green plot area does 
not constitute the design space, but it only shows where the overlay of the 
CMAs response surfaces meets the desired performances, providing 
additional information by highlighting the zone where the maximum 
number of criteria is fulfilled. 
 
Figure 29: Sweet spot plot obtained plotting RAMP vs. ACN% at three different 
values of T. 
The zones colored in green correspond to the zones where the requirements for all the ten CMAs 
are fulfilled. 
On the other hand, the MODR takes into account the concept of 
probability that the requirements are met [2] [7], and it was computed by 
MODDE software [128]. Considering all the response surface models and 
the settings of CMAs requirements, the risk of failure map (Figure 30) was 
drawn using Monte-Carlo simulations for risk analysis, taking into account 
the model parameters uncertainty, propagating the prediction error from 
parameters to responses and giving access to the responses distributions 
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for each RSM condition [132]. The selected level of probability (π) and the 
original set point for MODR identification were: π≥90%; ACN%, 33.3%; 
RAMP, 4.8 min; T, 64°C. Hence, the design space was graphically 
represented in the risk of failure map by the area coloured in green, within 
the iso-error curves corresponding to the probability failure ≤10%. Within 
the MODR, the following limits for CMPs ranges were identified: ACN%, 
32.0-34.6 %; RAMP, 4.0-5.6 min; T, 60-68°C. 
 
Figure 30: RP-UHPLC design space map by plotting RAMP vs. ACN% three 
different values of temperature: 55°C, 60°C, 65°C. 
In order to validate the MODR, the lower and higher limits of the design 
space ranges were selected as the -1 and +1 levels of a 23 Full Factorial 
Design [52], with 3 replicates of the original set point to estimate the 
experimental variance, and the agreement between RSM predicted 
values and experimental responses at the edges of failure was verified. 
Once the model validity was confirmed, a working point was chosen 
inside the lower risk region (π≥99%), taking into account some 
practicability factors such as the advantages of implementing an high-
throughput method and of choosing a temperature value as low as 
possible to avoid proteins damages or modifications.  
The selected working point for routine use was: ACN%, 33.0%; RAMP, 
4.0 min; T, 60°C. Under the selected conditions, a completely separation 
of the five antigens in about 5 minutes, with the desired selectivity and 
sensitivity, was obtained. The RP-UHPLC chromatogram of the mock 
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solution in the selected operative conditions is reported on bottom  
Figure 31. 
 
Figure 31: RP-UHPLC chromatogram in the working conditions for a mock 
solution. 
10 µgml-1 NHBA-GNA1030, fHbp-GNA2091, NadA and 5 µgml-1 Por B, PorA; Acquity H-
ClassBio UPLC system; Acquity RP-C4 BEH 300Å, 1.7µm, 2.1x150 mm; organic phase, ACN 
plus 0.1% TFA ion pair; injection volume, 30 µl; temperature, 60°C; ramp time,4 min (from 
33.0% to 75.0% ACN); photodiode array detector, 210 nm, 1.2 nm resolution, 20 points s-1. 
Robustness and control strategy 
For robustness study, a 8-run Full Factorial Design was employed to 
calculate the main effects on the CMAs of small CMPs changes around 
the chosen working conditions [130] and the experimental plan with the 
responses is shown in Table 12. The resulting graphical analysis of 
effects is shown Figure 32. The analysis of effects evidenced that the 
method could be considered robust, including a precautionary statement 
for ACN%. As a matter of facts, ACN% exerted a significant effect on K’, 
R2, A1 and AB also in this small interval. As for the other factors, RAMP 
was significant only on R2 and T on A1 and AB. Anyhow, all the results 
were within the CMAs desired limits for all the experiments. 
Finally, a preliminary control strategy [2] for the RP-UHPLC method was 
accomplished on the basis of all the development data, consisting in a 
continuous performance verification plan to control recombinant proteins 
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resolutions, efficiency and peak symmetry, setting the following system 
suitability limits. A standard mixture of the rMenB proteins (100 μg ml-1) 
should fulfil these requirements: resolution (NHBA-GNA1030/fHBp-
GNA2091) ≥9, resolution R4 (fHBp-GNA2091/NadA) ≥10, fHBp-GNA2091 
number of theoretical plate ≥50000 and 0.9≤ fHBp-GNA2091 peak 
symmetry ≤1.6. 
Exp. 
No. 
ACN% 
(v/v) 
RAMP 
(min) 
T 
(°C) 
K’ 
 
R1 
 
R2 
 
R3 
 
R4 
 
A1 
 
AB 
 
AA 
 
A2 
 
A3 
 
1 33.0 3.8 58 2.13 3.09 5.16 4.95 13.7 813447 132413 65189 979825 731861 
2 35.0 3.8 58 1.86 1.89 5.64 5.05 14.07 747892 115959 66659 989529 732180 
3 33.0 4.2 58 2.15 3.23 5.34 5.22 14.21 823484 134370 66505 989657 735569 
4 35.0 4.2 58 1.87 1.85 5.89 5.43 15.02 749966 112523 66679 980334 750354 
5 33.0 3.8 62 2.10 2.96 5.22 4.85 13.56 811993 113951 66916 978123 733266 
6 35.0 3.8 62 1.29 3.95 5.57 5.02 13.83 534618 113006 68008 992237 734331 
7 33.0 4.2 62 2.13 3.13 5.52 5.17 14.35 800452 113288 65846 977280 736316 
8 35.0 4.2 62 1.22 4.63 6.01 5.31 14.65 532770 108393 68268 984843 743607 
Table 12: Robustness study 
 
Figure 32: Robustness study: graphic analysis of effects of CMPs on CMAs. 
The precision of the regression coefficient was calculated as the 95% confidence interval and was 
superimposed as an error on each coefficient bar. 
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Method qualification 
Qualification of the RP-UHPLC developed method was carried out to 
ensure the suitability of the method for the quality control of the vaccine 
product. The method was qualified following ICH guidelines [130] for 
validation, using an experimental plan for testing the effect of noise factor 
on results variability: operator, column batch, sample preparation, 
instrument, day of analysis and analytical session. The qualification 
results showed the suitability of the method for the intended purpose, 
identity of antigens respect to standard solutions, selectivity, linearity, 
accuracy (recovery for antigens spike) and precision (data variation of the 
titred amount). Linearity was evaluated by preparing and analysing ten 
samples, two for each of five concentration values, ranging from 1 to 20 
μg ml-1 for rMenB antigens and from 0.5 to 10 μg ml-1 for OMV antigens; 
the related data are shown in Table 13. The recovery values for antigens 
spike were measured at three concentration values (1.5, 10 and 20 μg  
ml-1) performing 6 replicates and obtaining values included in the 
following intervals: NHBA-GNA1030, 92.3-113.9%;  PorB, 93.1-115.9%; 
PorA, 96.1-108.6%; fHBp-GNA2091, 99.3-106.3%; NadA, 90.9-104.7%. 
Precision was assessed for fHBp-GNA2091 (10 μg ml-1): as for 
repeatability, six analyses were run obtaining a RSD = 1.7% for the 
titrated amount; as for intermediate precision, calculated by performing 6 
replicates at three concentration values, the following RSD values for the 
titrated amount were found: 1.5 μg ml-1, RSD = 8.4%; 10 μg ml-1, RSD = 
7.9%; 20 μg ml-1, RSD = 2.8%. 
Antigen Range 
(μg ml-1) 
a b R2 
NHBA-GNA1030 1-20 8.91x104 1.59 x104 0.9996 
PorB 0.5-10 2.32 x104 1.74 x103 0.9996 
PorA 0.5-10 1.29 x104 6.21x102 0.9994 
fHBp-GNA2091 1-20 1.02x105 1.82x103 0.9998 
NadA 1-20 7.56x103 7.33x104 0.9999 
Table 13: Linearity data 
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The regression equation of above table is y = ax + b, where x is the 
antigen concentration (μg ml-1), y is the area of the antigen peak and R2 
the coefficient of determination or the linearity regressions. 
AAA Hydrolysis Design Space 
A fundamental critical quality attribute of Bexsero vaccine is the antigens 
content of the final drug product. The dug substances quantification is 
necessary to qualify the reference rMenB calibration standards for antigen 
content determination in Bexsero vaccine. The actual method for protein 
content determination of recombinant MenB proteins (rMenB) in the drug 
substances is the microBCA test. The bicinchoninic acid assay is a 
standard method for proteins titration, relatively old and with certain data 
variability. Following the Analytical Target Profile requirements, the AQbD 
framework was applied increasing the assays throughput, by reducing the 
manual operations, improving sensitivity and data precision with respect 
to the current microBCA assay used to control the above CQA. 
Materials and methods 
The Amino Acid Analysis (AAA) is a titration assay for the quantification of 
the protein content of analyte samples. AAA refers to a two-step 
procedure that quantitates amino acid molecules in proteins. The first step 
involves the digestion of a protein into free-amino acids, constituting the 
protein primary structure. The second step involves the chromatographic 
separation of the free-amino acids for the detection and quantification. 
AAA assay is based on the AccQ•TagUltra method, commercially 
available by Waters Corp. [133]. The method used the ACQ reagent  
(6-aminoquinolyl-N-hydroxysuccinimidyl carbamate) to add UV 
absorbance to free-hydrolysate amino acids. ACQ is an amine-
derivatization reagent specific for primary and secondary amino acids 
(Figure 33). AAA measures the concentration of each free-amino acid 
after the protein hydrolyses by acid conditions. A commercial free-amino 
acids standard solution is used for external standard calibration. 
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.  
Figure 33: AccQ•Tag Ultra reaction for amino acid derivatization [133] 
The hydrolysis procedure is crucial for the quality of the titration data and 
must be properly optimized in order to identify all the amino acids 
constituting the protein structure; avoiding at the same time the 
degradation. Hence, our study was focused to apply AQbD framework to 
develop and optimize a robust protein hydrolysis step. The RP-UHPLC 
method and the derivatization procedure (Figure 33) is already developed 
and verified by Waters Corp. AccQ•Tag kit [133]. An example of the RP-
UHPLC separation for the standard amino acids is reported on Figure 34. 
 
Figure 34: standard amino acids chromatogram by RP-UHPLC 
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Chemicals and reagents 
For the hydrolysis step optimization and AAA method validation, the 
rMenB drug substances and a Bovine Serum Albumin (BSA) standard 
solution were employed.  
NHBA-GNA130, fHbp-GNA2091and NadA antigens are produced by GSK 
group of companies (Siena, Italy). BSA 7% water solution is certified by 
National Institute of Standard and Technology (NIST, SRM 927e) and 
was purchased by NIST (U.S. Department of Commerce, USA). 6 M 
hydrochloric acid (HCl) water solution (amino acid analysis grade) and  
2.5 M amino acid hydrolysate standard mix solution in 0.1 M HCl (amino 
acid analysis grade) were purchased by Sigma-Aldrich (Saint Louis, MO 
USA). Phenol (C6H6O) solution 90% in water (ACS reagent grade) was 
purchased by Merck KGaA (Darmstadt, Germany). AccQ•Tag Ultra 
Derivatization kit (Eluent A AccQ•Tag; Eluent B AccQ•Tag; AccQ•Tag 
borato buffer; AccQ•Tag powder reagent; AccQ•Tag dilution reagent) and 
total recovery glass vials (12x32mm glass screw neck vial, Quick thread, 
Lectrabond cap, PTFE/silicone septa Total Recovery) were purchased by 
Waters Corp. (Milford, MA, USA). Ultrapure water was produced by 
Millipore Milli-Q system (Billerica, MA, USA). All solutions used have been 
filter on a nylon membrane of 0.22 µm porosity using Nalgene clepsydra 
filter (Nalgene, Rochester, NY, USA). 
Solutions and sample preparation 
The NHBA-GNA130, fHbp-GNA2091 and NadA antigen aliquots are 
stored at -20°C and thwarted at room temperature before analysis. Such 
as positive control for hydrolysis performance, the BSA 7% water solution 
titrated and certified by NIST was used. The commercial available BSA 
NIST solution was portioned in 125 µl aliquots and stored at -20°C for two 
months. The working solutions were obtained by dilution, with ultrapure 
waters, of the protein solutions within the amino acid standard calibration 
range; considering the primary structures of each protein and the seven 
most abundant amino acids. The calibration curve is built using the 2.5 M 
hydrolysate standard amino acidic solution, diluted with ultrapure water to 
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cover the 15-250 nM concentration range. The protein working solutions 
were prepared each day and have been showed to be stable for 1 week 
after hydrolysis. After derivatization step, the hydrolysate solutions are 
stored in autosampler at 20°C using the total recovery, Lectabond cap, 
glass vials and are stable for 24 hours. 
Equipment and analysis 
The rMenB proteins diluted in the working range are dried using a 
vacuum SpeedVac (thermo-fisher scientific, Waltham, MA, USA), at least 
for 2 hours at room temperature. The dry samples are reconstituted with  
6 M HCl solution, adding of phenol solution such as antioxidant. The new 
sample mixture is left to hydrolyse overnight in a heating chamber using  
4 ml clean glass vial with Teflon vite-cap, purchased by Wheaton Corp. 
(Millville, NJ, USA). Hydrolysis has been performed in a Binder oven 
(Bohemia, NY, USA). The hydrolysis working conditions (with the interval 
corresponding to the MODR) were as follows: 6 M HCl volume 300 µl 
(233-420 µl); PhOH volume 5 µl (1.3-6.0 µl); time 17 hours (16-21 hrs); 
temperature 112°C (105-118°C). Whereupon, the hydrolysate samples 
are neutralized by evaporation of the hydrochloric acid in a vacuum 
SpeedVac at least for 4 hours applying 45°C to accelerate the process. 
Hence, the dried free-amino acids samples are reconstituted with 0.1 M 
NaCl aqueous solution, for a better solubility. 
Both for hydrolysate free-amino acids samples and standards, the 
derivatization procedure was performed mixing 10 µl of working solution 
with 20 µl of ACQ reagent and 70 µl of AccQ•Tag borato buffer [133]. The 
mixing has been done directly in total recovery glass vials, sealing with 
not pre-slit lectabond caps, and derivatized in a thermoblock or an oven 
for 10 minutes (8-15 min) at controlled temperature, 55°C (50-60°C). 
The chromatographic configurations for the Screening DoEs and RSM 
are: Acquity UPLC BEH RP-C18 1.7 μm (2.1 x 150 mm) column and  
Acquity H-Class Bio UPLC system (Waters Corp.) equipped with bio-
Quaternary Solvent Manager (bioQSM) with 100 µl mixer, bio-Sample 
Manager (bioSM-FTN) with 15 µl injector needle, column oven CH-A with 
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actived pre-heater and photodiode array detector (ACQ-PDA) with 
analytical flow-cell (10 mm; 500 nL) and a specific 0.0025 ID inlet peek for 
bioFTN and PDA connection. The detection wavelength was 260 nm (4.8 
nm resolution and 10 points sec-1 sampling rate frequency). Sample 
injections were done by 1 µl of the working solution stored in the 
autosampler at 20°C [133]. 
Computations and software  
In order to verify the hydrolyse conditions the qualified BSA standard 
purchased by NIST was used. The BSA protein amount certified by NIST, 
considering also the related amount confidence interval such as 
desirability range, has been reported in Table 14. Empower 3 software 
[124] licensed by Waters Corp. was used for the Acquity H-Class Bio 
UHPLC instrument control and for the Chromatographic data 
computation. According to European Pharmacopoeia 8.0 indications 
[134], by using Empower 3 custom fields for automatic computation, the 
formula applied for total protein amount determination (µg/ml), starting 
from free-amino acids concentration (nM) found by analysis, has been 
following reported on Equation 11;  
𝐻𝑠𝑠𝑠𝑎𝑠𝑠 𝑠𝑎𝑎𝑠𝑠𝑎𝑎 𝑠𝑎𝑠𝑢𝑠𝑠 = 1
𝑁
�
𝐴𝐴 𝐶𝑠𝑠𝐶𝑖  
𝑠°𝐴𝐴𝑖  𝐷𝐹17
𝑖=3
 𝑀𝑊𝑖1000 
Equation 11: AAA formula for conversion of amino acids concentration to 
protein amount 
Were: 
Protein average amount (µg/ml): is the average concentration of the protein sample N : is the number of amino acids (i) considered for the computation of the average 
protein concentration, from a minimum to 4 to a maximum of 17. 
AA Conci (nM): is the concentration found for the i-esime amino acid 
n°AAi : is the abundance of the i-esime amino acid in the protein primary structure 
DF : is the starting dilution value of the protein sample for analysis 
MWi (g/mol): is the molecular weight of the i-esime amino acid 
Empower custom fields have been programmed to automatically exclude 
by computations the free-amino acids out of the standard calibration 
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range (concentration values < 15 nM and > 250 nM) and the A.A. based 
protein amounts  with a variability higher to 5 % respect to the average 
protein amount, according to European Pharmacopoeia 8.0 indications 
[134]. 
MODDE software [128] was purchased from S-IN (Vicenza, Italy) and was 
employed to generate the full Factorial Design (FFD) for screening DoE 
and to generate the graphic effects analysis and the Central Composite 
faced design (CCD) used for RSM. Moreover, to perform data analysis 
and to find the design space by means of risk failure maps computed 
using the Monte-Carlo simulations. The runs of all the DoE plans were 
carried out in a randomized order. 
AAA hydrolysis development and results 
The hydrolysis procedure development agreed the systematic AQbD 
framework described on Figure 19, previously applied to RP-UHPLC 
separation method, highlighting the flexibility and the goodness of the 
proposed approach for different analytical purposes. The following steps 
were applied:  
I) ATP definition, method scouting and CMAs;  
II) Risk assessment and pCMPs;  
III) MODR identification by RSM;  
IV) Working point definition; 
 V) Method control strategy and validation. 
Analytical target profile, method scouting and critical method 
attributes 
For the AAA hydrolysis study, ATP consists to obtain the accurate 
quantification of the three Bexsero recombinant components NHBA-
GNA1030, fHbp-GNA2091 and NadA. Moreover, general validation 
requirements according to ICHQ2(R1) guideline [129] [130] had to be 
fulfilled, including an adequate method throughput and feasibility to be 
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able to monitor rMenB antigen content in the drug substances. The AAA 
is important to quantify the protein concentration of rMenB reference 
materials to be used as external calibration standards for the antigen 
content determination in Bexsero vaccine. The component content is a 
product CQA of Bexsero. The selected CMAs are reported in Table 14 
and were: BSA NIST amount (BSA), R1 (fHbp-GNA2091 amount), R2 
(NHBA-GNA1030 amount) and R3 (NadA amount). 
Abbreviation CMA CMA requirement (µg/ml) 
BSA BSA NIST amount 59085 ≤BSA ≤71204# 
R1 fHbp-GNA2091 amount 1351 ≤R1 ≤2027* 
R2 NHBA-GNA1030 amount 615 ≤R2 ≤923* 
R3 NadA amount 1671 ≤R3 ≤2507* 
Table 14: AAA critical method attributes and selected requirements 
# BSA amount by NIST certification; * range target by microBCA variability. 
In order to reach the method target, different preliminary aspects had to 
be considered. First, scouting of different hydrolysis types was performed. 
On the base of literature research [134] [135] [136] [137] gas- and liquid-
hydrolysis were investigated to identify the best promising procedure for 
protein digestion. The gas-hydrolysis was investigated first by DoE 
experimentation for the following factors: 6M HCl volume (VOL), 
hydrolysis time (HT) and sample-support (SUPP). Each factor was 
studied at two levels (23), 10-20 ml for VOL, 24-48 hours for HT and 
Backer-Pasteur for SUPP. MODDE software [128] was employed to 
generate the symmetric full factorial screening matrix, used to estimate 
the coefficients of the following linear model with interactions:  
Y=b0+b1A(X1A)+b1B(X1B)+b2A(X2A)+b2B(X2B)+b3A(X3A)+b3B(X3B)+b1A2A(X1AX2A)
+b1A2B(X1AX2B)+b1A3A(X1AX3A)+b1A3B(X1AX3B)+b1B2A(X1BX2A)+b1B2B(X1BX2B)+ 
b1B3A(X1BX3A)+b1B3B(X1BX3B)+b2A3A(X2AX3A)+b2A3B(X2AX3B)+b2A3A(X2BX3A)+ 
b2A3B(X2BX3B) 
where: X1 is VOL, X2 is CONC and X3 is SUPP, b0 is the constant term 
and bi are the linear and interaction coefficients. 
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The model contains one constant term plus, for each factor, a number of 
terms equal to its number of levels and interactions. The 8-run 
experimental plan (23//8) is reported in Table 15. Each multivariate 
condition was triplicated in order to obtain a reliable estimation of the 
experimental variance. 
Exp. 
No 
Volume 
(ml) 
HT 
(hrs) 
SUPP 
 
BSA 
(µg/ml) 
R1 
(µg/ml) 
1 10 24 Backer 57333,8 1297,7 
2 20 24 Backer 57735,3 1303,2 
3 10 48 Backer 58717,9 1283,7 
4 20 48 Backer 56472,6 1290,5 
5 10 24 Pasteur 57926,7 1283,9 
6 20 24 Pasteur 57757,8 1324,5 
7 10 48 Pasteur 58345,0 1305,3 
8 20 48 Pasteur 56328,5 1279,0 
9 10 24 Backer 57851,8 1305,0 
10 20 24 Backer 57948,9 1274,1 
11 10 48 Backer 58008,7 1275,1 
12 20 48 Backer 54544,0 1268,5 
13 10 24 Pasteur 58064,5 1338,4 
14 20 24 Pasteur 57655,8 1294,3 
15 10 48 Pasteur 57212,8 1310,7 
16 20 48 Pasteur 57255,9 1203,7 
17 10 24 Backer 60232,2 1314,0 
18 20 24 Backer 58254,5 1319,6 
19 10 48 Backer 57906,9 1288,2 
20 20 48 Backer 56375,4 1253,6 
21 10 24 Pasteur 57811,1 1284,7 
22 20 24 Pasteur 57507,0 1297,4 
23 10 48 Pasteur 56384,3 1299,8 
24 20 48 Pasteur 57748,8 1214,9 
Table 15: 24-run symmetric screening matrix (23//8) for gas-hydrolysis 
For the hydrolysis screening, in order to manage a lower number of 
samples, only BSA and R1 CMAs were investigated. For all the conditions 
tested lower protein amounts and data reproducibility were obtained for 
gas-hydrolysis with respect to liquid-hydrolysis, both for BSA NIST and 
fHbp-GNA2091 samples. The DoE-graphic effects analysis (Figure 35) 
shows a minimization of recovery increasing both VOL and HT factors.  
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No SUPP and interactions effects are identified. It means a low probability 
to fulfil CMAs requirement by optimization DoE, considering the low 
recovery. Contrariwise, the liquid hydrolysis was tested by OFAT 
experimentation, adapting literature instructions [134] [135] [136] [137], 
and providing good recovery results within the CMAs requirement ranges 
(Table 14). Moreover, considering the lower HCl volume needed for 
liquid-hydrolysis (cost saving) the faster reaction rate (≤ 24h, time saving) 
more compliant with the analyst's time organization (assay feasibility) and 
finally the higher system reproducibility (assay ruggedness), the liquid-
hydrolysis was chosen for further proteolysis optimization. 
 
Figure 35: screening DoE-graphic effect analysis for gas-hydrolysis 
Risk assessment and potential critical method parameters 
The objective of a risk assessment is to develop understanding of 
procedure variables and their impact on the method reportable values for 
the identification of hazards and the analysis and evaluation of risks 
associated with exposure to those hazards [119] [131]. Tools such as 
process-map, fishbone diagram and cause-and-effect matrix are used, in 
addition to prior knowledge, to brainstorm the method factors and gain 
information-gathering to identify pCMPs [119]. In this study, a fishbone 
diagram (Figure 36) with the support of C&E matrix (Table 16:) were used 
to formalize the risk assessment and point out the risk factors associated 
with the characteristics of the AAA assay and thus to highlight the 
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potential CMPs which were supposed to potentially affect the selected 
CMAs. 
Some of the CMPs, generally not related to hydrolysis step and 
associated to AAA chromatographic system and amino acid 
derivatization, had been already studied and fixed by Waters Corp. AAA 
RP-UHPLC procedure [133]. For this reason the Ishikawa diagram was 
formalized for all AAA assay factors, step I (Hydrolysis) and step II 
(derivatization and chromatography), while the C&E matrix was 
prevalently focused to investigate the effect of the hydrolysis factors on 
proteolysis performance (AAA step I); considering the others category 
factors (AAA step II) well known and controlled (high knowledge level). 
The hydrolysis pCMPs identified, coloured by red in the Table 16, needed 
to be risk managed and in-depth studied by DoE to enhance knowledge 
on their effects on hydrolysis performances. 
 
Figure 36: Ishikawa diagram for AAA assay 
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Table 16: C&E matrix for hydrolysis performance 
Severity score (S) defines the impact of the method parameters on CMAs. S score is computed as 
the maximum impact factor assessed by C&E matric, using a severity discrete ranking from 1 to 
10, were: 1 (no impact), 4 (low impact), 7 (impact) and 10 (high impact). Method parameters with 
S score ≥ 7 are considered pCMPs. 
Knowledge score (K) defines the knowledge / uncertainty about the factor-CMA relationship and 
the controllability of the parameters. K score is used to prioritize actions for factors effect 
investigations and to demote pCMPs to not-critical if they are full known and controlled. For 
knowledge assessment was used a discrete ranking from 10 to 1, were: 10 (high knowledge and 
control), 7 (knowledge on CMAs effect), 4 (low factor knowledge) and 1 (no factor knowledge 
and high uncertainty). Method parameters with K = 10 are demote to not-critical, because known 
and controlled, not necessary to be studied further more. 
Design space definition by response surface methodology 
Due to low number of factors identify as pCMPs by risk assessment, all 
the hydrolysis parameters were investigated directly by optimization DoE. 
The four parameters identify as potentially critical for the hydrolysis 
performance were represented by hydrolysis time (HT), temperature (T), 
6 M HCl volume (VOL) and antioxidant phenol volume (PhOH). 
RSM was applied for in-depth investigations of the effects of HT, T, VOL 
and PhOH on the selected CMAs (Table 14), applying the new 
experimental domain reported in Table 17. 
Variables 
Category
Parameters Units
Ac
cu
ra
cy
Pr
ec
isi
on
Sp
ec
ifi
ci
ty
Ra
ng
e
An
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is 
tim
e
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ro
ug
hp
ut
n°
 v
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id
 ru
n
Severity
score (S)
Knowledge 
(K)
Criticality    
Sample dilution N/A 7 7 4 10 1 1 1 10,0 10,0 MP  
Hydrolysis type N/A 10 7 7 4 10 7 10 10,0 10,0 MP     
Hydrolysis time hrs 7 4 4 4 7 1 7 7,0 1,0 pCMP
Hydrolysis temperature °C 10 4 4 1 1 1 1 10,0 4,0 pCMP
HCl volume µl 7 7 1 10 1 1 7 10,0 4,0 pCMP
Phenol volume µl 7 7 1 4 1 1 7 7,0 1,0 pCMP
Derivatization temperature °C 7 7 1 1 1 1 4 7,0 10,0 MP
Derivatization time min. 7 7 1 1 1 1 4 7,0 10,0 MP
Instrument for derivatization N/A 1 1 1 1 1 1 4 4,0 10,0 MP   
sample recovery after 
hydrolysis
µl 4 4 4 1 1 1 1 4,0 10,0 MP  
Column type N/A 7 7 1 10 1 1 7 10,0 10,0 MP
Mobile Phases composition N/A 7 10 4 1 1 1 4 10,0 10,0 MP
Mobile Phases gradient %/min. 7 10 4 1 1 1 4 10,0 10,0 MP
auto-sampler stability hrs 7 10 1 1 1 1 7 10,0 10,0 MP
Sample preparation N/A 4 10 1 1 1 1 7 10,0 10,0 MP
hydrolysis session N/A 4 10 4 1 1 1 7 10,0 10,0 MP
Chromatography
Variability & 
Equipment
Hydrolysis
Derivatization
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A three-level four-factor faced CCD (34) was employed for building a 
quadratic model with interactions, making it possible to study all the 
selected chromatographic CMAs: BSA, R1, R2 and R3 (Table 14). 
The 25-run CCD experimental plan (34//25) with the measured responses 
is reported in Table 17, including three repetition of the central point to 
estimate the response variability.  
Exp 
No. 
HT 
(hrs) 
T 
(min) 
VOL 
(µl) 
PhOH 
(µl) 
BSA 
(µg/ml) 
R1 
(µg/ml) 
R2 
(µg/ml) 
R3 
(µg/ml) 
1 10 104 100 0 62661,8 1349,5 560,6 1642,8 
2 24 104 100 0 63035,3 1683,4 637,7 1734,1 
3 10 120 100 0 64018,0 1088,4 628,5 1738,6 
4 24 120 100 0 62286,1 1544,4 624,9 1749,6 
5 10 104 500 0 62237,0 1167,5 628,2 1608,8 
6 24 104 500 0 63892,4 1660,7 607,2 1675,1 
7 10 120 500 0 63399,4 1316,1 614,5 1664,1 
8 24 120 500 0 57709,4 1487,6 670,7 1672,0 
9 10 104 100 10 62127,3 989,2 617,7 1635,5 
10 24 104 100 10 65165,5 1783,5 566,9 1717,2 
11 10 120 100 10 64175,9 1470,7 656,1 1767,5 
12 24 120 100 10 64264,1 1625,0 663,2 1728,9 
13 10 104 500 10 62650,9 1047,1 629,9 1623,0 
14 24 104 500 10 64090,8 1599,0 735,9 1718,2 
15 10 120 500 10 64583,3 1451,2 616,1 1758,6 
16 24 120 500 10 64121,8 1585,7 634,1 1756,9 
17 10 112 300 5 52241,1 1472,5 634,6 1707,0 
18 24 112 300 5 55927,0 1524,8 646,6 1825,3 
19 17 104 300 5 63387,7 1487,0 598,4 1709,4 
20 17 120 300 5 65443,0 1536,6 635,5 1742,0 
21 17 112 100 5 76184,4 1536,2 620,5 1740,8 
22 17 112 500 5 60046,0 1530,6 630,3 1739,8 
23 17 112 300 0 58191,9 1500,5 631,9 1733,5 
24 17 112 300 10 76436,3 1574,7 642,9 1760,9 
25 17 112 300 5 64458,5 1545,8 642,3 1717,6 
26 17 112 300 5 69565,5 1500,1 635,7 1728,6 
27 17 112 300 5 65024,1 1507,6 630,3 1765,6 
Table 17: Response surface methodology: 25-run Central Composite Design 
experimental plan with three central points. 
Only the R1 responses were analysed without mathematical 
transformation. All the others responses were mathematical transformed 
to stabilize the variance and makes the data more normal distributed-like. 
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Following the Box-Cox plot indications, BSA and R3 responses were Y-2 
transformed, while R2 responses were Y-1.5 transformed. All the four 
models, calculated by multiple-linear regression, were significant in terms 
of ANOVA, without lack of fit. The goodness of fitting (expressed by 
determination coefficient R2) and of prediction (expressed as cross 
validated Q2) of the four identified models are reported in Table 18. BSA 
and R2 have a low Q2 due to the low data variability. It means that the 
effect on output responses of the hydrolysis factors variation is near to the 
pure model error (response variability estimated by central point 
repetitions). Additionally, as observable by CCD experimental matrix 
(Table 17) and response surfaces (Figure 37), the BSA and R2 results are 
always within the CMAs desirably ranges (Table 14). 
CMA R2 Q2 Regression 
p value 
Lack of fit 
p value  
BSA 0.598 0.386 0.032 0.285  
R1 0.842 0.504 0.000 0.058  
R2 0.452 0.294 0.038 0.044  
R3 0.910 0.710 0.000 0.737 
Table 18: Response surface methodology: quality of the calculated models for  
all the CMAs. 
In order to obtain detailed information of the behaviour of each CMAs 
throughout the experimental domain investigated, the contour plots  
were drawn reporting the calculated isoresponse curves (Figure 37). 
The analyses of contour plot response surfaces and models coefficients 
(Figure 38) allow understanding of the method performance behaviour in 
function of selected CMPs. 
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Figure 37: Isoresponse surfaces drawn by plotting HT vs. T, at three different 
values of VOL (100 µl, 300 µl, 500 µl) and three different values of 
PhOH (0 µl, 5 µl, 10 µl): (a) BSA, (b) R1, (c) R2, (d) R3. 
 
 
Figure 38: Response Surface Methodology: graphic analysis of effects of the 
CMPs on the CMAs 
R3 (d) 
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The sweet spot plots (Figure 39) highlight by different colours the areas 
where one or more predicted CMAs fulfil the related requirements (Table 
14). The different colours had the following meaning: blue only one CMA 
meet; brilliant blue two CMAs meet; light blue three CMAs meet; green 
where all the four CMAs criteria were fulfilled, namely the zone 
corresponding to the sweet spot. 
The green plot area does not constitute the design space. Sweet spot 
only shows where the response surfaces overlay meets the target 
performance for all CMAs, providing information about the space where 
the maximum numbers of criteria are fulfilled. 
 
Figure 39: Sweet spot plot obtained plotting HT vs. T at three different values of 
VOL and PhOH 
The green colour corresponds to the zone where the requirements for all the four CMAs are 
fulfilled. 
The sweet spot plot is identify by desirability function, considering all the 
response surface models and the CMAs target requirements. To achieve 
the MODR needs to be taken into account also the concept of probability 
that the requirements are met [2] [7]. The analytical design space was 
computed by MODDE software [128] and the risk of failure map (Figure 
40) was drawn using Monte-Carlo simulations. Monte-Carlo risk analysis 
takes into account the model parameters uncertainty, propagating the 
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prediction error from parameters to responses and giving access to the 
responses distributions for each RSM condition [132]. 
The selected level of probability (π) and the original set point for MODR 
identification were: π ≥ 95%; HT, 18.4 hrs; T, 107°C; VOL, 393 µl; PhOH, 
2.7 µl. The design space was graphically represented in the risk of failure 
map by the area coloured in green, within the iso-error curves 
corresponding to the probability failure ≤ 5%. Within the MODR, the 
following limits for CMPs ranges were identified: HT, 16.0-21.0 hrs;  
T, 105-118°C; VOL, 233-420 µl; PhOH, 1.3-6.0 µl. 
 
Figure 40: Hydrolysys design space map by plotting HT vs. T, at three different 
values of VOL: 150 µl, 60 µl, 65 µl and three different values of 
PhOH: 2 µl, 5 µl, 8 µl. 
The selected working point for routine use was: HT, 17 hrs; T, 112°C; 
VOL, 300 µl; PhOH, 5 µl. The selection was performed taking into 
account the assay feasibility (17 hours of hydrolysis are compatible with 
the overnight time) and additional practicability considerations, such as a 
suitable phenol volume to be withdrawn by automatic pipets (5 µl) and to 
reduce the exposition to the chemical substance. The MODR plateau 
response and the related risk of failure were additionally considered: 
112°C and 300 µl of HCl volume (combined with 5 µl of phenol and 17 
hours of hydrolysis) falls within the lower iso-error curve (π < 1%), with 
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good response robustness (area plateau). The MODR model and the 
selected set point for routine use were validated by the agreement of the 
RSM predicted value with the experimental data. 
Method control strategy and validation 
The qualification of the Neisseria meningitidis recombinant antigens by 
AAA method was carried out to ensure the suitability of the quality control 
of the vaccine components in the pharmaceutical drug product for 
humane use. The AAA assay is employed for the quantification of rMenB 
standard proteins to be used for calibrations in antigen content methods, 
e.g. the RP-UHPLC method for unadsorbed antigen content 
determination. In order to ensure that the standard proteins are well 
titrated, there is the necessity to be sure that AAA assay steps, hydrolysis 
(step I) and chromatography (step II), are well controlled and are 
performing according to quality requirements (Table 14). 
The control strategy for hydrolysis step has been planned by using the 
BSA NIST as positive control of the hydrolysis performance. On the base 
of the data collected by RSM, if the hydrolysis is complete and no issues 
are occurred during step I, for the BSA sample needs to be finding the 
NIST certificate amount values (concentrations used as CMAs 
requirements for RSM). The titration result of BSA positive control is used 
such as system suitability for the performance of the hydrolysis reaction in 
each analytical session. Additionally, each protein sample and control is 
prepared in triplicate and the sample preparation variability (expressed as 
minimum / maximum ratio) need to be equal or lower respect to amount 
ratio variability found in validation: ≥ 0.95 for fHbp-GNA2091, ≥ 0.90 for 
NHBA-GNA1030 and ≥ 0.94 for NadA. 
An additional chromatographic system suitability based on amino acids 
separation and peaks area precision is performed according to RP-
UHPLC AccQ•Tag method instructions [133] to control the AAA step II. 
The chromatographic SST is performed before each analysis session to 
be sure that the RP-UHPLC system has the required chromatographic 
performance. 
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Finally, the AAA assay was validated according to ICH guidelines [130], 
quantitative test for titration. For the assay validation it was used two 
experimental plans for testing the effect of noise factor on results 
variability: operator, column batch, sample preparation, instrument, day of 
analysis and analytical session. The validation results showed the 
suitability of the method for the intended purpose: identity respect to 
standard solutions, specificity (for the free-hydrolysed amino acids 
respect to sample matrix), accuracy (recovery for antigens spike), 
precision (data variation of the titrated amount) and sample linearity (the 
same protein amount is obtained for different protein dilutions within the 
amino acids working range and the area response is linear). The AAA 
assay satisfies the required data quality and the summary results of the 
method validation are reported on Table 19. 
Validation parameter Acceptance criteria Result Conclusion 
Accuracy Recovery percentage 
should be in the range 
80-120% with 90% CI 
90% CI ranges 
between 83% to 107% 
PASS 
Repeatability RSD% < 8% RSD% < 3% PASS 
Intermediate 
precision 
RSD% < 10% RSD% < 4% PASS 
Sample linearity R2 > 0.98 R2 > 0.996 PASS 
Specificity Specificity for  
free-hydrolysate  
amino acids 
No drug substance 
matrices effects; 
specificity for 
hydrolysate amino acids 
PASS 
Range the data quality are valid in the following working ranges: 
fHBp-GNA2091 34 – 145 µg/ml   
NHBA-GNA1030 35 – 110 µg/ml   
NadA 34 – 187 µg/ml   
Table 19: AAA validation summary results 
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OMV Protein Pattern Profile by RP-UHPLC 
The OMV component of Bexsero vaccine, previously introduced and 
illustrated in Figure 18, is a stable colloidal suspension that consists of 
small membranous spherical vesicles in which the native complex antigen 
composition of the sub-capsular cell surface of Neisseria meningitidis 
serogroup B is highly preserved (Figure 17). OMV contains the most 
abundant proteins of the outer membrane, PorA and PorB proteins are 
the main expressed, but also involve some minor outer membrane 
proteins such as OmpC, FetA, OmpA, fbpA (and many others) and 
Lipooligosaccharides (LPS) [41] [84] [85] [89]. 
The analytical method currently applied for the quality control of OMV 
proteins identity and purity is a densitometry SDS-PAGE assay. With the 
aim of developing a more state of the art method to replace the SDS-
PAGE, an ATP was developed (see following ATP section) and 
subsequently a method screening exercise was conducted that led to the 
selection of the RP-UHPLC (data not shown). In this context, the 
screening of commercially available UHPLC reverse phase columns was 
conducted using elements of the AQbD framework. Results are shown in 
this chapter. 
Material and methods 
The OMV bulk solution is produced by GSK group of company (Siena, 
Italy) and is stored at 4 ± 2°C controlled temperature. The OMV bulk was 
injected as it, without pre-dilution. 
Chemicals and reagents 
Trifluoroacetic acid ≥ 99% CF3COOH (TFA, LCMS & HPLC grade), formic 
acid HCOOH (FA, LCMS & HPLC grade), perfluoro-pentanoic acid 97% 
CF3(CF2)3COOH (PFPA, HPLC grade) were purchased by Sigma-Aldrich 
(Saint Louis, MO, USA). Methanol CH3OH ≥ 99.9% (HPLC grade) was 
purchased by Merck KGaA (Darmstadt, Germany). Acetonitrile (ACN) 
99.8% (LC-MS grade) was purchased by Panreac (Radnor, PA, USA).  
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Trypsin gold (Mass spectrometry grade) was purchased by Promega 
Corp. (Madison, WI, USA). Ultrapure water was produced by Millipore 
Milli-Q system (Billerica, MA, USA). All solutions used were filtered on a 
nylon membrane of 0.22 µm porosity, using Nalgene clepsydra filters 
(Nalgene, Rochester, NY, USA). 
Chromatographic equipment 
Chromatographic columns tested:  
• Acquity RP-C4 BEH 300Å, 1.7µm, 2.1x150 mm (BEH C4) from Waters 
Corp. (Milford, MA, USA);  
• Aeris WIDEPORE C4 200Å, 3.6 µm, 4.6x150 mm (AWPC4_150);  
• Aeris WIDEPORE C4 200Å, 3.6 µm, 4.6x250 mm (AWPC4_250);  
• Aeris WIDEPORE XB-C8 200Å, 3.6 µm, 4.6x100 mm (AWP C8); 
• Jupiter C5 300Å, 5 µm, 2.0x150 mm (Jupiter) from Phenomenex 
(Torrance, CA, USA);  
• ProSwift RP-3U monolithic column, 4.6x50 mm (RP-3U) from Thermo-
Fischer scientific (Waltham, MA, USA). 
The chromatographic configurations used for columns scouting and 
experimental designs were: NexeraX2 method scouting UHPLC series 30 
system equipped with LC-30AD pump, DGU-20A5R degasser unit and 
LPGE-unit, SIL-30AD autosampler, CTO-20AC oven with 180 µl mixer, 
FCV-34AH UHPLC switching valve, SPD-M30A PDA detector (detection 
wavelength 280 nm; 4 nm resolution) and high sensitive flow-cell (85 mm; 
9 µl) from Shimadzu Corp. (Kyoto, Japan). 
The LC-MS configurations for mass analysis were: Acquity H-Class Bio 
UHPLC system (equipped with bioQSM, bioSM-FTN and ACQ-PDA) form 
Waters Corp. (Milford, MA, USA) coupled with Exactive EMR system from 
Thermo Scientific (Waltham, MA, USA). The TriVersa NanoMate system 
(Advion, Inc. Ithaca, NY, USA) was adapted for LC-MS interface in order 
to reduce UHPLC flow and collect fractions. 
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Computation and software 
LabSolution Version 5 software equipped with Method Scouting start-up 
kit and licensed by Shimadzu Corp. [125] was used for the NexeraX2 
UHPLC instrument control and for the chromatographic data computation 
of purity and resolution of each chromatographic peak. Chromatographic 
resolutions (R) between two adjacent peaks were calculated using the 
retention times (tR) and the peak widths at half height (w), according to 
the following formula:  
1.18 (tR2 - tR1) / (w1+w2). 
Purity of each chromatographic peak (A%) was calculated by the 
percentage ratio of the peak Area (Ai) respect to total Area (ATOT), 
according to the following formula:  
A% = (Ai / ATOT) x 100 
Peak capacity was controlled counting the number of resolved peaks for 
each chromatographic run. 
BioPharma Finder Version 2.0 (Thermo Scientific) [138] and PEAKS 
Studio Version 8.0 (BioInformatics Solutions) [139] software were 
employed for computations of intact mass and MS peptide mapping 
respectively. 
RP-UPLC scouting and results 
Elements of the AQbD approach were applied to RP-UPLC technologies 
screening for ensuring clear information are obtained with a limited 
number of experiments. The following steps of the AQbD approach [7] 
have been applied to RP-UHPLC OMV protein pattern: 
I) Analytical target profile and critical method attribute definition; 
II) Method scouting; 
III) Quality risk assessment and identification of potential critical method 
parameters; 
VI) Investigation of knowledge space by screening DoE. 
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ATP definition and CMAs 
Upfront definition of the desired method performance is crucial to define 
the intended purpose of the method, by formalization of the Analytical 
Target Profile. For the SDS-PAGE OMV protein pattern replacement, the 
ATP main requirements were the following: 
- At least the same performance of the SDS-PAGE assay in terms of 
number of outer membrane proteins detected; 
- Method selectivity and specificity for PorB and FbpA proteins (not 
resolved by SDS-PAGE assay); 
- Improved method throughput and assay robustness; 
- General validation requirements according to ICHQ2(R1) guideline 
[129] [130]. 
For the scouting of the OMV protein pattern RP-UPLC columns, the ATP 
requirements were translated to the following CMAs surrogates: 
(I) Peaks capacity: capability to separate the maximum possible 
number of peaks. At least the eight outer membrane proteins 
identified by SDS-PAGE. 
(II) Columns selectivity: capability to identify the outer membrane 
proteins with base line resolution. 
Column scouting 
The selection process of RP column technology starts with the listing all 
the commercially available columns, with technology compatible with the 
goal of the method to be developed. Focusing prevalently to UHPLC 
columns, the selected stationary phases (Table 20) have been chosen to 
among the following chemistry (RP-C4, RP-C5 and RP-C8), supports 
(silica-particles and polypropylene-particles), column lengths (100, 150, 
250 mm), particles porosity (130, 200, 300 Å) and column technology 
(pore-particles, solid-core and monolithic). 
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Column Description Supplier Abbreviation 
Acquity RP-C4 BEH 300Å, 1.7µm, 2.1x150 mm silica pore Waters Corp. BEH C4 
Aeris WIDEPORE C4 200Å, 3.6µm, 4.6x150 mm silica solid-core Phenomenex  AWPC4_150 
Aeris WIDEPORE C4 200Å, 3.6µm, 4.6x250 mm silica solid-core Phenomenex AWPC4_250 
Aeris WIDEPORE XB-C8 200Å, 3.6µm, 4.6x100 mm solid-core endcap Phenomenex AWP C8 
ProSwift RP-3U, 4.6x50 mm PP monolitic Thermo-Fischer RP-3U 
Jupiter C5 300Å, 5µm, 2.0x150 mm silica pore Phenomenex Jupiter 
Table 20: reverse phase columns selected for scouting 
The NexeraX2 method scouting system allows the simultaneous 
screening of all the six columns in only one analytical session by 
automation testing of different mobile phases and linear gradients from 
low to high organic concentrations. The organic phases tested by OFAT 
experimentation were ACN + 0.1% TFA and MeOH + 0.1% TFA. 
The starting and final organic concentrations studied for linear gradient 
were: 5, 15, 25, 35, 45 % for starting and 5, 100, 90, 80, 60 % for final 
ramp concentration. Always, after the linear gradient, two minutes of 
washing step and 2 minutes of re-equilibration (in starting conditions) 
were performed. The results achieved by RP-UHPLC method scouting 
are reported on the following Figure 41, using the BEH C4 and the AWP 
C8 columns and represents the closest to the target. 
 
Figure 41: RP-UHPLC scouting results 
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 18.0 19.0 min
-50000
0
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200000
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300000
350000
400000
uV
Data4:OMV_BEH C4_0.1% TFA_ACN+0.1%_15_90_190.lcd PDA Ch3 280nm,4nm 
Data3:OMV_AWP C8_100_0.1% TFA_ACN+0.1%_15_90_280.lcd PDA Ch3 280nm,4nm 
Data2:OMV_AWP C8_100_0.1% TFA_MeOH+0.1%_35_90_112.lcd PDA Ch3 280nm,4nm 
Data1:OMV_BEH C4_0.1% TFA_MeOH+0.1%_25_90_016.lcd PDA Ch3 280nm,4nm 
AWP C8 with MeOH+TFA 
BEH C4 with MeOH+TFA 
AWP C8 with ACN+TFA 
BEH C4 with ACN+TFA 
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As a consequence of the preliminary screening, the BEH C4 and the 
AWP C8 were selected to be further studied by the following screening 
DoEs. 
Quality Risk Assessment and pCMPs 
After the method scouting, the process mapping [98] and fishbone 
diagram [7] were employed to develop understanding of method variables 
and their impact on the method reportable values (peak capacity and 
selectivity), for the identification of hazards and the analysis and 
evaluation of associated risks [119] [131]. The risk assessment exercise 
has been formalized in the following analytical method map (Figure 42) 
and Ishikawa diagram (Figure 43). The pCMPs, highlighted bold in Figure 
43, including detector and cell type, wavelength and autosampler 
temperature, are out of the scope of the optimization exercise since 
already studied and fixed by preliminary scouting experimentation (Figure 
41). All the rest of the pCMPs, highlighted in bold and underlined in Figure 
43, are in the scope of the risk management exercise and of the DoE with 
the objective of finding optimal method condition and achieve relevant 
knowledge on their effects on method performances (confirmation of 
criticality of pCMPs and definition of the design space). 
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Figure 42: RP-UHPLC analytical method map 
 
 
Figure 43: fishbone diagram for RP-UHPLC OMV protein pattern 
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Screening experimental designs 
As a result of RP-UHPLC scouting, the gradient shape reported on Figure 
44 has been designed to optimize the chromatographic selectivity. As a 
result of quality risk assessment (Figure 42 and Figure 43) the selected 
pCMPs to be investigated by DoE were represented by mobile phase type 
(MP), column type (COL), column temperature (TEMP), injection volume 
(VOL), time for gradient ramp A (RAMP A), time for gradient ramp B 
(RAMP B), time for gradient ramp C (RAMP C), starting organic % of 
ramp B (%A), ending organic % of ramp B (%B), mobile phase flow 
(FLOW) and ion-pairing agent (ION). 
 
Figure 44: RP-UHPLC gradient 
As per ATP, the CMAs selected as output for the study are the following: 
the total numbers of peaks (N), the number of peaks in the gradient ramp 
B (nB), the PorB kapacity factor (K’) and the resolution between PorB and 
PorA outer membrane protein (R1).  
Considering the high number of method parameters, the effect pCMPs 
onto CMAs were investigated by two different experimental designs. In a 
first 20-run asymmetric (2335//20) D-optimal design, the effect of MP, 
TEMP, VOL, COL, ION, RAMP A, RAMP B and RAMP C was 
investigated (Table 21). A centre point was included in the design and 
each run was duplicated in order to obtain a reliable estimation of the 
experimental variance (42 total runs, G-efficiency: 81%) and identifying 
the best conditions for the following factors: COL, AWP C8; TEMP, 70°C; 
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SOL, ACN; RAMP A, 6 min.; RAMP C, 10 min.; INJ, 10 µl. The DoE-
graphic effects analysis has been shown in Figure 45. 
Whereupon, a new 16-run fractional factorial (25//16) resolution V design, 
was employed to in depth study the effects of RAMP B and ION, with 
addition of %A, %B and FLOW  factors, onto selected CMAs. Each run 
was duplicated in order to obtain a reliable estimation of the experimental 
variance (Table 22). By the DoE-graphic effects analysis (Figure 46) the 
best factors condition identified were: ION, TFA; RAMP B, 15 min.; %A, 
30 %; %B, 40 % and FLOW, 0.5 ml/min.  
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Exp No MP ION TEMP 
°C 
VOL 
µl 
COL RAMP A 
min. 
RAMP B 
min. 
RAMP C 
min. 
R1 N nB K' 
1 ACN TFA 60 6 BEH C4 2 2 2 2,353 11 4 2,600 
2 ACN AF 50 2 AWP C8 6 2 2 1,868 8 3 3,432 
3 MeOH TFA 50 10 AWP C8 2 6 2 2,231 15 7 11,629 
4 ACN TFA 70 2 BEH C4 10 6 2 8,351 13 9 3,587 
5 MeOH AF 70 6 BEH C4 6 10 2 0,044 8 1 5,513 
6 MeOH AF 60 10 AWP C8 10 10 2 0,691 10 2 16,956 
7 MeOH TFA 70 10 BEH C4 6 2 6 1,596 14 8 5,684 
8 ACN AF 60 10 AWP C8 10 2 6 0,678 7 2 3,568 
9 ACN AF 70 6 AWP C8 2 6 6 0,001 5 1 2,500 
10 MeOH TFA 60 2 AWP C8 6 6 6 3,104 15 9 15,992 
11 ACN AF 50 10 BEH C4 2 10 6 0,162 7 3 1,606 
12 ACN AF 50 2 BEH C4 10 10 6 0,648 7 2 2,568 
13 MeOH TFA 60 6 AWP C8 10 10 6 3,370 13 8 23,554 
14 MeOH AF 70 2 AWP C8 2 2 10 0,632 9 2 6,036 
15 MeOH TFA 50 6 BEH C4 10 2 10 1,026 12 5 8,483 
16 ACN AF 60 10 BEH C4 6 6 10 0,601 7 2 1,277 
17 MeOH AF 50 6 BEH C4 10 6 10 0,001 9 1 8,747 
18 MeOH TFA 60 2 BEH C4 2 10 10 3,453 16 11 5,592 
19 ACN TFA 50 6 AWP C8 6 10 10 5,189 15 10 6,171 
20 ACN TFA 70 10 AWP C8 10 10 10 7,083 15 11 6,559 
21 MeOH TFA 70 10 AWP C8 10 10 10 4,459 15 9 20,251 
22 ACN TFA 60 6 BEH C4 2 2 2 2,360 11 4 2,613 
23 ACN AF 50 2 AWP C8 6 2 2 2,013 8 3 3,293 
24 MeOH TFA 50 10 AWP C8 2 6 2 2,211 15 7 10,886 
25 ACN TFA 70 2 BEH C4 10 6 2 7,696 13 9 3,499 
26 MeOH AF 70 6 BEH C4 6 10 2 0,001 8 1 5,585 
27 MeOH AF 60 10 AWP C8 10 10 2 0,985 10 2 17,141 
28 MeOH TFA 70 10 BEH C4 6 2 6 1,799 14 8 5,887 
29 ACN AF 60 10 AWP C8 10 2 6 0,613 7 2 3,523 
30 ACN AF 70 6 AWP C8 2 6 6 0,001 5 1 2,502 
31 MeOH TFA 60 2 AWP C8 6 6 6 3,129 15 9 15,835 
32 ACN AF 50 10 BEH C4 2 10 6 0,164 7 3 1,605 
33 ACN AF 50 2 BEH C4 10 10 6 0,755 7 2 2,398 
34 MeOH TFA 60 6 AWP C8 10 10 6 3,340 13 8 23,550 
35 MeOH AF 70 2 AWP C8 2 2 10 0,316 11 4 6,054 
36 MeOH TFA 50 6 BEH C4 10 2 10 1,005 12 5 8,805 
37 ACN AF 60 10 BEH C4 6 6 10 0,776 7 2 1,685 
38 MeOH AF 50 6 BEH C4 10 6 10 0,001 9 1 8,612 
39 MeOH TFA 60 2 BEH C4 2 10 10 3,542 16 11 5,564 
40 ACN TFA 50 6 AWP C8 6 10 10 5,176 15 10 5,999 
41 ACN TFA 70 10 AWP C8 10 10 10 7,088 15 11 6,527 
42 MeOH TFA 70 10 AWP C8 10 10 10 4,422 15 9 20,316 
Table 21: D-Optimal screening experimental design 
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Exp 
No 
RAMP B 
min. 
%A 
% 
%B 
% 
Flow 
ml/min 
ION N nB K' R1 
1 10 20 40 0.3 PFPA 11 5 25,000 1,576 
2 15 20 40 0.3 TFA 20 13 22,012 2,698 
3 10 30 40 0.3 TFA 20 13 10,681 3,125 
4 15 30 40 0.3 PFPA 11 5 32,206 1,66 
5 10 20 50 0.3 TFA 17 10 14,829 2,08 
6 15 20 50 0.3 PFPA 16 10 29,010 4,612 
7 10 30 50 0.3 PFPA 14 8 13,281 2,357 
8 15 30 50 0.3 TFA 19 12 10,534 2,761 
9 10 20 40 0.5 TFA 19 12 28,021 3,194 
10 15 20 40 0.5 PFPA 11 5 52,354 2,364 
11 10 30 40 0.5 PFPA 11 5 40,449 2,323 
12 15 30 40 0.5 TFA 22 15 17,615 6,714 
13 10 20 50 0.5 PFPA 16 10 35,528 5,458 
14 15 20 50 0.5 TFA 20 13 28,279 3,186 
15 10 30 50 0.5 TFA 20 13 15,690 2,996 
16 15 30 50 0.5 PFPA 16 10 37,907 1,22 
17 10 20 40 0.3 PFPA 11 5 24,620 1,569 
18 15 20 40 0.3 TFA 21 14 17,615 3,338 
19 10 30 40 0.3 TFA 20 13 10,735 3,337 
20 15 30 40 0.3 PFPA 11 5 32,112 1,686 
21 10 20 50 0.3 TFA 16 10 15,005 1,868 
22 15 20 50 0.3 PFPA 16 10 29,525 6,232 
23 10 30 50 0.3 PFPA 14 8 13,207 2,252 
24 15 30 50 0.3 TFA 20 13 10,507 2,741 
25 10 20 40 0.5 TFA 20 13 28,015 3,138 
26 15 20 40 0.5 PFPA 11 5 53,285 2,294 
27 10 30 40 0.5 PFPA 11 5 39,907 2,409 
28 15 30 40 0.5 TFA 21 14 17,293 7,067 
29 10 20 50 0.5 PFPA 16 10 33,755 5,641 
30 15 20 50 0.5 TFA 21 14 28,006 3,34 
31 10 30 50 0.5 TFA 21 14 15,638 3,211 
32 15 30 50 0.5 PFPA 16 10 37,500 1,252 
Table 22: fractional factorial experimental design 
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Figure 45: D-Otimal DoE-graphic effects analysis 
 
 
Figure 46: fractional factorial DoE-graphic effects analysis 
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The method screening has been then refined by an OFAT aimed to 
reduce dead times that lead to the final RP-UHPLC chromatography 
profiling for OMV protein pattern (Figure 47). With the identified 
conditions, the ATP was satisfied since: 
a) the proteins quantified in  the SDS-PAGE method used to release the 
OMV bulk are indeed identified by the new RP-HPLC method; 
b) PorB and FbpA proteins are selectively separated and identified; 
c) Further proteins are detectable and have been identified;  
d) Sample preparation requires a single step; 
e) Throughput of the assay has been increase. 
 
Figure 47: RP-UHPLC profile of OMV protein pattern 
Peaks identity provided by LC-MS analysis 
LC-MS characterization of RP-UHPLC OMV protein pattern 
Peaks identity of RP-UHPLC profile for OMV protein pattern (Figure 47) 
has been attributed with two different LC-MS approaches: 
I) LC-Intact Protein Mass Spectrometry analysis; 
II) LC-Fraction Collection-Peptide Mapping. 
LC-Intact Protein Mass Spectrometry analysis: 
Intact OMV proteins, eluted by the RP-UHPLC chromatography, pass 
through the TriVersa NanoMate system [140], which makes a split of the 
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flow, realizing a nano-flow to have a more stable signal in Mass 
Spectroscopy (MS). This flow goes to an interface chip to which is 
applied a voltage that ionizes the proteins and realizes the spray. Since 
the mass spectrometer reveals the mass to charge ratio, mass spectra 
does not see directly the mass of protonated protein, but multiple charge-
states that need to be deconvolved. Mass deconvolution has been done 
applying the specific algorithms reported in Equation 12. The 
deconvolution process is based on a system of two equations that allows 
defining the charge-state of a signal and consequently to calculate its 
molecular weight.  
�
�
𝑚
𝑧
�
2
= 𝑀+𝑧
𝑧
�
𝑚
𝑧
�
1
= 𝑀+𝑧+1
𝑧+1
    when solved, it brings to:  � 𝑧 = 𝑚1−1𝑚2−𝑚1𝑀 = (𝑚1−1)(𝑚2−1)
𝑚2−𝑚1
 
Equation 12: equations system for intact protein mass deconvolution 
Were z is for the charge determination of a charge-state, M is the mass 
determination taking into account 2 adjacent charge-state (m1, m2). 
The deconvolution has been done for all the identified and assigned 
charge-state, coupled by 2, and the final protein molecular weight has 
been assigned making the average of all results. BioPharma Finder 2.0 
software [138] has been used for molecular weight computations. 
 
Figure 48: Gaussian charge-states distibution of PorA protein 
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The PorA example in Figure 48 (orange peak) makes possible to observe 
a typical mass spectrum of an intact protein with a Gaussian distribution 
of charge-states. Figure 48 allows seeing the m/z value of adjacent 
charge-states. Applying the deconvolution algorithm (Equation 12) has 
been calculated the deconvolved mass from the 17+ and 16+ charge-
states, with a resulting value of 39658.80 Da. In order to have a 
measurement precision of 5-10 ppm, the same computation has been 
done for all the charge-states identified. By the average of the 
deconvolved masses, the final value obtained corresponds to the intact 
mass of PorA outer membrane protein (theoretical MW = 39657 Da).  
This kind of MS approach requires no sample treatment and is quite 
immediate. In order to have the correlation between the chromatographic 
peak and the protein identity, the calculated averaged molecular weight 
has to be compared with theoretical MW of OMV proteins. The WM 
computation has been made over all the protein signals found in MS 
spectra and it has been possible to assign the identity of the most 
abundant proteins / peaks. The identifications of the eight most abundant 
OMV proteins are shown from Figure 49 to Figure 52. 
 
Figure 49: intact mass analysis of opcA and nspA 
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Figure 50: intact mass analysis of PorB and fetA 
 
 
Figure 51: intact mass analysis of ompA and PorA 
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Figure 52: intact mass analysis of fbpA and yaeT 
The on-line LC-MS approach is very fast and accurate. The technique 
allows to drive chromatographic separation optimization directly, without 
wasting time in sample preparation. Since LC-Intact MS assigns protein 
identity on the base of correspondance between theoretical and 
calculated MW, the approach is applicable especially when there are few 
and well characterized antigens (which relative abundances are known); 
because of possible wrong assignment due to sample complexity are 
possible. For this reason, it was decided to complete the characterization 
study with LC-FC Peptide mapping approach to have an higher 
assignment confidence of proteins’ identity. 
LC-Fraction Collection-Peptide Mapping 
The final confirmation of OMV protein pattern identity was done by 
fraction collection of the most aboundant peacks in the chromatogram 
and conseguently proteins digestion for peptide mapping. Peptide 
mapping by LC-MS/MS is one of the most valuable methods for verifying 
the amino acid sequence of protein. LC-FC Peptide mapping approach  
assigns the proteins’ identity on the basis of the correspondence of 
experimental and theoretical amino acidic sequence found after tryptic 
digestion of collected fractions [141]. The TriVersa NanoMate system 
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[140] was employed for the fraction collection of the RP-UHPLC peaks. 
The fractio collection scheme has been reported in Figure 53. 
 
Figure 53: LC-FC scheme 
Peptide mapping is a MS technique consisting in two steps: (I) enzimatic 
digestion of the collected fraction and (II)  analysis of  the protein digests 
using LC-MS/MS technique. The experimental design scheme for peptide 
mapping has been reported in Figure 54. 
 
Figure 54: Peptide Mapping experimental design  
Each LC-FC fraction has undergone over a N2 evaporation process to 
remove the organic phase due to chromatographic elution. Afterwards, 
protein fractions have been dissolved in 50 mM ammonium bicarbonate  
buffer, compatible with tryptic digestion, to which 0.0125 µg/µl of trypsin 
has been added to have a digestion of collected proteins. The samples 
digestion are left overnight at 37°C. Finally, each sample has been 
acidified (0.1% HCOOH to stop the enzimatic reaction) and injected to 
LC-MS system to have the LC peptides separation and the fragmentation 
MS/MS in a Q-Orbitrap MS configuration. In particular, over the 
chromatographic separation, the peptide signal is selected, filtered by the 
quadrupole, fragmented in collision cell and revealed with high-resolution 
in Orbitrap. 
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PEAKS Studio 8.0 software [139] has been used for the data analysis of 
each protein fraction by MS/MS spectra interpretation for the amino 
acidic sequences. The peptide sequences have been matched with a 
database of proteins belonging to a specific bacterial strain, previously 
undergone to an in-silico tryptic digestion. After the collection of all 
correspondences, it was possible to assign the identity of all identified 
OMV proteins to their correspondent fraction, as reported in Figure 55 
below. 
 
Figure 55: Peptide Mapping protein matching 
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Chapter 6: Conclusions and remarks 
The present PhD thesis describes the theoretical context and the 
experimental activities performed to investigate the application of the 
Analytical Quality by Design (AQbD) approach in developing analytical 
methods, applicable to release and characterization of vaccines. In 
particular, the AQbD framework was successfully applied to the 
development of:  
- a fast RP-UHPLC method for the simultaneous determination of the 
four Bexsero components in the vaccine supernatant.  
- a robust and reliable method for testing the concentration of the 
Bexsero recombinants proteins (rMenB) in monovalent bulks by 
Amino Acidic Analysis, in order to use rMenB products as standards 
for the quantification of the components in the final vaccine.  
- an assay based on RP-UHPLC technology for characterizing the 
OVM protein pattern. 
The implementation of AQbD has been demonstrated powerful in 
achieving a deep understanding of such analytical methods. The 
development approach was performed by application of appropriate risk 
assessment tools and multivariate experimental designs. 
The experimental data were generated through preliminary screening 
experimentation and then by structured DoE studies for obtaining the 
Response Surface Models. The final MODR was identified (for the 
selected CMPs) by implementation of Monte-Carlo simulations to RSM 
models. The MODR controls the method performances and manages the 
related risks of failure, with a selected degree of confidence. Identification 
of a robust MODR represents a decisive added value in ensuring reliable 
and controlled analytical methods based on scientific knowledge and in 
potentially providing regulatory flexibility.  
All the developed methods can be considered suitable to be formally 
validated according to ICH and FDA requirements. For the first time (no 
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example reported in scientific literature), QbD was applied to drive the 
definition of analytical design space for a vaccine product, making 
progress in safety for both product quality and control strategy. 
 
  
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 155 of 157 
 
Chapter 7: Conflict of interest 
Funding and Conflict of Interest Statement: This study was funded by 
GlaxoSmithKline Biologicals SA. Luca Nompari is an employee of the GSK 
group of companies. 
Trademark Statement  
Bexsero is a trademark owned by or licensed to the GSK group of 
companies. 
 
  
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 156 of 157 
 
Acknowledgment 
The authors wish to thank Dr. Amin Khan for the strong sponsorship of QbD 
application and implementation inside GSK, supporting the PhD program at 
the basis of this study. 
We would also like to thank QbD Senior Advisors Dr. Timothy Schofield and 
Dr. William Egan, the QbD integration head Dr.ssa Cristiana Campa (that 
provide a fundamental contribute to allow the AQbD PhD opportunity). All the 
SMEs of QbD team for the good level of discussion and collaboration, in 
particular to Dr. Dominique Labbé, Dr. Gaël de Lannoy, Dr. Ghislain 
Delpierre and Dr. Olivier Vandeputte. 
Hence, Dr. Davide Serruto and Dr. Rino Rappuoli, GSK heads, for the 
possibility to shows Bexsero figures. 
Finally, the ARD organization heads Dr. Simona Cianetti, Dr. Francesco 
Norelli and Dr. Michele Rovini for the time and energy spent in supporting 
PhD activities.  
Special thanks to Prof. Sandra Furlanetto, Prof. Serena Orlandini, Dr.ssa 
Benedetta Pasquini, Dr.ssa Claudia Caprini and Prof. Sergio Pinzauti of the 
“Ugo Shiff” chemistry department at the University of Florence. Three year of 
wonderful collaboration and an high knowledge gathered on AQbD; very 
good scientists and very good people. 
Last but not least all the GSK ARD scientists that have collaborated and 
supported the thesis studies, sharing experiences, problems and successes 
during the PhD period. In particular, my special colleagues Dr. Guido Perra 
and Dr.ssa Letizia Fontana for separation sciences support and Dr. Nicola 
Messuti and Dr. Alessandro Vadi for LC-MS support. 
 
 
 
 
 Designing Quality:  
 Quality by Design in the analytical pharmaceutical development  
L. Nompari, PhD - XXX ciclo,  a.a. 2014 / 2017                                        Page 157 of 157 
 
 Publication Annexes 
The AQbD framework used for the method development of the analytical 
techniques discussed in the present thesis work are published in literature 
and/or under paper submission. The publication articles are annexes in the 
present section. 
Annex 1 
Title: Quality by Design approach in the development of an ultra-high performance 
liquid chromatography method for Bexsero Meningococcal Group B Vaccine 
Authors: Luca Nompari; Serena Orlandini; Benedetta Pasquini; Cristiana Campa; 
Michele Rovini; Massimo Del Bubba; Sandra Furlanetto 
Reference: Talanta 178 (2018) 552–562 (DOI: 10.1016/j.talanta.2017.09.077) 
Annex 2 
Title: Design space identification of hydrolysis conditions for amino acid analysis 
applying Quality by Design approach 
Authors: Luca Nompari; Serena Orlandini; Benedetta Pasquini; Letizia Fontana; 
Guido Perra; Michele Rovini; Sandra Furlanetto 
Status: article under drafting 
 
Contents lists available at ScienceDirect
Talanta
journal homepage: www.elsevier.com/locate/talanta
Quality by design approach in the development of an ultra-high-
performance liquid chromatography method for Bexsero meningococcal
group B vaccine
Luca Nomparia,b, Serena Orlandinib,⁎, Benedetta Pasquinib, Cristiana Campac, Michele Rovinia,
Massimo Del Bubbad, Sandra Furlanettob,⁎
a GSK, Analytical Research and Development (ARD), Via Fiorentina 1, 53100 Siena, Italy
b Department of Chemistry “U. Schiff”, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy
c GSK, Technical Research & Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
d Department of Chemistry “U. Schiff”, University of Florence, Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Florence, Italy
A R T I C L E I N F O
Keywords:
Bexsero
Experimental design
Neisseria meningitidis
Quality by design
Ultra-high-performance liquid chromatography
Vaccine
A B S T R A C T
Bexsero is the first approved vaccine for active immunization of individuals from 2 months of age and older to
prevent invasive disease caused by Neisseria meningitidis serogroup B. The active components of the vaccine are
Neisseria Heparin Binding Antigen, factor H binding protein, Neisseria adhesin A, produced in Escherichia coli
cells by recombinant DNA technology, and Outer Membrane Vesicles (expressing Porin A and Porin B), produced
by fermentation of Neisseria meningitidis strain NZ98/254. All the Bexsero active components are adsorbed on
aluminum hydroxide and the unadsorbed antigens content is a product critical quality attribute. In this paper the
development of a fast, selective and sensitive ultra-high-performance liquid chromatography (UHPLC) method
for the determination of the Bexsero antigens in the vaccine supernatant is presented. For the first time in the
literature, the Quality by Design (QbD) principles were applied to the development of an analytical method
aimed to the quality control of a vaccine product. The UHPLC method was fully developed within the QbD
framework, the new paradigm of quality outlined in International Conference on Harmonisation guidelines.
Critical method attributes (CMAs) were identified with the capacity factor of Neisseria Heparin Binding Antigen,
antigens resolution and peak areas. After a scouting phase, aimed at selecting a suitable and fast UHPLC op-
erative mode for the vaccine antigens separation, risk assessment tools were employed to define the critical
method parameters to be considered in the screening phase. Screening designs were applied for investigating at
first the effects of vial type and sample concentration, and then the effects of injection volume, column type,
organic phase starting concentration, ramp time and temperature. Response Surface Methodology pointed out
the presence of several significant interaction effects, and with the support of Monte-Carlo simulations led to
map out the design space, at a selected probability level, for the desired CMAs. The selected working conditions
gave a complete separation of the antigens in about 5 min. Robustness testing was carried out by a multivariate
approach and a control strategy was implemented by defining system suitability tests. The method was qualified
for the analysis of the Bexsero vaccine.
1. Introduction
Vaccine administration is one of the cheapest health-care inter-
ventions that have saved more lives than any other drug or therapy.
Due to successful immunization programs, some of the common dis-
eases of the early 20th century almost disappeared. The goal of new
approaches in the development of novel vaccines is to rationally design
effective vaccines where drug-based conventional approaches have
failed, and innovative strategies can effectively support a successful
development [1,2]. The design of an appropriate recombinant antigen
has a fundamental role to develop an effective vaccine, and the antigen
must be properly formulated with an adjuvant that helps triggering B
and T cells responses of right quality and sufficient potency [3].
Moreover, a well-designed analytical control strategy is also important
to ensure an appropriate monitoring of the vaccine product quality.
Bacterial meningitis is an infection of the membranes and
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cerebrospinal fluid surrounding the brain and spinal cord and it is a
major cause of death and disability worldwide. Three organisms are
responsible for most cases of bacterial meningitis: Neisseria meningitidis,
Haemophilus influenzae type b and Streptococcus pneumoniae [4–7]. N.
meningitidis is a pathogen bacterium that is transmitted through contact
with respiratory droplets. Transmission and colonization typically re-
sults in asymptomatic carriage in the upper respiratory tract, leading to
bacteremia that can quickly become life-threatening invasive me-
ningococcal disease, which most often presents meningitis and/or
septicemia, and less commonly pneumonia, septic arthritis, otitis media
and epiglottitis [8]. N. meningitidis is classified into serogroups based on
the immunological reactivity of the capsular polysaccharide. Me-
ningococcal serogroups A, B, C, W, Y and recently X account for the
majority of meningococcal diseases [9], with serogroup B (MenB) being
now the most prominent cause of infant bacterial meningitis and sep-
ticemia in Europe, Latin America, US and Canada [10,11]. Serogroup B
polysaccharide is immunologically similar to that of neural-cell adhe-
sion molecules and thus is poorly immunogenic, hindering its use in the
traditional polysaccharide conjugate-vaccine approach [11].
The application of reverse vaccinology, a new genome based ap-
proach [3], to MenB vaccine development allowed the identification of
new proteins able to induce bactericidal antibodies. Three highly im-
munogenic protein antigens, Neisseria Heparin Binding Antigen
(NHBA), factor H binding protein (fHbp) and Neisseria adhesin A
(NadA), constituting the three core proteins of recombinant meningo-
coccal B vaccine (rMenB), were combined with Outer Membrane Ve-
sicles (OMV) and formulated for human use in a multicomponent
vaccine, named 4CMenB (Bexsero, GSK) [12]. NHBA and fHbp have
been fused to two additional antigens (Genome-derived Neisseria An-
tigen: GNA1030 and GNA2091, respectively) to increase their im-
munogenicity [12–14]. NHBA-GNA1030, fHbp-GNA2091 and NadA
have been combined with OMV (expressing Porin A (PorA) and Porin B
(PorB), the most abundant outer membrane proteins), mimicking the
vesicles naturally released by Neisseria meningitidis, and displaying
protein antigens in a context similar to their native environment [14].
OMV have been shown to be safe and efficacious in many clinical trials
and able to combat MenB outbreaks [14], inducing immunity that is
mostly due to the highly variable PorA outer membrane protein, but
can also involve outer membrane proteins PorB, OmpC, FetA, and Li-
pooligosaccharides [15]. All the Bexsero active components are ad-
sorbed on aluminum hydroxide. Bexsero vaccine is the first MenB
vaccine based on recombinant proteins able to elicit a robust bacter-
icidal immune response in adults, adolescents and infants against a
broad range of isolated serogroup B [12] and has been recently licensed
for use in Europe, US and elsewhere [16–18].
The analytical control strategy for vaccine development should
cover all the critical quality attributes (CQAs) of the vaccine, including
component interactions, and should be able to evaluate factors that
could affect the safety, identity, strength, purity, and efficacy of the
vaccine. However, as the CQAs may not be known early in develop-
ment, a risk-based approach should be adopted in developing the
control strategy [19]. In 2004, the US Food and Drug Administration
outlined a new science- and risk-based approach that encourages
manufacturers to develop robust processes and appropriate control
strategies, thus supporting continuous improvement and product
quality [20]. Over the years this approach has been evolved among the
regulatory authorities and the pharmaceutical industry to a core con-
cept called Quality by Design (QbD), recommended and supported by
International Conference on Harmonisation (ICH) guidelines [21–23].
So far, in the field of vaccine production QbD principles have only been
applied to accelerate process development to manufacture a vaccine
candidate at commercial scale [24].
Many of the concepts associated with QbD for the manufacturing
process can be mapped to similar concepts in the analytical method
development [25–27] and the usefulness and the advantages of the QbD
methodology as an adaptive optimization tool have been demonstrated
[28]. Starting from the analytical target profile, that defines the in-
tended purpose of the measurement, analytical QbD (AQbD) empha-
sizes the need to thoroughly understand the analytical system by an in-
depth study of critical method parameters (CMPs) based on risk as-
sessment and multivariate tools. The design space (DS) is determined as
the multidimensional region of successful operating ranges for the
CMPs, which lead to desired values for critical method attributes
(CMAs) [29]. Recent examples of AQbD mostly refer to the pharma-
ceutical field, and concern mainly the development of separation
methods as HPLC [30–32], ultra-high-performance liquid chromato-
graphy (UHPLC) [33,34], hydrophilic interaction liquid chromato-
graphy [35], supercritical fluid chromatography [36,37], capillary zone
electrophoresis [38–42], micellar electrokinetic chromatography
[43,44] and microemulsion electrokinetic chromatography [45–47].
The AQbD approach intends to build quality of the analytical per-
formances during method development rather than testing it at the end
of the process, by the use of risk assessment tools and of design of ex-
periments (DoE) [48,49]. The result is consistent with controlled
method performances within predefined boundaries that ensure pre-
determined quality expectations are met. AQbD systematically in-
vestigates and controls CMPs leading to an increased knowledge of their
effects on the CMAs and to a reduced variability by controlling assay
conditions and risks. This systematic approach helps in achieving these
objectives by identifying, mitigating and controlling method risks, as
well as by a thorough examination of the method DS with respect to
required method performances to meet quality and business targets
[27]. Additional advantages in prospective method life cycle and reg-
ulatory flexibility are also provided [50].
A fundamental CQA of Bexsero vaccine is the unadsorbed antigens
content. rMenB and OMV components are characterized at the drug
substance level by the combination of multiple techniques [14,51,52]
and the actual state of art for unadsorbed antigens determination in the
commercial vaccine product is a sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) test.
In this study, for the first time in the literature, the QbD approach
was applied to design an analytical method aimed to control the quality
of a vaccine product. AQbD principles were applied to the development
of a new UHPLC method for the control of the mentioned product CQA.
UHPLC technique was selected due to its characteristics of efficiency,
selectivity and rapidity of analysis. By applying the AQbD approach to
the development of the UHPLC method the analytical target profile
requirements were reached, the assay throughput was increased by
reducing the manual operations, and selectivity and sensitivity with
respect to the current SDS-PAGE method were improved. In this way it
was possible to build an adequate method knowledge to ensure reg-
ulatory flexibility during lifecycle, as well as method robustness and
safety for product quality control. For sake of clarity, a list of ab-
breviations has been added in the Supplementary Information.
2. Materials and methods
2.1. Chemicals and reagents
For the development of the chromatographic method a mock stan-
dard solution was used. The mock solution was a mixture with the same
composition of antigens and excipients of the vaccine product, apart
from the aluminum hydroxide adsorbent which was removed for ana-
lytical needs and apart from the addition of 0.15% (p/v) Zwittergent
3–14 detergent. The mock solution was used as calibration for the
analysis and its composition enabled the target concentration range to
be achieved. The bulk drug substances used for mock formulation were
produced by GSK (Siena, Italy). L-histidine, trifluoroacetic acid (TFA)
≥ 99%, methanol (HPLC grade), Tween 80 and sucrose were purchased
by Sigma-Aldrich (Saint Louis, MO, USA). NaCl, KH2PO4, HCl, KOH
45% and Zwittergent 3–14 detergent were purchased by Merck KGaA
(Darmstadt, Germany). Acetonitrile (ACN) was purchased by Panreac
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(Radnor, PA, USA). Ultrapure water was produced by Millipore Milli-Q
system (Billerica, MA, USA) and filtered on a nylon membrane of
0.22 µm porosity using Nalgene clessidra filters (Nalgene, Rochester,
NY, USA).
2.2. Solutions and sample preparation
The L-Histidine buffers and the phosphate buffers were adjusted to
the proper pH by adding HCl and KOH, respectively. A 5% Zwittergent
3–14 detergent solution was prepared in pH 6.5 phosphate buffer 1 M.
The mock standard solutions were prepared each day by dilution of
the proper volumes of the drug substance bulks (each aliquot of rMenB
stored at −20 °C and of OMV stored at 4–8 °C) in 200 mM L-Histidine
pH 6.3 buffer plus 90 mg ml-1 NaCl and 5% (p/v) sucrose solutions up
to 100 μg ml-1 rMenB and 50 μg ml-1 OMV. The working solutions were
obtained by diluting the samples to the final concentration of 10 µg ml-1
rMenB and 5 μg ml-1 OMV, maintaining the same matrix composition,
with 0.15% (p/v) Zwittergent 3–14 detergent in pH 6.5 phosphate
buffer 1 M, added for the analytical purpose of applying the UHPLC
procedure also to the antigen content determination. The working so-
lutions were stored at 4–8 °C before the analysis. The samples were
stored in the autosampler using three different vials type: Clear Glass
Total Recovery (Waters Corp., Milford, MA, USA), LCMS Certified Total
Recovery vials (Waters Corp.) and Polypropylene Total Recovery vials
(Thermo Fisher Scientific, Waltham, MA, USA).
For mobile phase preparation, 500 µl of TFA≥ 99% were diluted up
to 500 ml ultrapure water to obtain a 0.1% (v/v) TFA aqueous solution
and 500 µl of TFA≥ 99% were added to 450 ml of ACN plus 49.5 ml of
ultrapure water to prepare a 0.1% (v/v) TFA and 90% (v/v) ACN or-
ganic phase. All buffers and solutions were filtered by a nylon mem-
brane of 0.22 µm porosity using Nalgene filters (Nalgene).
2.3. Chromatographic equipment and analysis
Different chromatographic columns were tested: Acquity RP-C4
BEH 300 Å, 1.7 µm, 2.1 × 150 mm (C4pore) and Acquity UPLC BEH
130 Å C8, 1.7 µm, 2.1 × 150 mm (C8pore) from Waters Corp. and Aeris
WIDEPORE C4 200 Å, 3.6 µm, 4.6 × 150 mm (C4shell) from
Phenomenex (Torrance, CA, USA) [53].
For the screening phase the Nexera X2 method scouting UHPLC
series 30 system was used, equipped with LC-30AD pump, DGU-20A5R
degasser unit and LPGE-unit, SIL-30AD autosampler, CTO-20AC oven
with 180 µl mixer and FCV-34AH UHPLC switching valve, SPD-M30A
PDA detector with high sensitive flow-cell (85 mm; 9 µl) from
Shimadzu Corp. (Kyoto, Japan). For Response Surface Methodology
(RSM) the Acquity H-ClassBio UPLC system (Waters Corp.) was used,
equipped with bio-Quaternary Solvent Manager (bioQSM) with 100 µl
mixer, bio-Sample Manager (bioSM-FTN) with 15 µl injector needle and
50 µl extension loop, column oven CH-A with pre-heater and photo-
diode array detector (ACQ-PDA) with analytical flow-cell (10 mm;
500 nL). Both the systems used low pressure mixing (quaternary
pumps), and no difference was observed in the chromatographic profile
and selectivity. Only a few seconds shift in retention times was ob-
served, corresponding to the difference of the void volumes when ap-
plying the same linear velocity of the mobile phase.
The detection wavelength was 210 nm. Sample injections were done
by 30 µl of the working solution stored in the autosampler at 4–8 °C.
After each injection the column was washed with 90% of ACN for one
minute and equilibrated for 3 min in the starting conditions. A new
column was conditioned with the mobile phase for 60 min before
starting the analysis. After the analysis the column was stored in pure
ACN filtered on 0.22 µm nylon membrane.
The optimal separation of the antigens was achieved using the
C4pore column. The working conditions (with the interval corre-
sponding to the DS) were as follows: starting organic phase con-
centration, 33.0% (32.0–34.6%) (%v/v); ramp time, 4.0 min
(4.0–5.6 min) to 75% (v/v) organic phase final concentration; column
temperature, 60 °C (60–68 °C).
2.4. Calculations and softwares
The chromatographic resolutions (R) between two adjacent peaks
were calculated using the retention times (tR) in min and the peak
widths at half height (w) in min, according to formula (1)
− +t t w w1.18x( )/( )R2 R1 1 2 (1)
The capacity factor (K′) of NHBA-GNA1030 antigen, measurement
of the retention time relative to column void volume (Vo), was calcu-
lated according to formula (2)
= −K t V V’ ( )/R o o (2)
LabSolution Version 5 software equipped with Method Scouting
startup kit and licensed by Shimadzu Corp [54]. was used for the
Nexera X2 UHPLC instrument control and for the chromatographic data
computation in the screening phase. Empower3 software [55] licensed
by WatersCorp. was used for the Acquity H-ClassBio UPLC instrument
control and for the chromatographic data computation in RSM.
Nemrod-W software [56] was used to generate the two asymmetric
screening matrices used for investigating the knowledge space, and the
two Full Factorial Designs used for selecting the verification points at
the edges of the design space and for testing robustness. MODDE soft-
ware [57] was purchased from S-IN (Vicenza, Italy) and was employed
to generate the Central Composite Design (CCD) used for RSM, to
perform data analysis and to find the design space by means of risk
failure maps calculated using the Monte-Carlo simulations. Multiple
Linear Regression (MLR) was used for fitting the models to the data,
hence each CMA was modeled independently. For estimating the
probability map, and thus calculating the DS, the possible factor ranges
are expanded from a set-point (optimum) to the largest possible range
where all response predictions still fulfill the requirements. The dis-
tributions of predictions simulate a real situation with a random com-
bination of factor setting disturbances within a given range. The dis-
tribution for each factor is expanded symmetrically around the set-
point until one or more response limits are exceeded according to the
specified defects per million opportunities (DPMO) target, set as
100,000 in this study (10% risk of failure). Model error was also in-
cluded in the predictions of the response distributions. The runs of all
the DoE plans were carried out in a randomized order.
3. Results and discussion
The method development followed the systematic approach of
AQbD workflow for separation methods [25], involving the following
steps: (i) Analytical target profile definition, method scouting and de-
finition of the CMAs; (ii) quality risk assessment and identification of
potential CMPs; (iii) investigation of knowledge space by screening
DoE; (iv) RSM and definition of DS; (v) working point definition and
robustness testing; (vi) method control.
3.1. Analytical target profile, method scouting and critical method attributes
The analytical target profile is the intended purpose of the method
and is defined by the selection of the analytes and of the analytical
performances to be achieved [25,58]. In this study, it consisted in ob-
taining the accurate quantitation of the five proteins NHBA-GNA1030,
fHbp-GNA2091, NadA, PorA and PorB. Moreover, general validation
requirements according to ICH Q2(R1) guideline [58,59] had to be
fulfilled, including an adequate selectivity and sensitivity, which cor-
responded in obtaining baseline resolution of the peaks and adequate
peak areas, to be able to monitor the unadsorbed antigens content
identified as a product CQA.
In order to approach this target, different preliminary aspects had to
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be considered. First, scouting of different UHPLC operative modes for
obtaining the separation of the five antigens in the vaccine was per-
formed. Prior knowledge and experimental studies led to choose reverse
phase UHPLC (RP-UHPLC) as analytical technique for method devel-
opment. Different RP-UHPLC operative modes were tuned and tested by
the Nexera X2 method scouting system, operating at 60 °C and changing
type of organic phase (mixtures of ACN/TFA or methanol/TFA), or-
ganic ramp (%/min), starting concentration (from 30% to 40%) and
ending concentration (from 75% to 100%) of the organic phase. The
aim was to approach to the experimental conditions leading to good
selectivity and fast analysis. The best results were achieved using an
organic mixture of 90/0.1/9.9 ACN:TFA:H2O (v/v) as organic phase
and a 4 min gradient from 34% to 75% of organic phase; these condi-
tions constituted the starting point for further in-depth optimization by
DoE. In these conditions, the retention order of the peaks was the fol-
lowing: NHBA-GNA1030, PorB, PorA, fHbp-GNA2091, NadA.
The second aspect was the definition of the surfactant needed for
the analysis, which was based on prior knowledge of antigens desorbing
from aluminum hydroxide and on preliminary experimental runs.
Different surfactants were tested, i.e. Tween 80 and Zwittergent 3–14
detergents in phosphate buffers. The selected surfactant was 0.15% (p/
v) Zwittergent 3–14, since it made it possible to maintain consistent
over time the chromatographic area of the proteins in mock solution
without aluminum hydroxide.
The selected CMAs are reported for clarity in Supplementary Table
S1 and were the resolution values between the peak pairs, named as R1
(NHBA-GNA1030/PorB), R2 (PorB/PorA), R3 (PorA/fHbp-GNA2091),
R4 (fHbp-GNA2091/NadA), the peak areas A1 (NHBA-GNA1030), AB
(PorB), AA (PorA), A2 (fHbp-GNA2091), A3 (NadA), and NHBA-
GNA1030 capacity factor K′, considered in the RSM for controlling the
elution of the first antigen peak with respect to column void volume.
3.2. Risk assessment and critical method parameters
The objective of a risk assessment is to develop understanding of
procedure variables and their impact on the method reportable values
for the identification of hazards and the analysis and evaluation of risks
associated with exposure to those hazards [60,61]. Tools such as pro-
cess maps and fishbone diagrams may be used, in addition to prior
knowledge, to provide structure to a brainstorming and information-
gathering exercise to identify CMPs [60]. In this study, a fishbone
diagram (Fig. 1) was used to formalize the risk assessment and point out
the risk factors associated with the characteristics of the RP-UHPLC
analysis and thus to highlight the potential CMPs which were supposed
to potentially affect the selected CMAs. Some of the CMPs, including
detector type and settings, sample surfactant, ion pair type and auto-
sampler temperature, had been already studied and fixed by pre-
liminary experiments and scouting. Other CMPs, underscored and with
grey background in Fig. 1, needed to be risk managed and in-depth
studied by DoE to enhance knowledge on their effects on method per-
formances.
3.3. Screening experimental designs
AQbD emphasizes the need to thoroughly understand the analytical
system by an in-depth study of CMPs and their interactions using DoE to
find cause-and-effect relationships [25,60,61]. As a result of RP-UHPLC
scouting and risk assessment, the selected CMPs to be investigated by
DoE were represented by vial type (VIAL), sample concentration
(CONC), injection volume (INJ), column type (COL), starting organic
phase concentration (ACN%), ramp time (RAMP), column temperature
(T). For sake of clarity, ACN% refers to the percentage of the organic
phase (made by 0.1% (v/v) TFA and 90% (v/v) ACN) in the whole
mobile phase. The other part of the mobile phase is the aqueous phase
(made by 0.1% (v/v) TFA aqueous solution), thus the concentration of
TFA was kept constant (0.1% v/v).
The first screening study involved the investigation of the effects of
VIAL and CONC for optimizing sample preparation, with the aim of
reaching adequate sensitivity before starting the optimization of the RP-
UHPLC conditions. The considered CMAs were the peak areas of the
five antigens A1, AB, AA, A2, A3. The vial type was studied at 3 levels
(Clear Glass Total Recovery vial, Polypropylene Total Recovery vial and
LCMS Certified Total Recovery vial). Sample concentration was ex-
amined at 4 levels (1–4–10–20 μg ml-1) in order to evaluate the possi-
bility of aggregation and/or aspecific absorption of antigens on vials
walls. The injection volume was adapted to inject, at each different
sample concentration, the same amount of sample in column. Nemrod-
W software [56] was employed to generate the asymmetric screening
matrix used to estimate the coefficients of the Free-Wilson model with
interactions (3) [49]:
= + + + +
+ + +
+ + +
+ +
Y b b b b b
b b b
b b b
b e
(X ) (X ) (X ) (X )
(X ) (X X ) (X X )
(X X ) (X X ) (X X )
(X X )
0 1A 1A 1B 1B 2A 2A 2B 2B
2C 2C 1A2A 1A 2A 1A2B 1A 2B
1A2C 1A 2C 1B2A 1B 2A 1B2B 1B 2B
1B2C 1B 2C (3)
where Y is the experimental response, X1 is VIAL and X2 is CONC, b0 is
the constant term, bi are the linear and interaction coefficients and e is
the experimental error. The model contains one constant term plus, for
each factor, a number of terms equal to its number of levels minus one.
The 12-run experimental plan (2131//12) is reported in Supplementary
Table S2; each analysis was duplicated in order to obtain a reliable
estimate of the experimental variance. The graphical plots describing
the effects of changing the levels of the factors on antigens areas are
shown in Supplementary Fig. S1, where A stands for the type of vial
(A1, Clear Glass Total Recovery vial; A2, Polypropylene Total Recovery
vial; A3, LCMS Certified Total Recovery vial) and B stands for level of
sample concentration (B1, 1 μg ml-1; B2, 4 μg ml-1; B3, 10 μg ml-1; B4,
20 μg ml-1). The type of vial had a significant influence only on area
responses of PorA and fHbp-GNA2091. The effects were opposite, as the
use of Clear Glass Total Recovery vial slightly enhanced PorA area but
reduced fHbp-GNA2091 area. The use of Polypropylene Total Recovery
vial had a negative effect on PorA area and an important positive effect
on fHbp-GNA2091 area. Glass Total Recovery Silicone Coated vial
caused the decrease of fHbp-GNA2091. As for the effects of CONC, in
general a decrease of the areas was observed by using the lower con-
centration value. The maximization of the areas was obtained by using
4 μg ml-1 for PorA and NadA, 10 μg ml-1 for NHBA-GNA1030 and PorB,
and 20 μg ml-1 for fHbp-GNA2091. Some interactions were also noticed,
evidencing in particular an important positive interaction between
1 µg ml-1 concentration value and polypropylene vial on A2 (A2-B1) and
other positive interactions involving AB (A1-B3) and A2 (A1-B2). Hence,
the vial type was selected as Polypropylene Total Recovery vial and
sample concentration was fixed at 1 µg ml-1, taking into account the
presence of the positive interaction A2-B1 for fHbp-GNA2091, the im-
portance of quantitation of fHbp-GNA2091 antigen (a rMenB compo-
nent) with respect to the OMV PorA and PorB antigens, and the pos-
sibility to reach a lower range concentration required by analytical
target profile in terms of sensitivity gain.
Once the sample conditions were selected, the AQbD framework
continued with the screening study of the chromatographic parameters
INJ, COL, ACN%, RAMP and T. The Free-Wilson model (4) was pos-
tulated [49]:
= + + + + +
+ + + + +
Y b b b b b b
b b b b e
(X ) (X ) (X ) (X ) (X )
(X ) (X ) (X ) (X )
0 1A 1A 2A 2A 2B 2B 3A 3A 3B 3B
4A 4A 4B 4B 5A 5A 5B 5B (4)
where Y is the experimental response, X1 is INJ, X2 is COL, X3 is ACN%,
X4 is RAMP and X5 is T, b0 is the constant term, bi the linear coefficients
of each factor and e is the experimental error. INJ was studied at two
levels, while the other four factors were studied at three levels, as re-
ported in Supplementary Table S3. A new asymmetric screening matrix
was designed for obtaining preliminary information throughout the
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knowledge space on the effects of the five selected factors on chroma-
tographic CMAs, i.e. resolutions R1, R2, R3 and peak areas AB and AA. In
this step R4 was excluded from the study, as it presented values above 2
in all the runs, while the other resolutions were critical. Only the OMV
areas were taken into account because PorB and PorA present the
lowest areas among the five antigens peaks, also due to the lower
concentration in the sample with respect to rMenB components.
The screening asymmetric matrix used to estimate the model coef-
ficients was made by 16 runs (2134//16), with three replicates for each
experiment in order to obtain a reliable estimate of the experimental
variance, and is reported in Supplementary Table S4 with the measured
responses. The graphic analysis of effects made it possible to obtain two
types of plots; the first type of plot, reported in Fig. 2, shows the effects
of the different levels of the factors on the responses, with the bar
length proportional to the effects (a longer bar corresponds to a max-
imization of the response). The second type of plot, shown in
Supplementary Fig. S2, shows the difference of the effects between the
two considered levels, and the bars colored in orange, exceeding the
reference line, correspond to the pair of factors for which a change of
level is significant on the response. By examining these plots, it was
possible to select the optimal value for some CMPs and to decide which
others should be further studied more deeply by RSM. As for injection
volume, its change exerted a limited or no effect on resolution values,
but the 50 µl value was definitely better for increasing both the areas, as
expected. Hence, this factor was fixed at an intermediate value of 30 µl,
in order to find a compromise between selectivity and sensitivity. As
regards the column, C4pore was selected for further studies, since it
gave the maximization of R3 value and led to good results also for the
other responses, taking into account that in general this column is
preferred for protein studies and for avoiding absorption. The highest
level for ACN% led to maximize all the resolution values, while low-
medium values were preferred for increasing area responses. Hence, the
new domain to be investigated was moved towards the values
28.0–38.0%. When considering RAMP, the value of 6 min led to the
maximization of all the responses apart from AB, and it was decided to
further study this CMP in the range 3–6 min, in the perspective of
keeping low analysis time. As concerns T, in general it presented a
lower influence on the CMAs with respect to the other CMPs, but it
showed conflicting effects on the different responses, thus it was
decided to continue to study this factor by RSM in the domain 50–70 °C.
3.4. Response surface methodology and design space
RSM [49] was applied for in-depth investigations of the effects of
ACN%, RAMP and T on the CMAs in the new experimental domain
reported in Supplementary Table S3. A three-factor CCD, fractionating
the experimental domain for each factor into 5 levels, was employed for
building a quadratic model with interactions making it possible to study
all the selected chromatographic CMAs, namely resolutions (R1, R2, R3,
R4) and peak areas (A1, AA, AB, A2, A3,) as above described. Ad-
ditionally, NHBA-GNA1030 capacity factor K’ was also considered
among the CMAs in order to control the elution of the first antigen peak
with respect to column void volume. As a matter of facts, from
screening DoE it was observed that high organic phase starting con-
centration values anticipate the chromatographic pattern of the anti-
gens. The 15-run CCD experimental plan with the measured responses
is reported in Supplementary Table S5, where each condition was twice
replicated, including a central point. The responses R1 and AB were
reverse (Y-1) and logarithmic (Log10Y) transformed, respectively, to
improve the model goodness of prediction Q2, while the others CMP
models were obtained without mathematical transformation. All the
models, calculated by MLR, were refined by deleting some of the in-
teraction and/or quadratic terms, which were not significant, in order
to increase the values of R2 and Q2. The resulting performances in-
dicators of the refined models are reported in Supplementary Table 6.
All the models were significant in terms of ANOVA, and were valid
apart from K′, R1, R2 and A1, for which a lack of fit was evidenced (p
values< 0.025). In the case of K’ model, the lack of validity could be
explained by the extremely high value of reproducibility observed
(equal to 0.9998). The parameter of reproducibility indicates the var-
iation of the response under the same conditions (pure error), compared
to the total variation of the response, and such a high value for K′
makes it difficult to obtain a valid model due to the extremely low
experimental variance. Anyway, all the other performances indicators
were very good for K′ model and also for R1, R2 and A1 models: the
values of R2 and Q2 ranged from 0.844 to 0.950 and from 0.652 to
Fig. 1. Fishbone diagram for RP-UHPLC method risk assessment. The factors considered as CMPs and evaluated by DoE are underscored with grey background.
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0.885, respectively: the difference between R2 and Q2 was lower than
0.2; reproducibility was> 0.9, thus confirming that the models can be
effectively used [62]. Hence, contour plots were drawn reporting the
calculated isoresponse curves, in order to obtain detailed information
on the behavior of each CMAs throughout the experimental domain
investigated.
The contour plots are shown Fig. 3 for K′ and resolution responses
and in Fig. 4 for area responses. The graphic analysis of coefficients is
reported in Supplementary Fig. S3, making it possible to point out the
terms for each model which were maintained after model refining. The
investigation of these two types of graphs allowed understanding the
method performance behavior in function of the selected CMPs. As for
K′ (Fig. 3a), the only significant effect was exerted by ACN%, which
showed both a negative linear and a negative quadratic effect; high
values of this factor anticipate the NHBA-GNA1030 peak toward the
column void volume and the zone corresponding to the maximization of
this factor was located at medium levels of all the CMPs. Concerning the
four resolutions, they were all maximized by high levels of ACN%
(Fig. 3b-e). RAMP presented a strong positive effect on resolution R3
and R4. T had a negative effect on R1 and R4 and a positive effect on R2.
Quadratic effects of ACN% were evidenced on all the resolution CMAs
apart from R4. Some significant interactions were also noticed: ACN
%-RAMP and ACN%-T on R1 and ACN%-T on R2. As for the CMAs re-
lated to areas (Fig. 4), different trends and curvatures in the contour
plots were noticed. The graphical analysis of effects in Supplementary
Fig. S3 evidenced negative effects for ACN% on A1 and AB and a po-
sitive effect on AA, while T showed a positive interaction with ACN% on
A1 and AB. RAMP showed no influence on area responses.
Fig. 2. Graphic analysis of effects for investigation of chromatographic resolutions and area responses. Resolutions: (a) resolution R1 between NHBA-GNA1030 and PorB; (b) resolution R2
between PorB and PorA; (c) resolution R3 between PorA and fHbp-GNA2091. Areas: (d) AB, area of PorB peak; (e) AA, area of PorA peak. The length of each bar indicates the effect of each
level of each factor under study.
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(c) R2
(d) R3
(b) R1
(a) K’
(e) R4
Fig. 3. Isoresponse surfaces drawn by plotting ramp time (RAMP) vs. organic phase starting concentration (ACN%) for: (a) NHBA-GNA1030 capacity factor K′, (b) resolution R1 between
NHBA-GNA1030 and PorB; (c) resolution R2 between PorB and PorA; (d) resolution R3 between PorA and fHbp-GNA2091; (e) resolution R4 between fHbp-GNA2091 and NadA at three
different values of temperature: 50 °C, 60 °C, 70 °C.
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Fig. 4. Isoresponse surfaces drawn by plotting ramp time (RAMP) vs. organic phase starting concentration (ACN%) for: (a) A1, area of NHBA-GNA1030 peak; (b) AB, area of PorB peak; (c)
AA, area of PorA peak; (d) A2, area of fHbp-GNA2091 peak; (e) A3 area of NadA peak at three different values of temperature: 50 °C, 60 °C, 70 °C.
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The sweet spot plots shown in Supplementary Fig. S4 made it pos-
sible to highlight by different colors the areas where one or more pre-
dicted CMAs fulfill the related requirements. For all the CMAs related to
resolution, a desired minimum value of 1.5 was set, while for the other
CMAs the limits were set as reported in Supplementary Table S1. The
different colors had the following meaning: purple, from 1 to 3 CMAs
criteria met; different blue gradations, from 4 to 5 and from 6 to 7
criteria met; light blue, from 8 to 9 criteria met; and finally, green
where all the ten CMAs criteria were fulfilled, namely the zone corre-
sponding to the sweet spot.
Anyway, the green plot area does not constitute the DS, but it only
shows where the overlay of the CMAs response surfaces meets the de-
sired performances, providing an additional information by high-
lighting the zone where the maximum number of criteria is fulfilled. On
the other hand, the DS takes into account the concept of probability that
the requirements are met [21,25], and it was computed by MODDE
software [57]. Considering all the response surface models and the
settings of CMAs requirements, the risk of failure map (Fig. 5) was
drawn using Monte-Carlo simulations for risk analysis, taking into ac-
count the model parameters uncertainty, propagating the prediction
error from parameters to responses and giving access to the responses
distributions for each RSM condition [63]. The selected level of prob-
ability (π) and the original set point for DS identification were: π ≥
90%; ACN%, 33.3%; RAMP, 4.8 min, T, 64 °C. Hence, the DS was gra-
phically represented in the risk of failure map by the area colored in
green, within the iso-error curves corresponding to the probability
failure ≤ 10%. Within the DS, the following limits for CMPs ranges
were identified: ACN%, 32.0–34.6%; RAMP, 4.0–5.6 min; T, 60–68 °C.
In order to validate the DS, the lower and higher limits of the DS ranges
were selected as the −1 and +1 levels of a 23 Full Factorial Design
[49], with 3 replicates of the original set point to estimate the experi-
mental variance, and the agreement between RSM predicted values and
experimental responses at the edges of failure was verified. Once the
model validity was confirmed, a working point was chosen inside the
lower risk region (π ≥ 99%), taking into account some practicability
factors such as the advantages of implementing an high-throughput
method and of choosing a temperature value as low as possible to avoid
proteins damages or modifications. The selected working point for
routine use was: ACN%, 33.0%; RAMP, 4.0 min; T, 60 °C, and made it
possible to completely separate the five antigens in about 5 min with
the desired selectivity and sensitivity, as from the chromatogram re-
ported in Fig. 6. From the observation of the final chromatogram, it is
worthwhile to note that NadA peak does not present a gaussian sym-
metry. This is due to the fact that the most intense peak is related to the
intact form of the core protein Neisseria Adhesin A, while the hump at
the end of the chromatographic signal is due to the truncated (C-
terminal deleted) forms [52]. All these forms are determined together,
and the quantification refers to the entire signal of NadA.
3.5. Robustness and control strategy
For robustness study, a 8-run Full Factorial Design was employed to
Fig. 5. Probability map by plotting ramp time (RAMP) vs. organic phase starting concentration (ACN%) at three different values of temperature: 55 °C, 60 °C, 65 °C, obtained by setting
the desired requirements as reported in Supplementary Table S1.
Fig. 6. RP-UHPLC chromatogram in the working conditions for a mock solution (10 µgml-1 NHBA-GNA1030, fHbp-GNA2091, NadA and 5 µgml-1 Por B, PorA). Acquity H-ClassBio™ UPLC
system; Acquity RP-C4 BEH 300 Å, 1.7 µm, 2.1 × 150 mm; organic phase, ACN plus 0.1% TFA ion pair; injection volume, 30 µl; temperature, 60 °C; ramp time,4 min (from 33.0% to
75.0% ACN); photodiode array detector, 210 nm, 1.2 nm resolution, 20 points s-1.
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calculate the main effects on the CMAs of small CMPs changes around
the chosen working conditions [59] and the experimental plan with the
responses is shown in Supplementary Table S7. The resulting graphical
analysis of effects is shown in Supplementary Fig. S5. The analysis of
effects evidenced that the method could be considered robust, including
a precautionary statement for ACN%. As a matter of facts, ACN% ex-
erted a significant effect on K′, R2, A1 and AB also in this small interval.
As for the other factors, RAMP was significant only on R2 and T on A1
and AB. Anyhow, all the results were within the CMAs desired limits for
all the experiments.
Finally, a preliminary control strategy [21] for the RP-UHPLC
method was accomplished on the basis of all the development data,
consisting in a continuous performance verification plan to control re-
combinant proteins resolutions, efficiency and peak symmetry, setting
the following system suitability limits. A standard mixture of the rMenB
proteins (100 μg ml-1) should fulfill these requirements: resolution
(NHBA-GNA1030/fHBp-GNA2091) ≥ 9, resolution R4 (fHBp-
GNA2091/NadA)≥ 10, fHBp-GNA2091 number of theoretical plates≥
50,000 and 0.9 ≤ fHBp-GNA2091 peak symmetry ≤ 1.6.
3.6. Qualification of the method
Qualification of the RP-UHPLC developed method was carried out to
ensure the suitability of the method for the quality control of the vac-
cine product. The method was qualified following ICH guidelines [59]
for validation, using an experimental plan for testing the effect of noise
factor on results variability: operator, column batch, sample prepara-
tion, instrument, day of analysis and analytical session. Specificity of
the method was evaluated by preparing and analyzing different mock
standard solutions where the antigens were removed one by one,
checking for the absence of the corresponding peak in the chromato-
gram. Also, separate solutions of the single drug substances and a mock
standard solution containing all the analytes were analysed and com-
pared, verifying the correspondence of the peaks in the chromatograms.
The qualification results showed the suitability of the method for the
intended purpose, identity of antigens respect to standard solutions,
selectivity, linearity, accuracy (recovery for antigens spike), precision
(data variation of the titred amount), quantitation limits. Quantitation
limits were determined by the analysis of samples with known con-
centrations of analyte and establishing the minimum level at which
each analyte can be quantified with acceptable accuracy and precision,
and corresponded to the lower limits of the linearity curves (1 μg ml-1
for rMenB antigens and 0.5 μg ml-1 for OMV antigens). Linearity was
evaluated by preparing and analyzing ten samples, two for each of five
concentration values, ranging from 1 to 20 μg ml-1 for rMenB antigens
and from 0.5 to 10 μg ml-1 for OMV antigens, and the related data are
shown in Supplementary Table S8. The recovery values for antigens
spike were measured at three concentration values (1.5, 10 and
20 μg ml-1) performing 6 replicates and obtaining values included in the
following intervals: NHBA-GNA1030, 92.3–113.9%; PorB,
93.1–115.9%; PorA, 96.1–108.6%; fHBp-GNA2091, 99.3–106.3%;
NadA, 90.9–104.7%. Precision was assessed for fHBp-GNA2091
(10 μg ml-1): as for repeatability, six analyses were run obtaining a RSD
= 1.7% for the titred amount; as for intermediate precision, calculated
by performing 6 replicates at three concentration values, the following
RSD values for the titred amount were found:1.5 μg ml-1, RSD = 8.4%;
10 μg ml-1, RSD = 7.9%; 20 μg ml-1, RSD = 2.8%.
4. Conclusions
A fast and fully QbD-compliant RP-UHPLC method was developed
for the simultaneous determination of the Bexsero components in the
vaccine supernatant. The implementation of AQbD allowed enhanced
understanding of the analytical method, whose development was ef-
fectively supported by experimental design for quality risk management
and performance evaluation. For the first time in the literature, QbD
was applied to drive to an analytical design space for a vaccine product.
The data gathered through well-suited experimental designs, which
were planned first in a screening phase and then in a RSM study, made
it possible to identify the DS, defined on the basis of the calculated
models for the CMPs and on the basis of Monte-Carlo simulations. The
DS consisted of a set of CMPs conditions which provided satisfactory
values for all the CMAs, with a selected degree of probability. QbD
applied to analytical method development, leading to DS identification,
represents an added value, providing advantages for adequate method
knowledge, ensuring regulatory flexibility during lifecycle, improving
method robustness and making progress in safety for both product
quality and control strategy. The developed method successfully passed
the qualification process demonstrating to be useful for routine analysis
of Bexsero vaccine.
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